securities exchange commission washington dc mark one annual report pursuant section securities exchange act fiscal year ended december cidcidcidcid transition report pursuant section securities exchange act transition period commission file gilead sciences inc exact name registrant specified charter delaware state jurisdiction incorporation organization irs employer identification lakeside drive foster city california address principal executive offices zip code registrants telephone number including area code securities registered pursuant section b act none securities registered pursuant section g act common stock par value title class indicate check mark whether registrant filed reports required filed section securities exchange act preceding months shorter period registrant required file reports subject filing requirements past days yes cid indicate check mark disclosure delinquent filers pursuant item regulation sk section chapter contained herein contained best registrants knowledge definitive proxy information statements incorporated reference part iii amendment cid indicate check mark whether registrant accelerated filer defined rule b act yes cid aggregate market value voting stock held nonaffiliates registrant based upon closing price common stock nasdaq stock market june number shares outstanding registrants common stock february documents incorporated reference specified portions registrants definitive proxy statement filed commission pursuant regulation connection annual meeting incorporated reference part iii report based closing price per share excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrant september registrant implemented twoforone stock split form stock dividend share per share amounts periods presented restated reflect stock splitgilead sciences inc annual report table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences hepsera viread vistide daunoxome ambisome emtriva truvada macugen registered trademark belonging eyetech pharmaceuticals inc sustiva registered trademark bristolmyers squibb company tamiflu registered trademark belonging hoffmannla roche report also includes trademarks service marks trade names companiespart item business forwardlooking statements risk factors report includes forwardlooking statements particular statements expectations beliefs plans objectives assumptions future events performance contained incorporated reference report based forwardlooking statements current expectations future events believe expectations reasonable forwardlooking statements inherently subject risks uncertainties many beyond control actual results may differ materially suggested forwardlooking statements various reasons including discussed report heading risk factors affect gilead beginning given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof undertake specifically decline obligation update statements publicly announce results revisions forward looking statements reflect future events developments used report unless otherwise indicated us refers gilead subsidiaries overview gilead sciences inc biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company eight approved products focus research clinical programs antiinfectives seeking add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy worldwide headquarters foster city california european headquarters paris france incorporated delaware june products viread oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat human immunodeficiency virus hiv infection adults sell viread united states us commercial team wholesalers major european countries european commercial team distributors japan corporate partner japan tobacco w e exclusive worldwide license patent rights related technology viread institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults sell emtriva united states us commercial team wholesalers major european countries european commercial team distributors exclusive worldwide license patent rights related technology emtriva emory university truvada oral tablet dosed day part combination therapy treat hiv infection adults fixeddose combination antihiv medications emtriva viread truvada combines mg emtricitabine emtriva mg tenofovir disoproxil fumarate viread truvada currently sold united states us commercial team wholesalers international commercial team began launching truvada european union following recent regulatory approval february exclusive worldwide license patent rights related technology components truvada iocbrega emory university ambisome proprietary liposomal formulation amphotericin b powerful antifungal agent treat serious invasive fungal infections caused various fungal species delivering amphotericin b proprietary liposomal formulation ambisome reduces rate severity kidney toxicity injectionrelated reactions associated amphotericin b allows patients receive higher doses amphotericin b ambisome approved sale countries including united states countries european union countries ambisome approved including united states authorized promote ambisome empirical treatment fungal infections treatment patients strong suspicion without definite confirmation exists potentially lifethreatening invasive fungal infection remaining countries ambisome approved use either firstline treatment serious invasive fungal infection secondline treatment conventional amphotericin b therapy fails conventional amphotericin b tolerated market ambisome major countries europe copromote ambisome united states fujisawa healthcare inc fujisawa hepsera oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dosed day treat chronic hepatitis b hepsera approved sale united states treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team wholesalers sell hepsera united states sell hepsera major european union countries european commercial team distributors licensed rights commercialize hepsera solely treatment hepatitis b china japan korea taiwan rest asia latin america certain territories glaxosmithkline gsk launched hepsera japan south korea taiwan exclusive worldwide license patent rights related technology adefovir dipivoxil iocbrega vistide antiviral medication treatment cytomegalovirus cmv retinitis patients aids cmv retinitis condition characterized lesions form patients retina affects persons weakened immune systems common patients aids vistide approved sale sold united states us commercial team gileads exus partner pfizer inc pfizer formerly pharmacia corporation countries treatment cmv retinitis patients aids daunoxome liposomal formulation anticancer agent daunorubicin approved sale sold countries treatment aidsrelated kaposis sarcoma sold united states us commercial team independent distributors abroad december decided discontinue selling product however subsequently received unanticipated requests europe reconsider selling daunoxome continuing sell product limited number countries currently evaluating supply sales strategy regard product royalty sources macugen antiangiogenic injection treatment neovascular agerelated macular degeneration amd drug inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases macugen approved fda united states december began selling january product yet approved outside united states macugen developed eyetech pharmaceuticals inc eyetech using technology licensed us eyetech holds exclusive rights manufacture sell macugen worldwide subject eyetechs obligation pay us percentage net revenues eyetech generates macugen sales patents technology license eyetech expire united states europe tamiflu oral pill treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors tamiflu approved countries including united states japan countries european union treatment influenza children adults tamiflu also approved united states european union prevention influenza adolescents adults developed tamiflu f hoffmannlaroche ltd roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales subject reduction certain defined manufacturing costs following table lists aggregate product sales major products thousands product product product sales sales sales viread emtriva truvada total hiv products ambisome total product sales see note consolidated financial statements financial information geographic area products marketed products clinical trials research development seeking add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy acquisition triangle pharmaceuticals inc completed january research scientists foster city san dimas california durham north carolina engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus area life threatening infectious diseases research includes working proprietary nucleotide analogues develop treatments viral infections particularly hiv hepatitis c infection total research development rd expenses million compared million million research efforts area hepatitis c viral infection hcv include collaborations chiron corporation chiron genelabs technologies genelabs achillion pharmaceuticals inc achillion august entered agreement chiron research develop commercialize small molecule therapeutics certain hcv drug targets october entered research development agreement genelabs technologies genelabs discover develop commercialize nucleoside rna polymerase inhibitors treatment hcv infection november entered research development agreement achillion discover commercialize novel inhibitors hcv replication addition several inhouse programs designed discover small molecule inhibitors hcv rna polymerase hcv protease believe small molecule therapeutics treatment hcv infection could one day lead better treatment outcomes patients programs require extensive investments take many years see note consolidated financial statements discussion commercial operations us international commercial sales operations marketing subsidiaries australia canada france germany greece ireland italy new zealand portugal spain united kingdom commercial teams promote hiv hbv products viread emtriva truvada hepsera direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv hiv products chronic hepatitis b hepsera teams also promote ambisome infectious disease specialists hematologists intensive care units hospitals home health care providers cancer specialists countries outside united states agreements thirdparty distributors including distributors certain countries marketing operations promote sell distribute products international distribution agreements generally provide distributor exclusive right sell one products particular country several countries specified period time december announced program pursuant sell viread cost countries africa fifteen countries designated least developed united nations expanded program august include truvada taking steps ensure viread truvada products sold program used serve patients developing world diverted markets see international distribution collaborative relationships part business strategy establish collaborations companies assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies description accounting relationships found note consolidated financial statements included report following list representative collaborative relationships collaborator program area year signing bristolmyers squibb hiv achillion hcv genelabs hcv japan tobacco hiv glaxosmithkline hepsera archemix selex technology eyetech macugen roche tamiflu pfizer vistide fujisawa ambisome bristolmyers squibb company december entered collaboration agreement bristolmyers squibb company bms develop commercialize fixeddose combination gileads truvada bmss sustiva efavirenz united states structured joint venture gilead bms formed limited liability company bristolmyers squibb gilead sciences llc approved new product would first complete highly active antiretroviral therapy haart treatment regimen hiv available fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together may help simplify hiv therapy patients providers joint venture companies work partnership complete development us regulatory filings fixeddose regimen subject receiving marketing approval fixeddose regimen companies share responsibility commercializing product united states companies provide funding fieldbased sales representatives support promotional efforts combination product terms collaboration gilead bms grant royaltyfree sublicenses joint venture use respective companyowned technologies return granted license use jointly created intellectual property gileads bms ownership interests joint venture reflect respective economic interests based fraction net selling price fixeddose combination product attributable truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva joint venturers respective economic interests joint venture may vary annually academic consulting relationships supplement research development efforts part regular business enter arrangements universities medical research institutions arrangements often provide us rights patents patent applications technology owned institutions return payments fees relating use rights emory university university georgia research foundation inc emtricitabine april triangle obtained january acquired part acquisition triangle exclusive worldwide license emory universitys rights purified forms emtricitabine use hiv hbv fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology united states third year first registration granted antihbv product incorporating emtricitabine technology certain major market countries hiv hbv indications respectively triangle began paying license maintenance fees development milestones yet achieved may emory gsk settled litigation pending united states district court relating emtricitabine became exclusive licensee us foreign patents patent applications filed burroughs wellcome co use emtricitabine treat hepatitis b settlement agreements obligated pay royalties gsk net sales products containing emtricitabine addition emory also received access development clinical data drug substance held gsk relating emtricitabine may emory gsk shire pharmaceuticals group plc shire settled worldwide patent disputes involving lamivudine emtricitabine terms settlement emory received exclusive license shire shires patents relating emtricitabine methods use manufacture shire gsk received exclusive licenses emorys patents relating lamivudine terms license agreement emory automatically acquired exclusive sublicense shire patents relating emtricitabine granted terms settlement thereby resolving previously pending patent disputes regarding emtricitabine md anderson cancer center entered agreement md anderson cancer center relating hepsera agreement currently pay md anderson cancer center percentage net revenues based upon sales hepsera agreement md anderson cancer center terminates later patent expiration ten years first commercial sale iocbrega entered agreements iocbrega relating viread hepsera vistide subsequently amended agreements include truvada agreements received iocbrega exclusive right manufacture use sell nucleotide compounds covered agreements agreements pay percentage net revenues based upon sales viread truvada hepsera vistide iocbrega agreements iocbrega terminate individual country basis later patent expiration ten years first commercial sale addition iocbrega may terminate licenses particular product key market absence commercial sales product within months regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation technology holding company university colorado boulder relating selex technology identify aptamers arrangement ulehi granted us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology computer software related selex technology required pay ulehi certain variable royalties based revenues generated sales products derived using selex technology including revenues based license agreement eyetech relating macugen developing world collaborations bill melinda gates foundation family health international october entered agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluating vireads effectiveness method reducing risk hiv infection among sexually active adults regularly exposed hiv clinical trials conducted fhi funded million threeyear grant gates foundation dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart trial evelopment nti r etroviral herapy africa aimed studying clinical versus laboratory monitoring practices structured treatment interruptions versus continuous antiretroviral therapy adults hiv infection subsaharan africa agreed provide viread cost dart study institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis clinical trial conducted institute one world health partnership world health organization international distribution various agreements distributors europe asia latin america middle east africa grant distributors exclusive right sell viread emtriva hepsera ambisome daunoxome particular country countries specified period time agreements also provide collaborative efforts us distributor obtaining regulatory approval product particular country marketing product country agreements establish price distributor must pay product require us deliver quantities product ordered distributor manufacturing ambisome manufacture ambisome commercial quantities two separate adjacent facilities san dimas california medicines control agency united kingdom fda approved commercial production ambisome facilities produced import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere use commercially available materials equipment manufacture products currently obtain amphotericin b cholesterol use manufacture ambisome single approved suppliers ambisome sold freezedried product currently freezedry ambisome san dimas manufacturing facility also use third party freezedry additional product needed given current projections ambisome demand believe sufficient capacity meet future demand also option installing additional freezedrying capacity san dimas additional supply become necessary unable install additional freezedrying capacity san dimas locate appropriate third parties meet need ability meet increased ambisome demand would diminished macugen manufacture macugen commercial quantities fda approved facilities san dimas california manufacturing agreement eyetech use commercially available materials equipment manufacture product currently eyetech provides raw materials used manufacture macugen including pegaptanib sodium active ingredient macugen single approved suppliers contracted eyetech part manufacturing process currently produce fill macugen san dimas manufacturing facility given eyetechs current projections macugen demand believe sufficient capacity meet future demand also option installing additional production filling capacity san dimas additional supply become necessary unable install additional production filling capacity san dimas locate appropriate third parties meet need ability meet increased macugen demand would diminished macugen sold liquid form filled syringes san dimas facilities syringes supplied single approved supplier contracted eyetech antiviral products contract third parties manufacture antiviral drugs clinical commercial purposes including viread emtriva truvada hepsera vistide manufacture tenofovir disoproxil fumarate bulk drug substance two contract manufacturers viread tablets manufactured two contract manufacturers manufacture emtricitabine bulk drug substance two contract manufacturers emtriva tablets manufactured one contract manufacturer us second contract manufacturer currently qualified manufacture truvada tablets single contract manufacturer united states second contract manufacturer currently qualified obtained qualification united states european union two contract manufacturers adefovir dipivoxil bulk drug substance two contract manufacturers hepsera tablet commercial supply europe two contract manufacturers one also qualified commercial supply united states second currently qualified two suppliers approved fda european union manufacture cidofovir bulk drug substance used vistide single fda emea approved supplier vistide drug product roche responsible manufacturing tamiflu january roche announced due production problems liquid suspension form tamiflu approved treatment children young one yearold available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roches sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems november chugai announced recall tamiflu resulting reduced net sales royalties roche however royalty income tamiflu net sales increased substantially due primarily severe flu season united states late commercialscale manufacturing facilities antiviral products future antiviral products need develop additional manufacturing capabilities establish additional third party suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities products approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct largescale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable believe compliance material environmental regulations related manufacture products patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products product candidates products us patent expiration european patent expiration vistide hepsera ambisome tamiflu viread emtriva truvada patents covering viread hepsera vistide emtriva truvada held third parties acquired exclusive rights patents agreements parties see collaborative relationships academic consulting relationships patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets patent filings covering forms hepsera china certain asian countries although applications pending various asian countries including china relate specific forms formulations hepsera asia major market hbv therapies may obtain patents compounds many years obtain marketing approval patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents vistide granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time including sometimes united states patent issues may pending patent applications patents eventually issue prevent us developing selling certain products unless obtain license use patented technology patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developed developing addition certain countries permit enforcement patents manufacturers able sell generic versions products countries also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions competition products development programs target number diseases conditions including viral fungal infections many commercially available products diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases current products compete available products based primarily efficacy safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing products market future also compete products offered competitors competitors introduce data show improved characteristics products improve increase marketing efforts simply lower price products sales products could decrease also certain products may develop future compare favorably products offered competitors existing future products compare favorably new products developed competitors ability competitive also depends upon ability attract retain qualified personnel obtain patent protection otherwise develop proprietary products processes secure sufficient capital resources substantial period takes develop product hiv products hiv competitive landscape becoming crowded complicated treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development twentysix branded drugs available united states zerit stavudine dt sold bristolmyers squibb bms fixed combination products combivir azt tc trizivir azt tc abc sold gsk represent direct competition hiv products companies process launching formulations existing drugs indicated fda oncedaily oral dosing including gsks mg dose epivir lamivudine tc recently approved antiretroviral products include epzicom fixed dose combination ziagen epivir gsk approved united states european union fuzeon injectable integrase inhibitor rochetrimeris reyataz atazanivir sulfate onceaday protease inhibitor bms tipranavir nonpeptidic protease inhibitor boehringeringelheim gsk filed application approval oncedaily dose ziagen abacavir sulfate companies competing hiv therapeutic category pfizer merck abbott bmss videx ec didanosine became first generic hiv product united states gsks retrovir azt expected face generic competition early united states effect overall us market hiv products unknown price decreases hiv products may result ambisome ambisome faces strong competition several current expected competitors current competitors include conventional amphotericin b made bms numerous generic manufacturers caspofungin product developed merck marketed cancidas united states caspofungin elsewhere voriconazole developed pfizer marketed vfend lipidbased amphotericin b products approved sale united states throughout europe including abelcet sold enzon corp united states canada japan medeus pharma ltd europe amphotec sold intermune pharmaceuticals inc presently unapproved expected competitors include class treatments called echinocandins including fujisawas micafungin received marketing approval japan october review regulatory approval united states canada anidulafungin vicuron inc formerly versicor inc product candidate evaluated multiple latestage clinical trials finally schering plough developing noxafil posaconazole currently phase trials competition current expected competitors eroded likely continue erode revenues receive sales ambisome hepsera hepsera faces significant competition existing expected therapies treating patients infected hbv significantly entecavir oral nucleoside analogue developed bms expected launched late daily oral antiviral bms filed approval us fda prescription drug user fee act pdufa action date april epivirhbv lamivudine developed gsk collaboration shire pharmaceuticals sold major countries throughout north south america europe asia orally administered nucleoside analogue inhibits hbv dna polymerase introna interferon alfab sold schering plough major countries throughout north south america europe asia introna injectable drug immunomodulatory effects hepsera may also face competition clinicalstage candidates including idenixs ldt oral nucleoside analogue currently phase trials well roches pegasys pegylated interferon alfaa expected approved chronic hepatitis b united states late tamiflu tamiflu competes relenza antiflu drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine oral tablet inhibits replication influenza virus rimantadine also oral antiviral vistide vistide competes number drugs also treat cmv retinitis including ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valganciclovir also marketed roche foscarnet intravenous drug sold astrazeneca formivirsen drug injected directly eye sold cibavision number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval process expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drugs potential safety benefits submit data fda investigational new drug application ind seeking approval test compound humans clinical trials fda accepts investigational new drug application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase compound appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase clinical trials fail rigorous reliable phase clinical trials fda approval process believe data phase clinical trials show adequate level safety effectiveness file new drug application nda fda seeking approval sell drug particular use fda review nda often hold public hearing independent advisory committee expert advisors asks additional questions regarding drug committee makes recommendation fda binding fda generally followed fda fda agrees compound met required level safety effectiveness particular use allow us sell drug united states use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require us complete additional testing provide additional data information improve manufacturing processes procedures facilities may require extensive postmarketing testing surveillance monitor safety benefits product candidates determines new drug application contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us well facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs may designated fast track products fda may eligible accelerated sixmonth review accelerated approval case viread truvada drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used decentralized system approval one country european union used obtain approval another country european union simplified application process approval centralized procedure pricing reimbursement approvals also required countries vistide viread hepsera emtriva february truvada approved european union centralized procedure viread hiv drug reviewed accelerated approval european union hepsera received traditional review emtriva march applied marketing applications truvada treatment hiv european union began european launch truvada following regulatory approval received february pricing reimbursement insurance companies health maintenance organizations hmos thirdparty payors federal state governments seek limit amount charge drugs example certain foreign markets pricing negotiations often required obtain approval product united states expect continue number federal state proposals implement drug price control addition managed care organizations becoming common united states continue seek lower drug prices announcement proposals efforts cause stock price decrease proposals adopted revenues could decrease ability sell drugs also depends availability reimbursement governments private insurance companies governments insurance companies often demand rebates predetermined discounts list prices expect products developing particularly hivaids indications subject reimbursement issues certain products obtain regulatory approval reimbursed governments insurance companies regulatory approval prices required foreign countries certain countries condition approval product agreement seller sell product certain price country past required price reductions connection product approval certain foreign countries also require price approved product reduced product marketed period time certain regulatory authorities future establish lower prices regulatory action reducing price products one country practical effect requiring us reduce prices countries european governments notably germany italy implemented considering legislation would require pharmaceutical companies sell products subject reimbursement mandatory discount mandatory discounts would reduce revenue receive drug sales certain developing countries significantly affected hiv aids parallel importing generic competition may occur adversely affect revenues sales market share viread addition governments could take regulatory action disallow pricing combination products truvada sum prices component drugs marketed particular country employees february approximately fulltime employees believe good relations employees website website address wwwgileadcom make available free charge website annual report quarterly reports form q current reports form k directors officers section reports required sec filings amendments reports soon reasonably practicable filing providing hyperlink edgar website containing reports risk factors affect gilead evaluating business carefully consider following risks addition information report following risks could materially adversely affect business operating results financial condition substantially revenues derived sales limited number products unable maintain continue growing sales hiv products maintain sales ambisome results operations may adversely affected currently dependent sales hiv products especially viread ambisome support existing operations although viread comprised hiv product sales important consider viread emtriva truvada collectively future sales three products intimately tied one another together sales hiv products ambisome accounted approximately total product revenues year ended december unable continue growing hiv product revenues maintain ambisome sales results operations likely suffer may need scale back operations hiv product sales year ended december million total revenues ambisome product sales royalties year ended december million total revenues may able continue growth rate sales hiv products current sales level ambisome reasons stated risk factor section particular following reasons face significant competition businesses substantially greater resources merck pfizer released new products compete ambisome glaxosmithkline markets fixeddose combination products compete truvada competitors products operated fields compete longer ambisome sales volumes relatively flat compared hiv products ambisome used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings labels narrow approved indications halt sales product could reduce revenues product matures private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products patients already taking hiv drugs successful encouraging physicians change patients prescriptions hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing may affected fail commercialize new products expand indications existing products prospects future revenues stock price may adversely affected introduce new products increase revenues existing products able grow revenues fail increase sales hiv products may able increase revenues expand research development efforts may successful efforts collaboration bristol myers squibb company formulate onceaday one pill combination truvada sustiva failure achieve objectives expected may material adverse effect business results operations significant safety issues arise marketed products sales may decline would adversely affect results operations data support marketing approvals products form basis safety warnings product labels obtained controlled clinical trials limited duration cases limited postapproval use components truvada emtriva viread studied individually safety efficacy studies truvada still ongoing following approval products used longer periods time many patients taking numerous medicines many underlying health problems would monitored dosing compliance drugs used longer periods time patients found expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings labels narrow approved indications could reduce market acceptance products serious safety resistance interaction issues arise marketed products sales products could limited halted us regulatory authorities operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials ambisome viread hepsera emtriva truvada currently approved additional uses anticipate file marketing approval additional countries additional products next several years products may fail receive marketing approval timely basis addition marketed products manufacture sell products subject extensive continued regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution recently formation independent drug safety office announced tasked monitoring safety approved products new office may increase difficulty length time required new drugs obtain marketing approval office may create postapproval obligations would required comply results clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products products development fail achieve primary endpoint clinical trials safety issues arise commercialization drug candidate could delayed halted addition clinical trials involving commercial products could raise new safety issues existing products reduce revenues manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis third parties fail perform required could impair ability deliver products timely basis cause delays clinical trials applications regulatory approval events could harm competitive position manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations manufacturers subject fdas current good manufacturing practices extensive regulations governing manufacturing processes stability testing recordkeeping quality standards similar regulations effect countries addition manufacturing operations subject routine inspections regulatory agencies viread hepsera vistide emtriva truvada rely third parties manufacture bulk drug substance final drug product clinical commercial purposes addition roche responsible manufacturing tamiflu thirdparty manufacturers may develop problems control problems may adversely affect business example january roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available japan flu season particularly severe roches sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales tamiflu royalty roche manufacture ambisome facilities san dimas california formulation manufacturing facilities united states manufacturing facility ireland conducts quality control testing labeling packaging addition use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome meet market needs may able obtain materials necessary manufacture products could limit ability generate revenues many materials utilize operations made one facility example depend single suppliers high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products suppliers key components materials must named new drug application filed fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship viread ambisome hepsera emtriva truvada vistide supply products development clinical trials depend relationships companies sales marketing performance revenues failure maintain relationships would negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance include collaborations fujisawa sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide japan tobacco viread emtriva truvada recently announced joint venture bristolmyers squibb develop commercialize fixeddose combination truvada sustiva certain countries rely international distributors sales ambisome viread emtriva european countries intend rely international distributors sales hepsera relationships also involve clinical development products partners reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan korea success hepsera territories depend almost entirely efforts gsk regard gsk promotes epivirhbv product competes hepsera consequently gsks marketing strategy hepsera may influenced promotion epivirhbv receive royalties gsk equal percentage gsks net sales hepsera well net sales gsks epivirhbv gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera may substantially reduced expenses associated clinical trials sales fluctuations result inventory levels held wholesalers may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval extremely expensive difficult accurately predict control amount timing expenses uneven unexpected spending programs may cause operating results fluctuate quarter quarter addition approximately product sales united states three distributors amerisourcebergen corp cardinal health inc mckesson corp inventory levels held wholesalers may fluctuate significantly could cause sales result operating results fluctuate unexpectedly quarter quarter example based review ndc health corp prescription trends ims health inc inventory data actual viread sales believe quarter ended june wholesalers built inventory levels estimated months believe inventory buildup followed equivalent possibly greater inventory reduction quarter ended september know inventory management agreements entered year three major us wholesalers continue effective matching inventory levels end user demand rely wholesalers estimate end user demand approximately half product sales occur outside united states currency fluctuations may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar equivalent sales negatively impact financial condition results operations use foreign currency forward contracts hedge percentage forecasted international sales primarily denominated euro currency also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable although use forward contracts reduce impact foreign currency fluctuations future results efforts may successful fluctuations could adversely affect results operations face credit risks european customers may adversely affect results operations particularly subject credit risk european customers european product sales government owned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices accounts receivable government owned supported customers countries totaled million december significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected plan supply viread truvada cost certain developing countries may expose us liability would material adverse affect results operations financial condition launched distribution program pursuant supply viread truvada cost countries africa fifteen countries designated least developed united nations supply distribution drugs resourcepoor environment complicated undertaking program develops could face unforeseen challenges risks could give rise unforeseen liabilities example patients less developed countries using viread truvada may closely supervised doctor would developed nations accordingly may increased likelihood viread truvadarelated complications going undetected untreated could result significant liability gilead product revenues could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly viread truvada agreed provide cost countries africa fifteen countries designated least developed countries united nations revenues would adversely affected addition european union required permit cross border sales allows buyers countries government approved prices products relatively high purchase products legally countries must sold lower prices additionally us consumers able purchase products including hiv medicines internet pharmacies countries substantial discounts crossborder sales could adversely affect revenues countries may required grant compulsory licenses hiv products face generic competition hiv products number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing sales certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide significant percentage sales viread hepsera subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general europe success hepsera tamiflu emtriva viread truvada also depend largely obtaining maintaining government reimbursement many european countries including united kingdom france patients use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization twelve months also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase well previous years seen significant price decreases products across much europe believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth results operations could adversely affected future health care reforms united states recent years new legislation proposed federal state levels would effect major changes health care system either nationally state level proposals included prescription drug benefit proposals medicare beneficiaries recently passed congress additionally states enacted health care reform legislation federal state developments possible impact proposed legislation reforms unclear may result pricing reimbursement restrictions could adversely impact revenues may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others number us foreign patents patent applications rights patents related compounds products technology risk however issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential least period time sometimes united states patent issues result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions addition patents may provide adequate protection certain countries africa asia including china competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufactures often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period near end exclusivity periods granted products patents may subject challenges may need spend significant resources defend may able defend patents successfully success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others although maintain product liability insurance successful product liability claim us may covered insurance could require us pay amounts beyond provided insurance either could impair financial condition ability clinically test market products expensive litigation may reduce earnings named defendant number lawsuits regarding use average wholesale price reimbursement rates medicaid also named lawsuits alleging violations federal securities laws adverse results lawsuits could result material damages could significantly reduce earnings cash flows changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects effective income tax rate factors include limited interpretations existing tax laws changes tax laws rates future levels research development spending changes accounting rules future levels capital expenditures changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings impact income tax provision resulting abovementioned factors may significant could negative impact results operations recently adopted changes accounting stock options may affect earnings financial accounting standards board fasb recently issued statement financial accounting standards revised sharebased payment sfas r required implemented third quarter provides new guidance accounting stock options new accounting guidance required record additional compensation expense related stock options equity incentives although currently evaluating various option valuation methodologies including blackscholes method binomial method methods allowed fas r impact earnings resulting new standard significant may negative impact results operations item properties corporate headquarters including principal executive offices research facilities located foster city california location approximately square feet space proximately located buildings currently occupy buildings also tenant occupying remaining buildings addition lease two office buildings approximately square feet space house commercial clinical development activities leases two buildings expire june respectively gilead option renew two fiveyear terms addition june may gilead option purchase two buildings specified amounts also occupy facilities san dimas california location lease approximately square feet space houses research development activities manufacturing certain administrative functions leases expire november renewal options present addition lease adjacent warehouse facility square feet space use product distribution administrative functions lease expires november renewal options durham north carolina lease approximately square feet administrative office laboratory space sublease approximately square feet third parties lease expires october gilead option renew lease two sevenyear terms addition lease approximately square feet space aggregate sales marketing regulatory finance information technology human resource operations europe australia including prepaid year lease square foot manufacturing distribution facility ireland leases various expiration dates believe facilities adequate suitable least current nearterm future needs item legal proceedings complaints following cases allege large number defendants including gilead overcharged governmental entity named plaintiff pharmaceutical products furnished participants medicaid program general complaints assert claims federal state law except alabama state action includes state law claims seek treble damage attorneys fees litigations preliminary stage possible predict outcome indeed date gilead served process cases except county westchester v abbott laboratories et al intend defend cases vigorously outcome cases predicted time amounts accrued county westchester v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended include approximately defendants january city new york v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended approximately defendants january county rockland v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit originally name gilead defendant amended include claims gilead well approximately defendants january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit filed gilead approximately defendants january purported class action complaint filed november united states district court northern district california gilead certain executive officers complaint alleges defendants violated federal securities laws specifically sections b securities exchange act rule b securities exchange commission making certain allegedly false misleading statements omissions plaintiff seeks unspecified damages behalf purported class purchasers gileads securities period july october similar actions subsequently filed court issued order consolidating lawsuits single action december february court issued order appointing lead plaintiffs consolidated action april lead plaintiffs behalf purported class filed consolidated amended complaint june gilead individual defendants filed motion dismiss consolidated amended complaint january court granted defendants motion dismiss leave amend december two purported shareholder derivative lawsuits filed individual shareholders behalf gilead directors certain executive officers superior court state california county san mateo alleging among things defendants violated california corporations code breached fiduciary duties gilead gilead named nominal defendant plaintiffs seek unspecified damages behalf gilead connection alleged insider trading period july october defendants alleged breach fiduciary duties abuse control waste mismanagement two cases consolidated single action january third similar case filed february later consolidated prior two cases plaintiffs filed consolidated complaint amended two times recently november gilead demurred consolidated complaint court granted demurrer december plaintiffs filed motion leave file third consolidated amended complaint january court granted plaintiffs motion rendering complaint operative complaint intend demur complaint trial scheduled june also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position item submission matters vote security holders matters submitted vote securities holders quarter ended december part ii item market registrants common equity related stockholder matters common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter september implemented twoforone stock split form stock dividends share per share amounts periods presented restated reflect stock split february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception anticipate paying foreseeable future item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues purchased inprocess research development total costs expenses income loss operations gain sale oncology assets provision benefit income taxes income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted gilead sciences inc selected consolidated financial data continued december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible debt accumulated deficit total stockholders equity gilead recorded gain million related warrants eyetech completed initial public offering also recorded makewhole payment million related redemption million convertible senior debt gilead completed acquisition net assets triangle aggregate purchase price million approximately million purchase price allocated purchased inprocess research development also recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets sold shares osi common stock recognized loss sale marketable securities million shares partial consideration sale oncology assets completed sale oncology assets related technology osi pharmaceuticals inc recorded nonoperating gain million also recorded nonoperating gain million sale percent interest proligo gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle effective first quarter gilead adopted secs staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle february march september gilead implemented twoforone stock splits form stock dividend share per share amounts periods presented restated reflect stock splits cash dividends declared paid common stock item managements discussion analysis financial condition results operations executive summary operating results marked another year growth total revenues reaching billion higher ending cash cash equivalents marketable securities billion driven large part operating cash flows million year although several factors contributed improved financial performance two important drivers continued growth experienced hiv products portfolio comprised viread emtriva truvada well maintenance ambisome revenues amidst increasing competition given increased international sales favorable foreign currency environment europe viread sales increased year year comprised total product sales august launched truvada coformulation viread emtriva united states began launching truvada european union following regulatory approval february time depending treatment regimens prescribed physicians expect see truvada sales partially replace product sales viread emtriva increase future sales hiv products entered joint venture collaboration agreement bms december develop commercialize fixeddose combination gileads truvada bms sustiva united states understanding importance clear view wholesalers channel inventory signed inventory management agreements three major us wholesalers keeping strategy active product acquisition inlicensing rounded entering collaboration agreements area hcv operating results impacted acquisition assets triangle n january completed acquisition expand antiviral pipeline triangle development stage company particular focus potential therapies hiv including aids hbv aggregate purchase price million included cash paid million fair value stock options assumed million direct transaction costs million employee related costs million approximately million consideration paid allocated purchased inprocess research development represented fair value triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date result transaction related purchased inprocess research development charge operating loss million acquisition important us compounds acquired also opportunity provided us create truvada coformulation viread emtriva single pill dosed day see note consolidated financial statements information triangle acquisition september gilead completed twoforone stock split effected form stock dividend stockholders record august accordingly share per share amounts periods presented restated reflect stock split addition certain prior year amounts also reclassified conform current year presentation managements discussion analysis read conjunction consolidated financial statements notes included elsewhere report forwardlooking statements risk factors following discussion contains forwardlooking statements involve risks uncertainties risk factors discussion read conjunction consolidated financial statements notes included elsewhere report critical accounting policies estimates judgments discussion analysis financial condition results operations based upon consolidated financial statements prepared accordance accounting principles generally accepted united states preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts inventories clinical trial accruals tax provision base estimates historical experience various marketspecific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured record estimated reductions revenue expected returns expired products distributor fees government rebate programs medicaid reimbursements customer incentives cash discounts prompt payment estimates distributor fees based contractually determined fixed percentages sales estimates government rebate programs cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates programs estimates product returns including new products based ongoing analysis industry historical return patterns includes monitoring feedback receive sales force regarding customer use satisfaction reviewing inventory data available us us wholesaler inventory management agreements assist us monitoring channel inventory levels purchase thirdparty data monitor prescriptions well new products review long shelf life products sold similar channels monitor activities clinical trials key competitors assess potential impact future sales return expectations necessary expected returns marketed drugs generally low shelf life products ranges months truvada months ambisome viread united states conditions become competitive markets served drugs circumstances change may take actions increase product return estimates may offer additional customer incentives would result incremental reduction future revenue time return estimate changed new incentives offered contract revenue research development recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenue recognized manufacturing obligation fulfilled ratably development period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations result increase allowance doubtful accounts inventories write inventory based historical review quantity bad batches experienced manufacturing process expectations production inventory levels also perform quality control reviews individual raw material batches generally record inventory writeoffs based estimated obsolescence risk competition primarily shelf life products long however current assumptions future production inventory levels demand competition change actual market conditions less favorable projected management inventory writedowns may required could negatively impact product gross margins results operations clinical trial accruals record accruals estimated clinical preclinical study costs clinical preclinical studies performed third party contract research organizations cros costs significant component research development expenses incurred million million million respectively cro costs accrue costs clinical studies performed cros straightline basis term service period adjust estimates required based upon ongoing review level effort actually incurred cro initially estimate work performed contracts occurs ratably periods expected milestone event total contract completion date expected completion dates estimated based upon terms contracts past experience similar contracts estimates may may match actual services performed organizations determined patient enrollment levels measures activities specified contract result validate accruals quarterly written vendor confirmations detailed reviews activities performed significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total costs associated start activities trial patient enrollment gilead extensively outsources clinical trial activities usually performs small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management budgeted basis costs typically total contract value actual basis percentage range significantly wider many contracts either expanded reduced scope compared original budget startup costs particular trial change significantly startup costs usually occur within months contract established milestone event driven nature remaining activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed unit prices vary length six months single dose phase study two years complex phase study average length contract upper end range order provide long term safety efficacy data support commercial launches viread truvada hepsera emtriva december differences actual estimated activity levels particular study significant enough require material adjustment material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated however management receive complete accurate information vendors underestimated activity levels associated study given point time would record additional potentially significant research development expenses future periods tax provision develop income tax provision including deferred tax assets liabilities based significant management judgment evaluate realizibility deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance would reduce valuation allowance period determination first made adjustment made fourth quarter determined likely certain deferred tax assets would realized therefore released related valuation allowance resulted income tax benefit approximately million million respectively similarly determine would able realize part deferred tax assets valuation allowance would increase valuation allowance period determination first made future effective income tax rate may affected factors changes tax laws rates changes interpretation laws impact accounting employee stock options beginning second half overall changes future levels earnings research development capital spending management discussed development selection critical accounting policies audit committee gileads board directors audit committee reviewed disclosure presented relating results operations total revenues total revenue billion million million included total revenue product sales royalty revenue contract revenue includes revenue earned research development rd manufacturing collaborations product sales product sales consisted following thousands change change viread emtriva truvada total hiv products ambisome total product sales product sales increased compared compared due primarily increase volume sales within hiv products significant percentage product sales continue denominated foreign currencies use forward contracts hedge percentage forecasted international sales primarily denominated euro reduces eliminate fluctuations sales due changes foreign currency exchange rates losses revenue hedges reduced increases product sales million million million due fluctuations exchange rates however product sales mainly viread ambisome benefitted overall primarily increases exchange rates euro british pound comparison us dollar million comparing million comparing prior experienced significant fluctuations us distribution channel inventory levels due speculative purchasing major wholesalers result experienced increased quarter quarter sales volatility purchasing patterns order help alleviate fluctuations n july entered inventory management agreements imas amerisourcebergen drug corporation cardinal health inc mckesson corporation three major pharmaceutical wholesalers distribute percent portfolio products sell united states agreements implemented limit speculative buying help ensure wholesaler purchasing consistent customer demand predictable agreements agreed pay wholesalers fee exchange product distribution inventory management services market research information return goods processing assistance counterfeit product detection services fees recorded reduction product sales consolidated statements operations additionally terms agreements wholesaler agreed exceed specified maximum levels inventory hand end december believe three major wholesalers inventories onhand gilead products less one months supply compliance contractually specified levels viread emtriva truvada approved sale united states october july august respectively viread emtriva approved sale european union february october respectively sales viread total product sales respectively viread sales million us sales increase versus million international sales increase versus viread sales million us sales increase versus million international sales increase versus since emtrivas introduction july sales increased significantly million million also since august truvada approved sale united states product sales totaled million december total hiv product sales million higher compared due favorable european currency environment majority relates viread sales believe product sales mix changes patients currently taking viread andor emtriva switching truvada looking hiv products sales collectively relevant basis periodoverperiod comparison sales hiv products percentage total product sales respectively expect sales hiv products billion billion full year sales ambisome total product sales respectively hiv hbv product sales continue increase ambisome sales decreasing percentage total product sales ambisome sales million us sales decrease versus million international sales increase versus ambisome sales million us sales decrease versus million international sales increase reported ambisome sales million higher due favorable currency environment compared volume basis ambisome sales united states decreased sales volume europe increased slightly compared analyzing decrease us sales important note us product sales decreased comparing volume decreased discussion us ambisome sales relates solely sales ambisome fujisawa recorded manufacturing cost due greater manufacturing efficiencies per unit manufacturing cost ambisome decreased thereby decreasing revenues reported sales fujisawa royalties earn sales ambisome fujisawa discussed continuing competition expect ambisome sales range million million royalty revenue recorded royalty revenues million compared million million three year period significant source royalty revenue resulted sales tamiflu roche sales ambisome united states fujisawa copromotion arrangement us royalty revenues earned sales tamiflu million million million respectively royalty revenues earned sales ambisome fujisawa million million million respectively difficult estimate third party product sales record royalty revenue roche one quarter arrears due severe influenza epidemic united states late early royalty revenues increased substantially first second quarters increased awareness discussion supply influenza treatments increased roches sales tamiflu consequently royalties third fourth quarters contract revenue total contract revenue million compared million million contract revenue consisted primarily million research milestone revenue earned eyetech pharmaceuticals included million net milestone payments earned upon filing new drug applications eyetech europe united states macugen pegaptanib sodium injection primary source contract revenue consisted million license fees earned conjunction licensing agreement eyetech macugen contract revenue primarily consisted million due licensing selex process patent estate archemix due collectibility concerns recognized cash basis million milestone payments roche european prophylaxis treatment approvals tamiflu december completed sale oncology assets osi terms agreement entitled additional payments osi million either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal products included sales manufacturing facility san dimas california recognized million million million respectively contract revenue manufacturing agreement cost goods sold product gross margins following table indicates cost goods sold product gross margins thousands change change total product sales cost goods sold gross margin percentage gross margin relatively flat positive impact improvements certain manufacturing processes favorable foreign currency environment offset changes product sales mix comparing gross margin improved primarily due change product mix viread higher margin product contributed significantly net product sales changes foreign currency exchange rates impact gross margins since price products currency country products sold significant majority manufacturing costs us dollars example increase value foreign currencies relative us dollar positively impact gross margins since manufacturing costs remain approximately revenues translated us dollars increase although weakening us dollar positively impacted gross revenues gross margins full effect foreign currency exchange rates moderated hedging program forecasted international sales except potential impact unpredictable uncontrollable changes exchange rates relative us dollar mix product sales various hiv products hepsera ambisome expect gross margins consistent within range research development expenses following table summarizes research development expenses major components thousands change change research clinical development pharmaceutical development total three major categories research development rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various support facilities related costs research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis prior clinical development consisted clinical trial expenses phases phase united states phase european clinical trials included sales general administrative sga order better reflect nature european phase clinical trials began recording clinical trial expenses research development order consistent current year presentation million million expenses reclassified selling general administrative research development expenses years ended december respectively million increase rd expenses primarily attributable increased salaries million due largely higher headcount increased contract research organization costs million associated increased clinical activities well million research license fees paid us relation hepatitis c collaboration agreements effective fourth quarter new collaborations entered achillion genelabs required us pay aggregate license fees million expensed rd underlying technology alternative future use increase rd activity partially offset decrease spending due discontinuation two programs gs gs focused development certain hiv investigational products also important note rd expenses included reimbursement gilead million settlement contractual dispute vendor million increase rd spending versus primarily attributable increased salaries million due largely higher headcount increased clinical supplies costs million increased clinical trials costs associated development emtriva truvada coformulation viread emtriva also mentioned settled contractual dispute vendor resulted reimbursement us million recorded research development expense expect rd expenses approximately million million estimated increase expenses levels reflects increased spending internal research development efforts well costs associated postmarketing studies support products excludes expenses may incur associated potential collaborations strategic acquisitions including license milestone fees cost sharing arrangements impact accounting employee stock based compensation beginning second half industry reports indicate biopharmaceutical company generally takes years average years research develop bring market new prescription medicine united states averages generally consistent projects undertake internally although recent product development timelines slightly accelerated basis drug development united states process includes several steps defined fda process begins filing ind successful allows opportunity clinical study potential new medicine clinical development typically involves three phases study phase generally accounts average seven years drugs total development time significant costs associated clinical development phase trials tend longest largest studies conducted drug development process currently products development phase studies successful development products highly uncertain completion dates rd expenses vary significantly product difficult predict even successful development fda approval product undertake additional studies try expand products label market potential complete discussion risks uncertainties associated completing development products see risk factors affect gilead section item selling general administrative expenses following table highlights year year changes selling general administrative expenses thousands change change selling general administrative sga expenses year ended december million compared million year ended december includes reclassification phase iv clinical trial expenses incurred rd million significant increase expenses compared primarily due increased salaries million due largely higher headcount increased consulting fees million related sarbanesoxley compliance business strategy consulting well increased costs million relating speakers programs grants journal advertising remainder increase sga expenses compared due increased global marketing efforts increased infrastructure required support growth business part infrastructure investments implemented reorganization sales marketing functions newly created commercial division conjunction reorganization created filled new position executive vicepresident commercial operations responsibility global commercial operations strategy product portfolio increase expenses compared includes reclassification phase iv clinical trial expenses rd million primarily due increased salaries million due largely higher headcount increase hedging costs million increased costs million relating marketing meetings grants well increased general directors officers insurance million remainder increase sga expenses due global sales marketing efforts including expansion us european sales forces increased infrastructure required support growth business expect sga expenses approximately million million primarily due anticipated launch costs truvada european union well ongoing investment global commercial organization hiring promotional programs excludes expenses may incur associated potential collaborations strategic acquisitions impact applying new standard accounting employee stock based compensation beginning second half purchased inprocess research development connection acquisition net assets triangle completed january recorded purchased inprocess research development expenses million first quarter charge due triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date value purchased inprocess research development determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete development approval product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets summary programs acquisition date updated subsequent developments february follows estimated acquisition date fair value program description status development millions emtricitabine hiv nucleoside analogue four phase studies completed shown prior acquisition date us inhibitor hiv replication marketing approval received patients fda july emtriva european union approval received european commission october emtricitabinetenofovir df fixeddose acquisition date work fixed dose combination coformulation tenofovir commenced potential co hiv therapy emtricitabine formulation except extent work emtricitabine single agent progressing march applications marketing approval submitted united states european union august marketing approval united states received fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union received february amdoxovir hiv purine dioxolane program phase trials nucleoside may offer acquisition date terminated advantages licensing agreement emory marketed nucleosides university university activity georgia research foundation inc drug resistant development discontinued viruses exhibited patients hiv infection clevudine hbv pyrimidine nucleoside program phase trials analogue acquisition date august shown inhibitor licensing agreement bukwang hbv replication patients pharm ind co ltd terminated chronically infected development discontinued hbv emtricitabine hbv inhibitor hbv one phase trial completed replication patients december chronically infected hbv asset impairment recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment noncash charge driven decision december terminate liposomal research development activities san dimas discontinue daunoxome product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related estimated undiscounted cash flows wrote carrying value longlived assets estimated fair value subsequent decision discontinue daunoxome product line received unanticipated requests europe asking gilead reconsider selling daunoxome result requests management decided continue selling product certain countries still evaluating supply sales strategy respect daunoxome accordance us generally accepted accounting principles new cost basis impaired assets adjusted new facts circumstances gain loss marketable securities pursuant agreement eyetech entered march received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted fair value warrant resulting gain million time fair value warrant estimated using blackscholes valuation model volatility rate discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares owned realized gain approximately million included interest income net year ended december july sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million year ended december makewhole payment debt redemption october gilead called redemption outstanding convertible senior notes due december november convertible senior notes called provisional redemption based upon market price gilead common stock exceeding certain thresholds aggregate principal amount outstanding notes million convertible senior notes redeemable redemption price equal principal amount notes plus cash payment equal accrued unpaid interest redemption date cash makewhole payment equal per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date interest convertible senior notes ceased accrue redemption date remaining right holders thereafter receive redemption payment including accrued unpaid interest redemption date makewhole payment alternatively note holders could elect convert notes shares gilead common stock price per share shares gilead common stock per principal amount notes holders substantially outstanding notes converted notes shares gileads common stock prior november redemption date result conversions shares common stock issued note holders connection redemption gilead paid aggregate makewhole payments million note holders interest income net recorded interest income million compared million million increase compared primarily attributable higher cash balances yields past year decrease compared attributable significant decline interest rates lower average cash balance due acquisition net assets triangle purchase foster city campus partially offset positive cash flow operations interest income depend principally upon prevailing interest rates level cash cash equivalent marketable securities balances interest expense incurred interest expense million compared million million decrease primarily due conversion million convertible subordinated debt shares common stock december outstanding debt consisted million convertible senior debt issued december november converted convertible senior notes significant increase due full year interest million convertible senior notes issued december interest expense consisted primarily interest million convertible subordinated notes converted shares common stock december expect interest expense decrease compared primarily due conversion million convertible senior notes november provision benefit income taxes provision benefit income taxes million million million respectively effective income tax rate differs us federal statutory rate generally due state taxes offset recognition previously unbenefitted net operating losses tax credit carryforwards certain earnings taxed foreign tax rate jurisdictions lower tax rates us taxes provided earnings planned permanently reinvested outside united states tax benefit includes reversal valuation allowance certain deferred tax assets december concluded likely would realize portion benefit related deferred tax assets accordingly reduced valuation allowance assets recorded tax benefit million recognition deferred tax assets impact cash flows partially offsetting tax benefit income tax expense associated income earned foreign subsidiaries foreign losses benefitted lower tax rates nontax deductibility purchased inprocess research development significant net operating loss carryforwards used reduce us tax liability excluding benefit relating reversal valuation allowance write purchased inprocess research development effective tax rate income tax expense primarily associated income earned foreign subsidiaries significant net operating losses united states provision reduced change us income tax law law allowed net operating loss carryforward deductions offset alternative minimum taxable income resulting reduction us income tax recorded previous years million october american jobs creation act ajca signed law ajca allows deduction certain foreign earnings repatriated defined ajca may elect apply provision qualifying earnings repatriations fiscal started evaluation effects repatriation provision however expect able complete evaluation congress treasury department provide additional clarifying language key elements provision expect complete evaluation effects repatriation provision within reasonable period time following publication additional clarifying language range possible amounts considering repatriation provision zero million maximum amount allowable us defined ajca currently related potential range impact income taxes reasonably estimated liquidity capital resources cash cash equivalents marketable securities totaled billion december million december increase million primarily due net cash provided operations million proceeds issuances stock employee stock plans million partially offset capital expenditures million cash decrease million primarily due acquisition triangle net cash impact million purchase foster city campus million capital expenditures million partially offset proceeds issuance stock employee stock plans million working capital december billion compared billion december significant changes working capital included million decrease current deferred tax assets offset million increase accounts receivable million increase inventory million decrease current deferred tax assets primarily due utilization net operating losses tax credit carryforwards offset taxable income accounts receivable increase million primarily due increased sales viread united states europe sales new product truvada launched united states latter half million increase inventory primarily due increase purchase raw materials production viread truvada inventory meet increasing sales demand current liabilities increased million primarily due following million increase medicaid rebate obligations associated higher sales viread million increase deferred revenue primarily due royalties received roche million increase liability associated fair value forward currency contracts us dollar continued weaken european currencies million increase accounts payable primarily due increases raw material purchases support viread truvada sales growth million increase increased compensation costs employee benefits added headcount increase million distributors fees owed yet paid inventory management agreements entered july increase current liabilities partially offset million decrease accrued clinical preclinical expenses result decreasing activity associated clinical trial programs viread hepsera towards end made capital expenditures million compared million million expenditures primarily domestic international facilities improvements including approximately million associated completion pilot plant foster city used develop drug processes prepare materials supply clinical trials well additional spending laboratory manufacturing equipment accommodate growth capital expenditures related research development million spent million spent million spent expect capital spending million million due increased infrastructure needs higher rd spending believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including commercial performance current future products progress scope research development efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring manufacturing capabilities additional office facilities possibility acquiring companies new products establishment additional collaborative relationships companies defense costs associated settlements adverse results litigation may future require additional funding could form proceeds equity debt financings universal shelf registration statement filed december potential issuance million securities additional collaborative agreements corporate entities funding required assure available favorable terms subsidiaries established variety subsidiaries various countries purpose conducting business locations subsidiaries consolidated financial statements variable interest entities unconsolidated financial statements also involved nonexchange traded commodity contracts accounted fair value commercial commitments related parties except employee loans contractual obligations contractual obligations form capital operating leases noncancelable raw material supply arrangements clinical research organization contracts following table summarizes contractual obligations december thousands payments due period less one contractual obligations total year years years years capital lease obligations operating lease obligations capital commitments inventory purchase obligations clinical trials total december firm capital project commitments approximately million relating facilities improvement addition budgeted significant capital expenditures mainly due anticipated increased infrastructure needs higher rd spending may capital spending future years december firm commitments purchase active pharmaceutical ingredients amounts disclosed represent minimum purchase requirements actual purchases may differ significantly amounts december several clinical studies various clinical trial phases significant expenditures contract research organizations although contracts cancelable generally cancelled contracts amounts reflect commitments based existing contracts reflect future modifications existing contracts anticipated potential new contracts recent accounting pronouncement december fasb issued sfas revised sharebased payment sfas r revision sfas sfas r supercedes apb amends sfas statement cash flows sfas r requires sharebased payments employees directors including grants stock options recognized statement operations based fair values beginning first interim annual period june early adoption permitted pro forma disclosures previously permitted sfas longer alternative financial statement recognition expect adopt sfas r third quarter fiscal beginning july sfas r must determine appropriate fair value model used valuing sharebased payments amortization method compensation cost transition method used date adoption transition methods include prospective retroactive adoption options retroactive options prior periods may restated either beginning year adoption periods presented prospective method requires compensation expense recorded unvested stock options restricted stock beginning first quarter adoption sfas r retroactive methods would record compensation expense unvested stock options restricted stock beginning first period restated currently evaluating requirements sfas r well option valuation methodologies related employee director stock options employee stock purchase plan although yet determined method adoption effect adopting sfas r expect adoption sfas r material impact consolidated results operations earnings per share impact adoption sfas r predicted time depend among things levels sharebased payments granted future method adoption option valuation method used sfas r also requires benefits tax deductions excess recognized compensation cost reported financing cash flow rather operating cash flow required current literature requirement reduce net operating cash flows increase net financing cash flows periods adoption estimate amounts future depend among things employees directors exercise stock options amount operating cash flows recognized prior periods related tax deductions million million million respectively current estimates option values using blackscholes method may indicative results valuation methodologies ultimately adopted gilead item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states well sales activities europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business mitigate impact changes currency exchange rates cash flows foreign currency sales transactions enter foreign exchange forward contracts hedge foreign currencydenominated net monetary assets liabilities significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition prior hedge exposure impact fluctuating foreign exchange rates forecasted sales january began use forward contracts hedge percentage forecasted international sales primarily denominated euro currency recent years due weakening us dollar foreign currency exchange fluctuations positively impacted product sales gross margin however full impact favorable foreign currency environment moderated hedge contracts entered following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands fair value currency notional amount average rate december british pound euro australian dollar total notional amount million fair value million open foreign exchange forward contracts december compares total notional amount million fair value million open foreign exchange forward contracts december significant increase outstanding contracts primarily attributed projected increase revenues forecast periods interest rate risk portfolio availableforsale investment securities fixedrate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates fixedrate interestbearing assets fixedrate liabilities december dollars thousands years e ndin g decem ber df eca eir v ba erl u e thereafter total assets availableforsale securities average interest rate liabilities longterm obligations including current portion average interest rate longterm obligations consist capital leases operating leases net noncancelable subleases interest portion payments due included international credit risk accounts receivable balance december million compared million december million december growth accounts receivable balances primarily due higher product sales viread united states europe certain countries payments typically slow primarily greece italy portugal spain accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase credit risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled approximately million approximately million days past due date experienced significant losses respect collection accounts receivable believe substantially accounts receivable balances collectible perform credit evaluations customers financial condition generally required collateral item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined sec rules controls procedures company designed ensure information required disclosed company reports files securities exchange act exchange act recorded processed summarized reported within required time periods based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined securities exchange act rule af internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including principal executive officer principal financial officer conducted evaluation effectiveness internal control financial reporting using criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework based evaluation concluded internal control financial reporting effective december ernst young llp independent registered public accounting firm audited consolidated financial statements included herein issued audit report assessment internal control financial reporting c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information none part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statement headings nominees executive officers board directors audit committee compliance section securities exchange act gileads written code ethics applies directors employees including executive officers code ethics available gileads website httpwwwinvestorsgileadcom changes waivers code ethics disclosed website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee report item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings compensation committee interlocks insider participation certain transactions executive compensation item principal accountant fees services information required item incorporated reference sections proxy statement heading principal accountant fees services part iv item exhibits financial statement schedules following documents filed part index list financial statements reports independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc dated november agreement plan merger among registrant simbolo acquisition sub inc wholly owned subsidiary registrant triangle pharmaceuticals inc dated december amended restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc agreement plan merger dated february among registrant gazelle acquisition sub inc nexstar pharmaceuticals inc registration rights agreement dated december registrant goldman sachs co first amendment amended restated rights agreement dated october registrant mellon investor services llc form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees registrants incentive stock option plan related agreements registrants supplemental stock option plan related agreements registrants employee stock purchase plan amended march registrants stock option plan amended restated april amended january amended january form nonqualified stock option issued certain executive officers directors letter agreement dated september registrant iocbrega exhibits certain confidential information omitted amendment agreement dated october registrant iocbrega related license agreements exhibits certain confidential information omitted amendment agreement dated december registrant iocbrega registrants nonemployee directors stock option plan amended january amended january development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc dated september certain confidential information omitted nexstar pharmaceuticals incs incentive stock plan adopted february amended nexstar pharmaceuticals incs director option plan adopted july vestar inc stock option plan lease dated february registrant majestic mapa properties llc lease dated february registrant majestic mapa properties llc assignment royalty agreement dated december effective june vestar inc city hope national medical center agreement fujisawa usa inc vestar inc dated august amendment thereto dated may amendment agreement fujisawa usa inc vestar inc dated april fujisawa usa inc vestar inc certain confidential information omitted amendment agreement fujisawa usa inc registrant dated march agreement fujisawa usa inc vestar inc dated august lease dated july among registrant majestic realty co majesticmapa properties llc first amendment thereto dated march license distribution agreement dated september sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc certain confidential information omitted settlement agreement dated august among nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omitted amendment dated april sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc license distribution agreement dated september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement dated april gilead world markets limited glaxo group limited employment agreement dated july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch dated august license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd dated march license agreement triangle pharmaceuticals inc emory university coviracil ftc dated april exclusive license agreement among triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may settlement agreement among triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may first amendment license agreement triangle pharmaceuticals inc emory university dated may first amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated july second amendment license agreement triangle pharmaceuticals inc emory university dated july supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories dated july settlement exclusive license agreement among triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august second amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated august manufacturing supply agreement gilead world markets ltd ppgsipsy sas entered january gilead sciences inc severance plan adopted effective january third amendment license agreement triangle pharmaceuticals inc emory university dated may lease agreement dated june th registrant gra associates limited llc premises located university drive durham north carolina master clinical commercial supply agreement dated january among gilead world markets ltd gilead sciences inc patheon inc toll manufacturing agreement dated august among gilead world markets ltd gilead sciences inc altana pharma oranienburg gmbh licensing agreement dated march amended may december april gilead sciences inc eyetech pharmaceuticals inc amendment licensing agreement dated may eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement dated december eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement dated august eyetech pharmaceuticals inc gilead sciences inc amendment dated may licensing agreement dated april glaxo group limited gilead world markets limited amendment dated january licensing agreement dated april glaxo group limited gilead world markets limited employment agreement dated april gilead sciences inc mark l perry gilead sciences inc equity incentive plan amended july collaboration agreement among gilead sciences inc gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated december th amendment license agreement triangle pharmaceuticals inc emory university dated may subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature section certification section certification section certification filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed march incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed march exhibit nexstar pharmaceuticals incs registration statement form file incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals incs registration statement form amended incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs current report form k filed september incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act gilead sciences inc consolidated financial statements years ended december contents reports independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december audits also included financial statement schedule listed item annual report financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states effectiveness gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated march expressed unqualified opinion thereon ernst young llp palo alto california march report independent registered public accounting firm board directors stockholders gilead sciences inc audited managements assessment included accompanying managements annual report internal control financial reporting included item gilead sciences inc maintained effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion managements assessment opinion effectiveness gilead sciences incs internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment gilead sciences inc maintained effective internal control financial reporting december fairly stated material respects based coso criteria also opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december related financial statement schedule report dated march expressed unqualified opinion thereon ernst young llp palo alto california march gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid expenses total current assets property plant equipment net noncurrent deferred tax assets ther noncurrent assets liabilities stockholders equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits accrued liabilities deferred revenue longterm obligations due within one year total current liabilities longterm deferred revenue longterm obligations due one year convertible senior debt commitments contingencies stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss deferred stock compensation accumulated deficit otal stockholders equity see accompanying notes gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenue contract revenue total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development asset impairment total costs expenses income loss operations gain loss marketable securities makewhole payment convertible debt redemption interest income net interest expense income loss provision benefit income taxes provision benefit income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted see accompanying notes gilead sciences inc consolidated statement stockholders equity thousands accumulated additional comprehensive total commo n stock paidin income deferred stock accumulat ed stockholde rs shares amount capital loss compensation deficit equity ba nla en tc ie n ca ot mde ec ember unrealized loss availableforsale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions balance ecember net loss unrealized loss availableforsale securities net foreign currency translation adjustment unrealized loss ca sh flow hedges net comprehensive loss conversion convertible subordinated debt acquisition triangle pharmaceuticals inc issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock co mpensation compensatory stock transactions balance dec ember net income unrealized loss availableforsale securities net foreign currency translation adjustment unrealized loss cash f low hedges net comprehensive income conversion convertible senior debt net debt issuance costs issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock co mpensation compensatory stock transactions b alance december see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided operating activities depreciation amortization purchased inprocess research development asset impairment loss disposal property plant equipment loss gain marketable securities deferred tax assets tax benefits employee stock plans noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable accrued liabilities deferred revenue net cash provided operating activities investing activities purchases marketable securities proceeds sales maturities marketable securities acquisition triangle net assets net cash acquired acquisition real estate capital expenditures issuance note triangle net cash provided used investing activities financing activities proceeds issuances common stock repayments longterm debt proceeds issuance convertible senior notes net issuance costs net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities common stock issued upon conversion debt reclassification deferred debt issuance costs additional paidin capital upon conversion debt see accompanying notes gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead sciences inc gilead incorporated delaware june biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company revenues eight approved products marketing operations eleven countries focus research clinical programs antiinfectives currently market viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cmv retinitis roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us january eyetech started market macugen pegaptanib sodium injection united states treatment neovascular agerelated macular degeneration milestone royalty paying collaborative agreement us accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries significant intercompany transactions eliminated certain prior year amounts reclassified consistent current year presentation see research development expenses stock splits march september gilead completed twoforone stock splits effected form stock dividends stockholders record february august respectively accordingly share per share amounts periods presented reflect stock splits critical accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis management evaluates estimates including related revenue recognition allowance doubtful accounts inventories clinical trial accruals tax provision base estimates historical experience various market specific relevant assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured provide customers general right product return however accept returns products united states expired one year expiration products gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued deemed damaged defective received customer upon recognition revenue product sales provisions made estimated future returns products may expire government reimbursements certain distributor fees customer incentives cash discounts prompt payment estimates government reimbursements cash discounts based contractual terms expectations regarding utilization rates programs estimates distributor fees based contractual terms estimates product returns including new products based ongoing analysis industry historical return patterns well third party data assist us monitoring channel inventory levels subsequent prescriptions contract revenue research development recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenue recognized manufacturing obligation fulfilled ratably development period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales hepsera tamiflu vistide recognized received quarter following quarter corresponding sales occur shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components research development rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations cros materials supplies overhead allocations consisting various administrative facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials pharmaceutical development costs consist product formulation chemical analysis gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued charge research development costs including clinical preclinical study costs expense incurred consistent statement financial accounting standards sfas accounting research development costs costs significant component rd expenses clinical preclinical studies performed third party cros accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cro initially estimate work performed contracts occurs ratably service periods expected milestone event total contract completion date expected completion dates estimated based upon terms contracts past experience similar contracts monitor levels performance contract including extent patient enrollment activities communications cros adjust estimates required quarterly basis expenses reflect actual effort expended cro material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated contracts include additional termination payments become due payable gilead terminates contract additional termination payments recorded contract terminated order better reflect nature european phase clinical trials gilead began recording costs rd expenses amounts previously classified selling general administrative expenses consolidated statements operations order consistent current period presentation million million expenses reclassified selling general administrative research development expenses years ended december respectively advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation accordance provisions sfas accounting stockbased compensation amended sfas accounting stockbased compensationtransition disclosure sfas elected continue follow accounting principles board opinion apb accounting stock issued employees interpretation fin accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stock option plans apb exercise price gileads employee director stock options equals exceeds fair value underlying stock date grant compensation expense recognized although elected follow intrinsic value method prescribed apb evaluate approach accounting stock options light recent industry regulatory developments gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued table presents net income loss basic diluted net income loss per share compensation cost gilead nexstar pharmaceuticals inc nexstar triangle stock option plans employee stock purchase plan espp determined based estimated fair value awards plans grant purchase date accordance sfas thousands except per share amounts year ended december net income lossas reported add stockbased employee compensation expense included reported net income loss net related tax effects deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income loss net income loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility employee stock options characteristics significantly different traded options models may developed future may generate fair values differ calculated based blackscholes calculate estimated fair value awards used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued fourth quarter refined volatility assumptions used arrive fair value stock awards purposes calculating expected volatility rate began using time period better reflected current stage development length time public company several drug approvals past years enabled us achieve positive cash flow operations believe estimated volatility rates better reflect expected volatility common stock future recent threeyear time period used purposes calculating expected volatility twoyear time period used derive weighted average volatility fourth quarter weighted average volatility first three quarters weighted average estimated fair value espp shares purchased earnings loss per share basic earnings loss per share calculated based weightedaverage number common shares outstanding year diluted earnings loss per share calculated based weightedaverage number common shares dilutive securities dilutive potential common shares resulting assumed exercise outstanding stock options equivalents determined based treasury stock method dilutive potential common shares resulting assumed conversion convertible notes determined based ifconverted method following table reconciliation numerator denominator used calculation basic diluted earnings loss per share thousands year ended december numerator net income loss used calculation basic earnings loss per share interest expense makewhole payment convertible debt redemption net income loss used calculation diluted earnings loss per share denominator weightedaverage common shares outstanding used calculation basic earnings loss per share effect dilutive securities stock options equivalents convertible debt weightedaverage common shares outstanding used calculation diluted earnings loss per share gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued diluted net loss per share excludes prorated effect million convertible subordinated notes would convert approximately million shares effect million convertible senior notes would convert approximately million shares outstanding stock options equivalents million shares effects antidilutive diluted net income per share excludes effects million convertible subordinated notes would convert approximately million shares million convertible senior notes would convert approximately million shares effects assumed conversions antidilutive cash cash equivalents consider highly liquid investments insignificant interest rate risk remaining maturity three months less purchase date cash equivalents may enter overnight repurchase agreements purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repurchase agreements repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist solely debt securities time purchase reevaluate designation balance sheet date marketable securities classified availableforsale carried estimated fair values reported either cash equivalents marketable securities december cash cash equivalents include million securities designated availableforsale million december unrealized gains losses available forsale securities excluded earnings reported separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline reductions required past three years result entering collaborations time time gilead may hold stock nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review investments indicators impairment investments nonmarketable securities material periods presented recognized otherthantemporary declines past three years gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued concentrations risk subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales significant amount trade accounts receivable arises product sales viread united states europe certain countries payments typically slow primarily greece italy portugal spain accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled approximately million approximately million days past due based contractual terms receivables december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable net allowances reflected consolidated balance sheet collectible perform credit evaluations customers financial condition generally required collateral many materials utilize operations made one facility example depend single suppliers high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol used manufacture ambisome well currently one contract manufacturer qualified manufacture truvada tablets supplies suppliers interrupted reason may unable ship viread ambisome hepsera emtriva vistide truvada supply products development clinical trials accounts receivable trade accounts receivable recorded net allowances cash discounts prompt payment doubtful accounts government chargebacks sales returns estimates cash discounts government chargebacks sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual obligations historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices historically level uncollectible accounts receivable written insignificant consistent managements expectations gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventory order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized historically inventory writedowns insignificant consistent managements expectations property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method land depreciated estimated useful lives follows years description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements life related lease office computer equipment includes capitalized computer software capitalized software purchased internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction progress included property plant equipment interest capitalized insignificant intangible assets intangible assets definite lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable inplace lease intangible asset amortized remaining period related lease term discussed note impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued significant adverse change legal factors business climate affects value asset adverse action assessment us food drug administration another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets liabilities grouped lowest level identifiable cash flows largely independent cash flows generated groups undiscounted future cash flows less carrying amount asset impairment loss measured excess carrying value asset estimated fair value recognized cash flow estimates used calculations based managements best estimates using appropriate customary assumptions projections time foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income loss accumulated separate component stockholders equity net foreign exchange transaction gains losses reported selling general administrative expenses consolidated statements operations realized losses million million realized gains million hedge certain foreign currency exposures related outstanding trade accounts receivable forecasted product sales foreign exchange forward contracts general market risks contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major us banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions write options presently hedge net investment foreign subsidiaries accounting hedges net monetary assets liabilities record changes fair value selling general administrative expense derivative instruments designated hedges sfas nos accounting derivative instruments hedging activities collectively referred sfas gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued selectively hedge anticipated currency exposures purchasing forward contracts hedge anticipated product sales next year less designated cash flow hedges sfas unrealized gains losses underlying forward contracts recorded comprehensive income recognized earnings forecasted transaction occurs december december net unrealized losses open foreign exchange forward contracts million million respectively losses revenue hedges reduced product sales million million million notional amounts forward exchange contracts outstanding million december million december contracts maturities one year less see note discussion derivative financial instruments fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain non current assets forward foreign exchange contracts accounts payable longterm obligations cash cash equivalents marketable securities forward foreign exchange contracts hedge accounts receivable reported respective fair values balance sheet forward foreign exchange contracts hedge firmly committed purchases forecasted sales recorded fair value net related deferred gain loss resulting reported net balance zero gilead called convertible senior notes redemption october converted million shares gilead common stock november december fair value convertible senior notes million carrying value million gilead called convertible subordinated notes redemption november converted million shares gilead common stock december fair value convertible senior notes december determined obtaining quotes market maker notes believe remaining financial instruments reported consolidated balance sheet amounts approximate current fair values recent accounting pronouncement december fasb issued sfas revised sharebased payment sfas r revision sfas sfas r supercedes apb amends sfas statement cash flows sfas r requires sharebased payments employees directors including grants stock options recognized statement operations based fair values beginning first interim annual period june early adoption permitted pro forma disclosures previously permitted sfas longer alternative financial statement recognition expect adopt sfas r third quarter fiscal beginning july sfas r must determine appropriate fair value model used valuing sharebased payments amortization method compensation cost transition method used date adoption transition methods include prospective retroactive adoption options retroactive options prior periods may restated either beginning year adoption periods presented prospective method requires compensation expense recorded unvested stock options restricted stock beginning first quarter gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued adoption sfas r retroactive methods would record compensation expense unvested stock options restricted stock beginning first period restated currently evaluating requirements sfas r well option valuation methodologies related employee director stock options employee stock purchase plan although yet determined method adoption effect adopting sfas r expect adoption sfas r material impact consolidated results operations earnings per share impact adoption sfas r predicted time depend among things levels sharebased payments granted future method adoption option valuation method used sfas r also requires benefits tax deductions excess recognized compensation cost reported financing cash flow rather operating cash flow required current literature requirement reduce net operating cash flows increase net financing cash flows periods adoption estimate amounts future depend among things employees directors exercise stock options amount operating cash flows recognized prior periods related tax deductions million million million respectively current estimates option values using blackscholes method may indicative results valuation methodologies ultimately adopted gilead derivative financial instruments derivatives recognized either assets liabilities measured fair value enter foreign currency forward contracts hedge changes fair value significant monetary assets liabilities denominated nonfunctional currency derivative designated meets definition fair value hedge changes fair value derivative hedged item recognized earnings enter foreign currency forward contracts generally maturities months less hedge future cash flows related forecasted product sales foreign denominated currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified hedges related forecasted foreign currency product sales designated documented inception respective hedge designated cash flow hedges evaluated effectiveness monthly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract estimated change fair value underlying hedged item effective component hedge recorded accumulated comprehensive income see note substantially values reported accumulated comprehensive loss december reclassified earnings within months residual changes fair value instruments including resulting cancellation dedesignation hedge contracts ineffectiveness recognized immediately selling general administrative expense impact ineffectiveness significant consolidated statements operations losses million million million hedging contracts recognized consolidated statements operations respectively gilead sciences inc notes consolidated financial statements continued december derivative financial instruments continued result entering collaboration arrangement gilead held warrants purchase stock nonpublic company completed initial public offering january see notes warrants exercised february warrants net exercise feature pursuant sfas classified derivative instruments noncurrent assets december acquisition triangle pharmaceuticals inc january completed acquisition net assets triangle expand antiviral pipeline triangle development stage company particular focus potential therapies hiv including aids hepatitis b virus hbv triangles portfolio consisted several drug candidates clinical trials including emtriva emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july us food drug administration fda granted marketing approval emtriva treatment hiv october european commission granted marketing authorisation emtriva fifteen member states european union triangle acquisition accounted acquisition assets rather business combination accordance criteria outlined emerging issues task force triangle development stage company commenced planned principal operations lacked necessary elements business completed products therefore ability access customers results operations triangle since january included consolidated financial statements primarily consist research development expenses lesser extent selling general administrative expenses december part arrangements contemplated proposed acquisition triangle gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissory note upon completion acquisition january loan eliminated consolidated financial statements aggregate purchase price million including cash paid million outstanding stock fair value stock options assumed million direct transaction costs million employee related costs million part purchase established workforce reduction plan also assumed obligations various change control agreements acquisition date approximately million employee termination costs change control obligations recorded liability paid period approximately two years december approximately remained liability gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued following table summarizes purchase price allocation january thousands net tangible assets assembled workforce deferred compensation nprocess research development million net tangible assets includes assumed liabilities million million value assigned assembled workforce amortized three years estimated useful life asset deferred compensation represents intrinsic value unvested stock options assumed transaction amortized remaining vesting period options extends january upon reversal deferred tax asset valuation allowance fourth quarter remaining million assembled workforce asset eliminated see note gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued approximately million purchase price allocated purchased inprocess research development represented fair value triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date summary programs acquisition date updated subsequent developments follows estimated acquisition date fair value program description status development millions emtricitab ine f nucleoside analogue four phase studies completed prior hiv shown acquisition date us marketing approval inhibitor hiv replication received fda july patients emtriva european union approval received european commission october emtricitabine fixeddose coformulation acquisition date work tenofovir df tenofovir emtricitabine commenced potential coformulation fixed dose except extent work combination emtricitabine single agent hiv progressing march applications therapy marketing approval submitted united states european union august marketing approval united states received fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union received february amdoxovir purine dioxolane program phase trials hiv nucleoside may offer acquisition date terminated advantages licensing agreement emory university marketed nucleosides university georgia research activity foundation inc development drug resistant discontinued viruses exhibited patients hiv infection clevudine pyrimidine nucleoside program phase trials hbv analogue acquisition date august licensing shown inhibitor agreement bukwang pharm ind co hbv replication patients ltd terminated development chronically infected hbv discontinued emtricitabine inhibitor hbv one phase trial completed hbv replication patients december chronically infected hbv gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued value acquired inprocess research development determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete development approval product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets acquisition real estate september completed purchase foster city california campus approximately million cash purchase included buildings totaling square feet office laboratory space accordance sfas business combinations sfas goodwill intangible assets purchase price allocated land buildings existing inplace leases based estimated relative fair values land buildings recorded million million respectively fair value buildings depreciated remaining economic life estimated years used market approach value existing leases acquired recorded intangible asset approximately million amortized straightline basis net rental income approximately two years remaining term leases accumulated amortization intangible asset million million december december respectively net rental income generate leases amortization intangible asset included interest income net approximately million year ended december million year ended december future net rental income received existing leases million million prior amortization inplace lease asset asset impairment fourth quarter recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment classified held use noncash charge driven decision terminate liposomal research development activities san dimas discontinue daunoxome daunorubicin citrate liposome injection product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related estimated undiscounted cash flows wrote carrying value longlived assets estimated fair value accordance sfas accounting impairment disposal longlived assets sfas estimated fair value derived using expected cash flow approach gilead sciences inc notes consolidated financial statements continued december asset impairment continued subsequent decision discontinue daunoxome product line received unanticipated requests europe asking gilead reconsider selling daunoxome result requests management decided continue selling product certain countries still evaluating supply sales strategy respect daunoxome accordance sfas write assets continue used daunoxome product line established new cost basis assets adjusted new facts circumstances gain loss marketable securities eyetech pharmaceuticals march entered agreement eyetech pharmaceuticals inc eyetech relating proprietary aptamer eye currently known macugen pegaptanib sodium injection pursuant agreement received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted carrying value warrant estimated fair value resulting gain million included consolidated statement operations year ended december gain loss marketable securities fair value warrant estimated using blackscholes valuation model volatility rate discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares held realized gain approximately million included interest income net consolidated statement operations year ended december osi pharmaceuticals july gilead sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million reflected consolidated statement operations year ended december gain loss marketable securities gilead sciences inc notes consolidated financial statements continued december availableforsale securities following summary availableforsale securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross unrealized gross amortized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total debt securities consist primarily money market funds december december securities net unrealized gain loss approximately million million respectively following table presents certain information related sales availableforsale securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december million portfolio marketable securities excludes million assetbacked securities contractual maturity less one year million portfolio contractual maturity greater one year less three years none estimated maturities assetbacked securities exceed three years december marketable securities continuous unrealized loss position one year gilead sciences inc notes consolidated financial statements continued december balance sheet detail thousands december inventories raw materials work process finished goods total property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment c onstruction inprogress less accumulated depreciation amortization subtotal land total accrued compensation employee benefits accrued bonuses accrued compensation employee benefits total accrued liabilities accrued medicaid rebates fair value forward foreign currency contracts value added taxes payable income taxes payable accrued royalty expenses liabilities total joint venture bristolmyers squibb december entered collaboration bristolmyers squibb company bms develop commercialize fixed dose combination gileads truvada bmss sustiva efavirenz united states structured joint venture gilead bms formed limited liability company bristolmyers squibb gilead sciences llc terms collaboration gilead bms granted royaltyfree sublicenses joint venture use respective companyowned technologies return granted license joint venture use intellectual property results collaboration ownership interests joint venture gilead bms gilead sciences inc notes consolidated financial statements continued december joint venture bristolmyers squibb continued reflect respective economic interests based fraction estimated net selling price fixeddose combination product attributable truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva gileads bmss respective economic interests joint venture may vary annually gilead primary responsibility clinical development activities regulatory filings relating new products resulting collaboration bms gilead share marketing sales efforts parties provide equivalent sales force efforts minimum number years daily operations joint venture governed four primary joint committees gilead responsible accounting financial reporting product distribution joint venture parties agreed provide respective bulk active pharmaceutical ingredients joint venture approximate market values joint ventures total equity investment risk expected sufficient allow finance operational activities without ongoing funding gilead bms joint venture attributes believe result representing variable interest entity set forth fasb interpretation consolidation variable interest entities fin r expect consolidate results operations financial position joint venture concluded primary beneficiary party absorb majority joint ventures expected losses although primary beneficiary legal structure joint venture limits recourse creditors general credit assets gilead financial information consolidate operations joint venture yet begun december capital contributions made gilead bms beginning expect consolidate joint venture record minority interest owned bms significant intercompany transactions eliminated collaborative arrangements contracts achillion pharmaceuticals november entered exclusive license collaboration agreement achillion pharmaceuticals inc achillion agreement granted worldwide rights research development commercialization certain small molecule hcv replication inhibitors involving hcv protease treatment infection hepatitis c virus hcv collaboration achillion obligated continue development compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofofconcept shared equally gilead achillion following proofofconcept study gilead obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration gilead paid million upfront license fee recorded research development expense gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued future alternative use licensed technology also made million investment purchased million shares achillions convertible preferred stock recorded noncurrent assets additionally also agreed make payments achillion upon achievement certain milestones outlined agreement pay royalties future net sales products arising collaboration genelabs technologies september entered license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelabs novel nucleoside inhibitors hcv polymerase treatment chronic infection caused hcv conjunction signing collaboration agreement paid million upfront license fee recorded research development expense future alternative use technology initially agreed upon term three years genelabs obligated lead research efforts gilead option extend research term collaboration additional year gilead lead development commercialization activities agreed provide annual funding full time equivalents fte expect record research development expense obligated make additional payments upon achievement certain milestones pay royalties future net sales selected compounds developed approved relation collaboration chiron corporation august entered nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutics selected hcv drug targets agreement gilead received nonexclusive rights use chirons hcv technology develop commercialize products treatment hcv terms agreement paid chiron upfront license fee million recorded research development expense future alternative use licensed technology also agreed make additional payments chiron certain clinical regulatory contractually determined milestones met made million payments chiron recorded research development expense additionally obligated make royalty payments event product developed using licensed technology japan tobacco inc july gilead entered licensing agreement japan tobacco inc japan tobacco japan tobacco commercialize products hiv product portfolio japan agreement includes viread emtriva truvada terms agreement received upfront license fee million entitled receive additional cash payments upon achievement certain milestones japan tobacco also pay us royalty net sales products japan upfront fee recorded deferred revenue amortized contract revenue period supply products japan tobacco approximately years december received million milestone payments japan tobacco related japanese regulatory approval marketing authorization viread amortizing gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued remaining period upfront license fee january japan tobacco submitted marketing authorization applications emtriva truvada japanese regulatory authorities emory university april triangle obtained january acquired part acquisition triangle exclusive worldwide license emory universitys emory rights purified forms emtricitabine use hiv hepatitis b fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology united states third year first registration granted antihepatitis b product incorporating emtricitabine technology certain major market countries triangle began paying license maintenance fees development milestones yet achieved due launch emtriva began paying royalties emory respect emtricitabine hiv indication paid royalties million million respectively net sales emtriva net sales truvada also incorporates emtricitabine technology launched license agreement emory terminates upon later patent expiration expiration obligation pay royalties addition right terminate agreement entirety respect one indications hiv hbv one countries prior expiration time upon days notice glaxosmithkline april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada eastern western europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan korea taiwan addition gsk paid us upfront licensing fee million could pay us million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera million received canadian approval hepsera aggregate million received commercial approvals hepsera japan south korea taiwan gsk full responsibility development commercialization hepsera territories upfront license fee approval milestones recorded deferred revenue total million million million recognized contract revenue respectively million balance deferred revenue december amortized contract revenue period supply hepsera gsk agreement approximately years addition gsk required pay gilead royalties net product sales gsk generates sales hepsera epivir hbvzeffix gsks hepatitis product gsk territories gilead began receiving royalties gsks sales hepsera first quarter recorded million royalty revenue recognize royalty revenue gsk quarter following quarter related hepsera sales occur gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued osi pharmaceuticals december completed sale oncology assets osi pharmaceuticals osi terms agreement entitled additional payments osi million either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal products included sale manufacturing facility san dimas california recognized million million million respectively contract revenue manufacturing agreement archemix october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million required license agreement license equity holdings inc ulehi paid receipts ulehi therefore recognizing million million contract revenue respectively also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant upon receipt since transferred remainder warrant ulehi additional payments due archemix agreement eyetech march entered agreement eyetech pharmaceuticals inc relating macugen macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen responsible research development costs received million upfront license fee eyetech april recognized revenue ratably oneyear period provided clinical supplies product eyetech also entitled additional cash payments eyetech million eyetech reaches certain macugen milestones well royalties worldwide net sales macugen december entered agreement eyetech supply macugen eyetech three years recorded contract revenue million million respectively connection clinical supplies provided eyetech milestones achieved eyetech recognized contact revenue million milestone payments eyetech second third quarters upon filing new drug applications europe us macugen january eyetech received fda approval sale macugen united states agreement eyetech expires upon later ten years first commercial sale product developed date last patent expires agreement gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note discussion warrant fujisawa rights market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa terms fujisawa agreement amended fujisawa gilead copromote ambisome united states fujisawa sole marketing rights ambisome canada exclusive marketing rights ambisome rest world provided pay royalties fujisawa connection sales significant asian markets including china india japan korea taiwan connection us sales fujisawa purchases ambisome gilead manufacturing cost sales canada fujisawa purchases ambisome manufacturing cost plus specified percentage fujisawa collects payments sale ambisome united states canada receive fujisawas gross profits sale ambisome united states gross profits include deduction cost goods sold giving us current effective royalty rate approximately fujisawas net sales ambisome united states connection agreement recorded royalty revenue million million million sumitomo september gilead sumitomo entered agreement pursuant sumitomo agreed develop market ambisome japan terms agreement sumitomo paid us initial million licensing fee less withholding taxes million october million milestone payment less withholding taxes million march sumitomo also required make additional payments us certain clinical commercial milestones met pay us royalties japanese ambisome sales agreement gilead obligated provide certain quantity ambisome sumitomo charge recognizing payments received revenue supply period ambisome yet approved marketing japan roche september gilead entered collaboration agreement hoffmannla roche roche develop commercialize therapies treat prevent viral influenza agreement roche received exclusive worldwide rights gileads proprietary influenza neuraminidase inhibitors recognized contract revenue million milestone payments european approval tamiflu treatment prophylaxis recognized contract revenue million milestone payments japanese approval tamiflu prophylaxis last milestones receivable agreement addition roche required pay gilead royalties net product sales tamiflu subject reduction certain defined manufacturing costs recorded total million million million tamiflu royalties respectively recognize royalty revenue roche quarter following quarter related tamiflu sales occur gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered agreement include vistide hepsera viread exclude tamiflu august agreements iocbrega amended include truvada future fixeddose combination products contain licensed technology gilead currently makes quarterly payments iocbrega based percentage vistide hepsera viread truvada net sales paid royalties million million million iocbrega respectively december agreements iocbrega amended provide reduced royalty rate future sales hepsera viread return upfront payment gilead million upon signing agreement payment recorded longterm prepaid royalty classified noncurrent assets balance sheet december prepaid royalty recognized royalty expense expected commercial life viread hepsera amortization million payment began product launch dates viread hepsera longterm obligations longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging total longterm obligations less current portion longterm obligations due one year future minimum lease payments capital lease obligations follows thousands year ending december less amount representing interest total gilead sciences inc notes consolidated financial statements continued december longterm obligations continued terms various agreements require us comply certain financial operating covenants december compliance covenants convertible notes december gilead issued million convertible senior notes due december notes convertible total shares gilead common stock per share convertible senior notes provisionally redeemable whole part option gilead time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes gilead called convertible senior notes redemption october issued shares gilead common stock note holders upon conversion november redemption price equal principal amount notes redeemed plus accrued unpaid interest redemption date connection redemption gilead paid makewhole payment million note holders representing equivalent per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date upon conversion million unamortized balance related debt issuance costs reclassified additional paidin capital december gilead issued million convertible subordinated notes due december convertible subordinated notes convertible total shares gilead common stock per share convertible subordinated notes redeemable whole part option gilead time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance convertible subordinated notes recorded noncurrent assets amortized interest expense straightline basis contractual term convertible subordinated notes november gilead called convertible subordinated notes redemption converted notes shares common stock december upon conversion million unamortized balance related debt issuance costs reclassified additional paidin capital commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases foster city california san dimas california durham north carolina expire various dates foster city lease two fiveyear renewal options addition gilead option purchase foster city properties specified amount durham lease two sevenyear renewal options also operating leases sales marketing administrative facilities europe australia various terms equipment leases include corporate airplane initial term two years annual renewal option ten years gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued lease expense operating leases totaled approximately million million million aggregate noncancelable future minimum rental payments operating leases follows thousands years ending december operating leases hereafter legal proceedings complaints following cases allege large number defendants including gilead overcharged governmental entity named plaintiff pharmaceutical products furnished participants medicaid program general complaints assert claims federal state law except alabama state action includes state law claims seek treble damage attorneys fees litigations preliminary stage possible predict outcome indeed date gilead served process cases except county westchester v abbott laboratories et al intend defend cases vigorously outcome cases predicted time amounts accrued county westchester v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended include approximately defendants january city new york v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended approximately defendants january county rockland v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit originally name gilead defendant amended include claims gilead well approximately defendants january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit filed gilead approximately defendants january gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued purported class action complaint filed november united states district court northern district california gilead certain executive officers complaint alleges defendants violated federal securities laws specifically sections b securities exchange act rule b securities exchange commission making certain alleged false misleading statements plaintiff seeks unspecified damages behalf purported class purchasers gileads securities period july october similar actions subsequently filed court issued order consolidating lawsuits single action december february court issued order appointing lead plaintiffs consolidated action april lead plaintiffs behalf purported class filed consolidated amended complaint june gilead individual defendants filed motion dismiss consolidated amended complaint january court granted defendants motion dismiss leave amend amounts accrued date december two purported shareholder derivative lawsuits filed individual shareholders behalf gilead directors certain executive officers superior court state california county san mateo alleging among things defendants violated california corporations code breached fiduciary duties owing gilead gilead named nominal defendant plaintiffs seek unspecified damages behalf gilead connection alleged insider trading period july october defendants alleged breach fiduciary duties abuse control waste mismanagement two cases consolidated single action january third similar case filed february later consolidated prior two cases plaintiffs filed consolidated complaint amended two times recently november gilead demurred consolidated complaint court granted demurrer december plaintiffs filed motion leave file third consolidated amended complaint january court granted plaintiffs motion rendering complaint operative complaint intend demur complaint trial scheduled june outcome cases predicted time amounts accrued also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position commitments contingencies normal course business may subject contingencies may arise matters product liability claims legal proceedings shareholder suits tax matters accrue contingencies accordance sfas accounting contingencies normal course business entered various firm minimum purchase commitments inventoryrelated materials certain active pharmaceutical ingredient suppliers december approximately million purchase commitments follows million million million million gilead sciences inc notes consolidated financial statements continued december stockholders equity preferred stock gilead shares authorized preferred stock issuable series board directors board authorized determine designation powers preferences rights series reserved shares preferred stock potential issuance preferred share purchase rights plan preferred stock outstanding december employee stock purchase plan gileads employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensation purchase price per share must equal least lower market value date offered date purchased total million shares common stock reserved issuance espp december million shares total shares reserved issued espp million shares december stock option plans may gileads stockholders approved gilead adopted equity incentive plan plan replacement stock option plan plan nonemployee directors stock option plan directors plan adoption plan included increase number shares available issuance remaining shares available issuance plan directors plan plan provides issuance various types equity awards incentive stock options nonstatutory stock options stock appreciation rights sar dividend equivalent rights restricted stock performance units performance shares phantom shares plan exercise purchase price incentive stock options shall less fair value gileads common stock date grant case nonstatutory stock options sars per share exercise price shall less fair value gileads common stock date grant case types awards exercise purchase price determined plan administrator incentive stock options typically vest five years pursuant formula determined board expire ten years term awards shall term stated award agreement ten years date grant eligible participants include employees directors consultants gilead except employees eligible incentive stock options compensation committee delegate determines awards granted well vesting terms december shares remaining available future grant plan november gilead adopted plan issuance common stock employees consultants options issued plan discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gileads common stock date grant options vest five years pursuant formula determined board expire ten years plan amended restated april extend term plan may stockholders approved amendment plan increased gilead sciences inc notes consolidated financial statements continued december stockholders equity continued total number authorized shares plan may remaining shares available future grant plan transferred plan additionally options granted plan expire otherwise terminate without exercised shares common stock reserved options become available future grant plan november gilead adopted directors plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors plan must least equal fair value gileads common stock date grant options granted january vesting five years date grant quarterly five percent installments initial options granted january new directors vest three years date grant equal annual installments annual grants thereafter existing directors vest one year options expire ten years may stockholders approved amendment directors plan increased total number authorized shares plan may remaining shares available grant plan transferred plan additionally options granted plan expire otherwise terminate without exercised shares common stock reserved options become available future grant plan stock plans assumed gilead merger nexstar include stock option plan incentive stock plan director option plan collectively nexstar plans options pursuant nexstar plans issued outstanding july converted options purchase gilead common stock result merger remain subject original terms conditions shares available grant future options nexstar plans stock plans assumed gilead acquisition net assets triangle include stock option plan separate plan former chief executive officer triangle collectively triangle plans options pursuant plan issued outstanding january converted options purchase approximately million shares gilead common stock result acquisition remain subject original terms conditions shares available grant future options either triangle plans gilead sciences inc notes consolidated financial statements continued december stockholders equity continued following table summarizes activity gilead nexstar triangle stock option plans option grants presented table exercise prices less fair value underlying stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted assumed forfeited exercised outstanding end year exercisable end year weighted average fair value options granted following summary gilead options outstanding options exercisable december options thousands options outstanding options exercisable weighted average weighted weighted remaining average average exercise options contractual exercise options range exercise prices outstanding life years price exercisable price total preferred share purchase rights plan november adopted preferred share purchase rights plan rights plan rights plan provides distribution preferred stock purchase right dividend share gilead common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price gilead sciences inc notes consolidated financial statements continued december stockholders equity continued per purchase right purchase rights voting privileges attached automatically trade gilead common stock october october board directors approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october comprehensive income loss comprehensive income loss comprised net income certain changes stockholders equity excluded net income excluded items comprehensive income loss includes changes fair value untriggered effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statement stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized loss arising year availableforsale securities net tax benefit respectively net unrealized gain loss arising year cash flow hedges reclassification adjustments net tax benefit provision respectively comprehensive loss balance accumulated comprehensive income loss net taxes reported balance sheet consists following components thousands december net unrealized loss availableforsale securities net unrealized loss cash flow hedges net foreign currency translation gain accumulated comprehensive income loss gilead sciences inc notes consolidated financial statements continued december disclosures segments enterprise related information gilead operates one business segment primarily focuses development commercialization human therapeutics infectious diseases products included one segment major products viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate collectively hiv products ambisome amphotericin b liposome injection accounted product sales years ended december respectively similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december hiv products viread emtriva truvada total hiv products ambisome hepsera vistide daunoxome total product revenues following table summarizes revenues external customers collaborative partners geographic region revenues attributed countries based location customer collaborative partner thousands year ended december united states france spain united kingdom italy germany switzerland european countries countries total revenues gilead sciences inc notes consolidated financial statements continued december disclosures segments enterprise related information continued december net book value property plant equipment million approximately assets located united states december net book value property plant equipment million approximately assets located united states following table summarizes revenues three largest customers distribute drugs primarily united states total revenues year ended december cardinal health inc amerisourcebergen corp mckesson corp income taxes provision benefit income taxes consisted following thousands year ended december federal current deferred state current deferred foreign current deferred foreign pretax income loss million million million gileads foreign subsidiaries generated operating losses reflecting costs building commercial infrastructure europe foreign subsidiaries investment research development efforts unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately million december residual us tax liability amounts remitted would approximately million gilead sciences inc notes consolidated financial statements continued december income taxes continued difference provision benefit taxes income amount computed applying federal statutory income tax rate income loss provision benefit income taxes explained thousands year ended december income loss provision benefit income taxes tax federal statutory rate state taxes net federal benefit benefitted losses change valuation allowance foreign earnings different rates research experimentation credits inprocess research development charge foreign losses different rates provision benefit income taxes tax benefits associated stock option exercises employee stock purchase plan resulted tax benefit million year ended december benefit credited additional paidin capital realized gilead sciences inc notes consolidated financial statements continued december income taxes continued deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities december follows thousands december deferred tax assets net operating loss carryforwards research tax credit carryforwards reserves accruals currently deductible depreciation related capitalized research development expenses ther net valuation allowance total deferred tax assets deferred tax liabilities unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance decreased million million years ended december respectively valuation allowance million million december respectively concluded based standard set forth sfas accounting income taxes likely realize benefits related deferred tax assets assess need valuation allowance quarter end based available evidence approximately million valuation allowance december relates tax benefits stock option deductions credited additional paidin capital realized december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards expire various dates utilized addition federal state tax credit carryforwards approximately million million respectively expire various dates utilized utilization net operating losses tax credit carryforwards may subject annual limitation due ownership change limitations provided internal revenue code similar state provisions annual limitation may result expiration net operating losses credits utilization october american jobs creation act ajca signed law ajca includes deduction certain foreign earnings repatriated defined ajca may elect apply provision qualifying earnings repatriations fiscal started gilead sciences inc notes consolidated financial statements continued december income taxes continued evaluation effects repatriation provision however expect able complete evaluation congress treasury department provide additional clarifying language key elements ajca expect complete evaluation potential effects repatriation provision within reasonable period time following publication additional clarifying language range possible amounts considering repatriation ajca zero million maximum allowable company defined ajca related potential range income tax reasonably estimated december deferred compensation plans gilead maintains one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation gilead makes matching contributions gilead plan contribute employees first contributions annual maximum match total matching contribution expense gilead plan million million million gilead maintains deferred compensation plan directors officers may defer compensation income tax purposes internal revenue code plan officers may contribute annual salaries annual management bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheet beginning directors may also elect receive portion annual cash retainer phantom shares december issued phantom shares participants elect one several distribution dates available plan receive deferred compensation payment gilead sciences inc notes consolidated financial statements continued december quarterly results operations unaudited following table thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income loss net income loss per sharebasic net income loss per sharediluted first quarter gilead recorded pretax gain million related warrants eyetech completed initial public offering fourth quarter gilead recorded expense million connection makewhole payment convertible senior debt holders relation redemption conversion convertible senior debt first quarter gilead completed acquisition net assets triangle recorded charge million purchased inprocess research development third quarter gilead reimbursed million research development expenses resulting settlement contractual dispute vendor fourth quarter gilead recorded noncash impairment charges certain longlived assets million addition recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets september gilead implemented twoforone stock split form stock dividends share per share amounts periods presented restated reflect stock split gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged charged end period expense deductions period year ended december accounts receivable allowances inventory reserve valuation allowance deferred tax assets year ended december accounts receivable allowances inventory reserve valuation allowance deferred tax assets year ended december accounts receivable allowances inventory reserve valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized gilead sciences inc john c martin john c martin president chief executive officer power attorney know persons presents person whose signature appears constitutes appoints john c martin mark l perry true lawful attorneysinfact agents full power substitution resubstitution name place stead capacities sign amendments report file exhibits thereto documents connection therewith securities exchange commission granting unto said attorneysinfact agents full power authority perform every act thing requisite necessary done connection therewith fully intents purposes might could person hereby ratifying confirming said attorneysinfact agents substitute substitutes may lawfully cause done virtue hereof pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date john c martin president chief executive officer director march john c martin principal executive officer john f milligan executive vice president chief financial officer march john f milligan principal financial accounting officer james denny c hairman board directors march james denny paul berg irector march paul berg etienne f davignon irector march etienne f davignon gordon e moore irector march gordon e moore nicholas g moore irector march nicholas g moore george p shultz irector march george p shultz gayle e wilson irector march gayle e wilson exhibit southern california chapter society industrial office realtors inc industrial real estate lease singletenant facility article one basic terms article one contains basic terms lease landlord tenant named articles sections paragraphs lease referred article one explain define basic terms read conjunction basic terms section date lease february section landlord include legal entity majesticmapa properites llc california limited liabil ity company ddress landlord crossroads parkway north th floor city industry ca section ten ant include legal entity gilead sciences inc delaware corporation ddress tenant lakeside drive foster city ca section property include street address approximate square footage description approximately square foot building commonly known covina boulevard san dimas california outlined red exhibit subject nonexclusive use area outlined green section lease term years months beginning december date specified lease ending november section permitted uses see article five general office laboratory warehousing manufacturing pharmaceutical products section tenants guarantor none state none section b rokers see article fourteen none state landlords broker majestic realty co tenants broker none section commission payable landlords broker see article fourteen per separate agreement section initial security deposit see section section vehicle parking spaces allocated tenant per exhibit section rent charges payable tenant base rent fiftyeight thousand six hundred fifty dollars per month first sixty months provided section shall increased first day sixtyfirst st months commencement date sixtyfour thousand five hundred fifteen dollars b periodic payments real property taxes see section ii utilities see section iii insurance premiums see section iv impounds insurance premiums property taxes see section v maintenance repairs alterations see article six section landlords share profit assignment sublease see section fifty percent profit landlords share southern california chapter society industrial nd office realtors inc singletenant net form gilead sciences inc covina blvd san dimas casection riders following riders attached made part lease none state addendum pages exhibits b c article two lease term section lease property lease term landlord leases property tenant tenant leases property landlord lease term lease term period stated section shall begin end dates specified section unless beginning end lease term changed provision lease commencement date shall date specified section beginning lease term unless advanced delayed provision lease section intentionally deleted section intentionally deleted section holding tenant shall vacate property upon expiration earlier termination lease tenant shall reimburse landlord indemnify landlord damages landlord incurs tenants delay vacating property tenant vacate property upon expiration earlier termination lease landlord thereafter accepts rent tenant tenants occupancy property shall monthtomonth tenancy subject terms lease applicable monthto month tenancy except base rent effect shall increased twentyfive percent section see addendum article three base rent section time manner payment upon execution lease tenant shall pay landlord base rent amount stated paragraph first month lease term first day second month lease term month thereafter tenant shall pay landlord base rent advance without offset deduction prior demand base rent shall payable landlords address place landlord may designate writing section intentionally deleted section security deposit increases upon execution lease tenant shall deposit landlord cash security deposit amount set forth section landlord may apply part security deposit unpaid rent charges due tenant cure defaults tenant landlord uses part security deposit tenant shall restore security deposit full amount within ten days landlords written request tenants failure shall material default lease interest shall paid security deposit landlord shall required keep security deposit separate accounts trust relationship created respect security deposit b time base rent increased tenant shall deposit additional funds landlord sufficient increase security deposit amount bears relationship adjusted base rent initial security deposit bore initial base rent section termination advance payments upon termination lease article seven damage destruction article eight condemnation termination resulting tenants default tenant vacated property manner required lease landlord shall within sixty days tenant delivering exclusive possession property landlord refund tenant tenants successor unused portion security deposit advance rent advance payments made tenant landlord amounts paid real property taxes reserves apply time periods termination lease article four charges payable tenant section additional rent charges payable tenant base rent called additional rent unless lease provides otherwise tenant shall pay additional rent due next monthly installment base rent term rent shall mean base rent additional rent section property taxes real property taxes tenant shall pay real property taxes property including fees taxes assessments result tenant improvements installed property benefit tenant lease term subject paragraph c section payment shall made least ten days prior delinquency date taxes within ten day period tenant shall furnish landlord satisfactory evidence real property taxes paid landlord shall reimburse tenant real property taxes paid tenant covering period time prior lease term tenant fails pay real property taxes due landlord may pay taxes tenant shall reimburse landlord amount tax payment additional rent b definition real property tax real property tax means fee license fee license tax business license fee commercial rental tax levy charge assessment penalty extent caused tenants acts omissions tax imposed taxing authority property ii tax landlords right receive receipt rent income property landlords business leasing property iii tax charge fire protection streets sidewalks road maintenance refuse services provided property governmental agency iv tax imposed upon transaction based upon reassessment property due change ownership defined applicable law transfer part landlords interest property v charge fee replacing tax previously included within definition real property tax real property tax however include landlords federal state income franchise inheritance estate taxes c joint assessment property separately assessed landlord shall reasonably determine tenants share real property tax payable tenant paragraph assessors worksheets reasonably available information tenant shall pay share landlord within fifteen days receipt landlords written statement personal property taxes tenant shall pay taxes charge trade fixtures furnishings equipment personal property belonging tenant tenant shall try personal property taxed separately property ii tenants personal property taxed property tenant shall pay landlord taxes personal property within fifteen days tenant receives written statement landlord personal property taxes e tenants right contest taxes tenant may attempt assessed valuation property reduced may initiate proceedings contest real property taxes required law landlord shall join proceedings brought tenant however tenant shall pay costs proceedings including costs fees incurred landlord upon final determination proceeding contest tenant shall immediately pay real property taxes due together costs charges interest penalties incidental proceedings tenant pay real property taxes due contests taxes tenant shall default lease nonpayment taxes tenant deposits funds landlord opens interestbearing account reasonably acceptable landlord joint names landlord tenant amount deposit shall sufficient pay real property taxes plus reasonable estimate interest costs charges penalties may accrue tenants action unsuccessful less applicable tax impounds previously paid tenant landlord deposit shall applied real property taxes due determined proceedings real property taxes shall paid protest deposit payment protest necessary prevent property sold tax sale similar enforcement proceeding section utilities tenant shall pay directly appropriate supplier cost natural gas heat light power sewer service telephone water refuse disposal utilities services supplied property however services utilities jointly metered property landlord shall make reasonable determination tenants proportionate share cost utilities services tenant shall pay share landlord within fifteen days receipt landlords written statement section insurance policies liability insurance lease term tenant shall maintain policy commercial general liability insurance sometimes known broad form comprehensive general liability insurance insuring tenant liability bodily injury property damage including loss use property personal injury arising operation use occupancy property tenant shall name landlord additional insured policy initial amount insurance shall three million dollars per occurrence shall subject periodic increase based upon industry standards similar facilities liability insurance obtained tenant paragraph shall primary noncontributing ii contain crossliability endorsements iii insure landlord tenants performance section matters giving rise indemnity section result negligence tenant amount coverage insurance shall limit tenants liability relieve tenant obligation lease landlord may also obtain comprehensive public liability insurance amount coverage determined landlord insuring landlord liability arising ownership operation use occupancy property policy obtained landlord shall contributory shall provide primary insurance b property rental income insurance lease term landlord shall maintain policies insurance covering loss damage property full amount replacement value policy shall provide protection loss damage due fire casualties covered within classification fire standard extended coverage vandalism malicious mischief sprinkler leakage perils landlord deems reasonably necessary landlord shall right obtain terrorism flood earthquake insurance forms insurance required lender holding security interest property landlord shall obtain insurance tenants fixtures equipment building improvements installed tenant property lease term landlord shall also maintain rental income insurance policy loss payable landlord amount equal one years base rent plus estimated real property taxes insurance premiums tenant shall liable payment deductible amount landlords tenants insurance policies maintained pursuant section provided however landlords insurance deductible shall exceed ten thousand dollars tenant shall permit anything done invalidates insurance policies upon tenants request landlord shall provide tenant certificate evidencing insurance c payment premiums subject section tenant shall pay premiums insurance policies described paragraphs b whether obtained landlord tenant within fifteen days tenants receipt copy premium statement evidence amount due except landlord shall pay premiums nonprimary comprehensive public liability insurance landlord elects obtain provided paragraph insurance policies maintained landlord cover improvements real property property landlord shall deliver tenant statement premium applicable property showing reasonable detail tenants share premium computed lease term expires expiration insurance policy maintained landlord tenant shall liable tenants prorated share insurance premiums commencement date tenant shall deliver landlord copy policy insurance tenant required maintain section least thirty days prior expiration policy tenant shall deliver landlord renewal policy alternative providing policy insurance tenant shall right provide landlord certificate insurance executed authorized officer insurance company showing insurance tenant required maintain section full force effect containing information landlord reasonably requires general insurance provisions insurance tenant required maintain lease shall include provision requires insurance carrier give landlord less thirty days written notice prior cancellation modification coverage ii tenant fails deliver policy certificate renewal landlord required lease within prescribed time period policy cancelled modified lease term without landlords consent landlord may obtain insurance case tenant shall reimburse landlord cost insurance within fifteen days receipt statement indicates cost insurance iii landlord tenant shall maintain insurance required lease companies holding general policy rating better set forth current issue best key rating guide landlord tenant acknowledge insurance markets rapidly changing insurance form amounts described section may available future tenant acknowledges insurance described section primary benefit landlord time lease term tenant landlord unable maintain insurance required lease landlord tenant shall nevertheless maintain insurance coverage customary commercially reasonable insurance industry tenants type business coverage may change time time landlord makes representation adequacy insurance protect landlords tenants interests therefore tenant shall obtain additional property liability insurance tenant deems necessary protect landlord tenant iv landlord tenant hereby waive rights recovery officers employees agents representatives loss damage property property others control loss damage covered insurance policy force whether described lease time loss damage upon obtaining required policies insurance landlord tenant shall give notice insurance carriers mutual waiver subrogation landlords tenants insurance policies described section shall contain provision waiving carriers right subrogation section late charges tenants failure pay rent promptly may cause landlord incur unanticipated costs exact amount costs impractical extremely difficult ascertain costs may include limited processing accounting charges late charges may imposed landlord ground lease mortgage trust deed encumbering property therefore landlord receive rent payment within ten days becomes due provided landlord given tenant fortheight hours written notice tenant still failed pay base rent fortyeight shall run concurrently ten day period tenant shall pay landlord late charge equal eight percent overdue amount parties agree late charge represents fair reasonable estimate costs landlord incur reason late payment section interest past due obligations amount owed one party hereunder paid due shall bear interest rate fifteen percent per annum due date amount however interest shall payable late charges paid tenant lease payment interest amounts shall excuse cure default lease interest rate specified lease higher rate permitted law interest rate hereby decreased maximum legal interest rate permitted law section impounds insurance premiums real property taxes tenant ten days late payment base rent twice consecutive twelve month period tenant shall pay landlord sum equal onetwelfth annual real property taxes insurance premiums payable tenant lease together payment base rent landlord shall hold payments noninterest bearing impound account unknown landlord shall reasonably estimate amount real property taxes insurance premiums due tenant shall pay deficiency funds impound account landlord upon written request tenant defaults lease landlord may apply funds impound account obligation due lease section see addendum article five use property section permitted uses tenant may use property permitted uses set forth section section manner use tenant shall cause permit property used way constitutes violation law ordinance governmental regulation order annoys interferes rights tenants landlord constitutes nuisance waste tenant shall obtain pay permits including certificate occupancy required tenants occupancy property shall promptly take actions necessary comply applicable statutes ordinances rules regulations orders requirements regulating use tenant property including occupational safety health act see addendum section see addendum section section signs auctions tenant shall place signs property without landlords prior written consent tenant shall conduct permit auctions sheriffs sales property see addendum section section indemnity tenant shall indemnify landlord hold landlord harmless costs claims liability arising tenants use property b conduct tenants business anything else done permitted tenant done property c breach default performance tenants obligations lease misrepresentation breach warranty tenant lease e acts omissions tenant tenant shall defend landlord cost claim liability tenants expense counsel reasonably acceptable landlord landlords election tenant shall reimburse landlord legal fees costs incurred landlord connection claim material part consideration landlord tenant assumes risk damage property injury persons property arising cause tenant hereby waives claims respect thereof landlord except claim arising landlords landlords employees agents contractors active negligence willful misconduct used section term tenant shall include tenants employees agents contractors invitees applicable see addendum section section landlords access landlord agents may enter property reasonable times show property potential buyers investors tenants parties act inspect conduct tests order monitor tenants compliance applicable environmental laws laws governing presence use hazardous material purpose landlord deems necessary landlord shall give tenant hour prior notice entry except case emergency landlord agrees allow representative tenant accompany landlord agrees comply tenants reasonable security measures landlord may place customary sale lease signs property section quiet possession tenant pays rent complies terms lease tenant may occupy enjoy property full lease term subject provisions lease article six condition property maintenance repairs alterations section existing conditions subject provisions lease tenant accepts property condition execution lease subject recorded matters laws ordinances governmental regulations orders except provided herein tenant acknowledges neither landlord agent landlord made representation condition property suitability property tenants intended use tenant represents warrants tenant made inspection inquiry regarding condition property relying representations landlord broker respect thereto landlord landlords broker provided property information sheet disclosure statement regarding property copy attached exhibit lease section exemption landlord liability landlord shall liable damage injury person business loss income therefrom goods wares merchandise property tenant tenants employees invitees customers person property whether damage injury caused results fire steam electricity water gas rain b breakage leakage obstruction defects pipes sprinklers wires appliances plumbing air conditioning lighting fixtures cause c conditions arising property sources places act omission tenant landlord landlord shall liable damage injury even though cause means repairing damage injury accessible tenant provisions section shall however exempt landlord liability landlords landlords employees agents contractors active negligence willful misconduct section landlords obligations see addendum section section tenants obligations except provided section article seven damage destruction article eight condemnation tenant shall keep portions property including structural nonstructural interior exterior landscaped areas portions systems equipment good order condition repair including interior repainting refinishing needed portion property system equipment property tenant obligated repair fully repaired restored tenant shall promptly replace portion property system equipment property regardless whether benefit replacement extends beyond lease term benefit useful life replacement extends beyond lease term term may extended exercise options useful life replacement shall prorated remaining portion lease term extended tenant shall liable portion cost applicable lease term extended tenant shall maintain preventive maintenance contract providing regular inspection maintenance heating air conditioning system licensed heating air conditioning contractor subject provisions section div part property damaged act omission tenant tenant shall pay landlord cost repairing replacing damaged property whether landlord would otherwise obligated pay cost maintaining repairing property intention landlord tenant times tenant shall maintain portions property tenant obligated maintain attractive firstclass fully operative condition b tenant shall fulfill tenants obligations section tenants sole expense tenant fails maintain repair replace property required section using reasonable efforts landlord may upon ten days prior notice tenant except notice shall required case emergency enter property perform maintenance repair including replacement needed behalf tenant case tenant shall reimburse landlord costs incurred performing maintenance repair immediately upon demand section alterations additions improvements tenant shall make alterations additions improvements property without landlords prior written consent shall unreasonably withheld except nonstructural alterations exceed sixty thousand dollars cost per project visible outside building property part landlord may require tenant provide demolition andor lien completion bonds form amount satisfactory landlord tenant shall promptly remove alterations additions improvements constructed violation paragraph upon landlords written request alterations additions improvements shall done good workmanlike manner conformity applicable laws regulations contractor approved landlord shall unreasonably withheld upon completion work tenant shall provide landlord built plans copies construction contracts proof payment labor materials b tenant shall pay due claims labor material furnished tenant group property tenant shall give landlord least twenty days prior written notice commencement work property regardless whether landlords consent work required landlord may elect record post notices nonresponsibility property section condition upon termination upon termination lease tenant shall surrender property landlord broom clean condition received except ordinary wear tear tenant otherwise obligated remedy provision lease however tenant shall obligated repair damage landlord required repair accordance lease addition landlord may require tenant remove alterations additions improvements whether made landlords consent prior expiration lease restore property prior condition tenants expense alterations additions improvements landlord required tenant remove shall become landlords property shall surrendered landlord upon expiration earlier termination lease except tenant may remove tenants trade fixtures machinery equipment removed without material damage property tenant shall repair tenants expense damage property caused removal trade fixtures machinery equipment event however shall tenant remove following materials equipment shall deemed landlords property without landlords prior written consent power wiring power panels lighting lighting fixtures wall coverings drapes blinds window coverings carpets floor coverings heaters air conditioners heating air conditioning equipment fencing security gates similar building operating equipment decorations see addendum section article seven damage destruction section partial damage property tenant shall notify landlord writing immediately upon occurrence damage property property partially damaged ie less fifty percent property untenantable result damage less fifty percent tenants operations materially impaired proceeds received landlord insurance policies described paragraph b sufficient pay necessary repairs lease shall remain effect landlord shall repair damage soon reasonably possible landlord may elect required repair damage tenants fixtures equipment improvements b landlord maintained insurance required maintained paragraph b insurance proceeds received landlord sufficient pay entire cost repair ii cause damage covered insurance policies iii holder mortgage property shall require insurance proceeds portion thereof used retire mortgage debt landlord may elect either repair damage soon reasonably possible case lease shall remain full force effect ii terminate lease date damage occurred landlord shall notify tenant within thirty days receipt notice occurrence damage whether landlord elects repair damage terminate lease landlord elects repair damage tenant shall pay landlord deductible amount landlords insurance policies damage due act omission tenant tenants employees agents contractors invitees difference actual cost repair insurance proceeds received landlord landlord elects terminate lease tenant may elect continue lease full force effect case tenant shall repair damage property building property located tenant shall pay cost repairs except upon satisfactory completion repairs landlord shall deliver tenant insurance proceeds received landlord damage repaired tenant tenant shall give landlord written notice election within ten days receiving landlords termination notice c damage property occurs last six months lease term damage require thirty days repair either landlord tenant may elect terminate lease date damage occurred regardless sufficiency insurance proceeds party electing terminate lease shall give written notification party election within thirty days tenants notice landlord occurrence damage section substantial total destruction property substantially totally destroyed cause whatsoever ie damage property greater partial damage described section regardless whether landlord receives insurance proceeds lease shall terminate later date destruction occurred ii date tenant ceases business property notwithstanding preceding sentence property rebuilt within six months date destruction landlord may elect rebuild property landlords expense case lease shall remain full force effect landlord shall notify tenant election within thirty days tenants notice occurrence total substantial destruction landlord elects landlord shall rebuild property landlords sole expense except destruction caused act omission tenant tenant shall pay landlord difference actual cost rebuilding insurance proceeds received landlord section temporary reduction rent property destroyed damaged landlord tenant repairs restores property pursuant provisions article seven rent payable period damage repair andor restoration shall reduced according degree tenants use property impaired except possible reduction base rent insurance premiums real property taxes tenant shall entitled compensation reduction reimbursement landlord result damage destruction repair restoration property section waiver tenant waives protection statute code judicial decision grants tenant right terminate lease event substantial total destruction leased property tenant agrees provisions section shall govern rights obligations landlord tenant event substantial total destruction property article eight condemnation portion property taken power eminent domain sold threat power called condemnation lease shall terminate part taken sold date condemning authority takes title possession whichever occurs first twenty percent floor area building property located located property taken either landlord tenant may terminate lease date condemning authority takes title possession delivering written notice within ten days receipt written notice taking absence notice within ten days condemning authority takes title possession neither landlord tenant terminates lease lease shall remain effect portion property taken except base rent additional rent shall reduced proportion reduction floor area property condemnation award payment shall distributed following order first ground lessor mortgagee beneficiary deed trust encumbering property amount interest property b second tenant amount award specifically designated loss damage tenants trade fixtures removable personal property c third landlord remainder award whether compensation reduction value leasehold taking fee otherwise lease terminated landlord shall repair damage property caused condemnation except landlord shall obligated repair damage tenant reimbursed condemning authority severance damages received landlord sufficient pay repair landlord shall right either terminate lease make repair landlords expense article nine assignment subletting section landlords consent required portion property tenants interest lease may acquired person entity whether sale assignment mortgage sublease transfer operation law act tenant without landlords prior written consent except provided section landlord right grant withhold consent provided section attempted transfer without consent shall void shall constitute noncurable breach lease section tenant affiliate see addendum section section release tenant transfer permitted article nine whether without landlords consent shall release tenant change tenants primary liability pay rent perform obligations tenant lease landlords acceptance rent person waiver provision article nine consent one transfer consent subsequent transfer tenants transferee defaults lease landlord may proceed directly tenant without pursuing remedies transferee landlord may consent subsequent assignments modifications lease tenants transferee without notifying tenant obtaining consent action shall relieve tenants liability lease section offer terminate tenant desires assign lease sublease property landlord elects writing terminate lease pursuant section lease shall terminate commencement date new lease landlord proposed assignee subtenant terms provisions lease governing termination shall apply landlord elect lease shall continue effect otherwise terminated provisions section respect proposed transfer shall continue apply section landlords consent tenants request consent transfer described section shall set forth writing details proposed transfer including name business financial condition prospective transferee financial details proposed transfer eg term rent security deposit payable proposed assignment sublease information landlord reasonably deems relevant landlord shall right elect terminate lease withhold consent reasonable grant consent based following factors business proposed assignee subtenant proposed use property ii net worth financial reputation proposed assignee subtenant iii tenants compliance obligations lease landlord objects proposed assignment solely net worth andor financial reputation proposed assignee tenant may nonetheless sublease assign portion property proposed transferee terms proposed transfer b tenant assigns subleases following shall apply tenant assigns subleases seventy percent building located property aggregate tenant shall pay landlord additional rent lease landlords share stated section profit defined transaction received tenant unless landlord gives written notice tenant assignee subtenant landlords share shall paid assignee subtenant landlord directly profit means amounts paid tenant assignment sublease including key money monthly rent excess monthly rent payable lease fees consideration paid assignment sublease including fees collateral agreements less b costs expenses directly incurred tenant connection execution performance assignment sublease real estate brokers commissions costs renovation construction assignment sublease real estate brokers commissions costs renovation construction tenant improvements required assignment sublease tenant entitled recover costs expenses tenant obligated pay landlords share landlord profit case sublease less property rent allocable subleased space percentage square footage basis ii tenant shall provide landlord written statement certifying amounts paid assignment sublease property within thirty days transaction documentation signed landlord may inspect tenants relevant books records verify accuracy statement written request tenant shall promptly furnish landlord copies transaction documentation shall certified tenant complete true correct landlords receipt landlords share shall consent assignment subletting breach tenants obligation paragraph b shall material default lease section merger merger shall result tenants sublease property article nine tenants surrender lease termination lease manner event landlord may terminate subtenancies succeed interest tenant sublandlord subtenancies article ten defaults remedies section covenants conditions tenants landlords performance obligation lease condition well covenant tenants right continue possession property conditioned upon tenants performance time essence performance covenants conditions section defaults tenant shall material default lease tenant fails pay rent abandons property tenants vacation property results cancellation insurance described section b tenant fails pay rent due charge within ten days receipt bill statement landlord c tenant fails perform tenants nonmonetary obligations lease period thirty days written notice landlord provided thirty days required complete performance tenant shall default tenant commences performance within thirty day period thereafter diligently pursues completion notice required paragraph intended satisfy notice requirements imposed law landlord addition requirement tenant makes general assignment general arrangement benefit creditors ii petition adjudication bankruptcy reorganization rearrangement filed tenant dismissed within thirty days iii trustee receiver appointed take possession substantially tenants assets located property tenants interest lease possession restored tenant within thirty days iv substantially tenants assets located property tenants interest lease subjected attachment execution judicial seizure discharged within thirty days court competent jurisdiction determines acts described subparagraph default lease trustee appointed take possession tenant remains debtor possession trustee tenant transfers tenants interest hereunder landlord shall receive additional rent excess rent consideration paid connection assignment sublease rent payable tenant lease e guarantor lease revokes otherwise terminates purports revoke otherwise terminate guaranty potion tenants obligations lease unless otherwise expressly provided guaranty lease revocable section remedies occurrence material default tenant landlord may time thereafter following three days written notice demand may form three day notice pay rent quit time may run concurrently therewith without limiting landlord exercise right remedy landlord may terminate tenants right possession property lawful means case lease shall terminate tenant shall immediately surrender possession property landlord tenant shall served demand payment past due rent charge payments rendered thereafter cure default tenant shall made cashiers check event landlord shall entitled recover tenant damages incurred landlord reason tenants default including worth time award unpaid base rent additional rent charges landlord earned time termination ii worth time award amount unpaid base rent additional rent charges landlord would earned termination time award exceeds amount rental loss tenant proves landlord could reasonably avoided iii worth time award amount unpaid base rent additional rent charges tenant would paid balance lease term time award exceeds amount rental loss tenant proves landlord could reasonably avoided iv amount necessary compensate landlord detriment proximately caused tenants failure perform obligations lease ordinary course things would likely result therefrom including limited costs expenses landlord incurs maintaining preserving property default costs recovering possession property expenses reletting including necessary renovation alteration property landlords reasonable attorneys fees incurred connection therewith real estate commission paid payable used subparts ii worth time award computed allowing interest unpaid amounts rate fifteen percent per annum lesser amount may maximum lawful rate used subpart iii worth time award computed discounting amount discount rate federal reserve bank san francisco time award plus one percent tenant abandoned property landlord shall option retaking possession property recovering tenant amount specified paragraph andor ii proceeding paragraph b b maintain tenants right possession case lease shall continue effect whether tenant abandoned property event landlord shall entitled enforce landlords rights remedies lease including right recover rent becomes due landlord shall remedy described california civil code section lessor may continue lease effect lessees breach abandonment recover rent becomes due lessee right sublet assign subject reasonable limitations c pursue remedy hereafter available landlord laws judicial decisions state property located section intentionally deleted section automatic termination notwithstanding term provision hereof contrary lease shall terminate occurrence act affirms landlords intention terminate lease provided section hereof including filing unlawful detainer action tenant termination landlords damages default shall include costs fees including reasonably attorneys fees landlord incurs connection filing commencement pursuing andor defending action bankruptcy court court respect lease obtaining relief stay bankruptcy restraining action evict tenant pursuing action respect landlords right possession property damages suffered apart base rent rent payable hereunder shall constitute pecuniary damages must reimbursed landlord prior assumption lease tenant successor tenant bankruptcy proceeding section cumulative remedies landlords exercise right remedy shall prevent exercising right remedy article eleven protection lenders section subordination landlord shall right subordinate lease ground lease deed trust mortgage encumbering property advances made security thereof renewals modifications consolidations replacements extensions thereof whenever made recorded tenant shall cooperate landlord lender acquiring security interest property lease tenant shall execute documents assurances lender may require form attached hereto exhibit b form required landlords lender provided agreement contains nondisturbance agreement favor tenant provided tenants obligations lease shall increased material way performance ministerial acts shall deemed material tenant shall deprived rights lease tenants right quiet possession property lease term shall disturbed tenant pays rent performs tenants obligations lease otherwise default ground lessor beneficiary mortgagee elects lease prior lien ground lease deed trust mortgage gives written notice thereof tenant lease shall deemed prior ground lease deed trust mortgage whether lease dated prior subsequent date said ground lease deed trust mortgage date recording thereof see addendum section section attornment landlords interest property acquired ground lessor beneficiary deed trust mortgagee purchaser foreclosure sale tenant shall attorn transferee successor landlords interest property recognize transferee successor landlord lease tenant waives protection current future statute rule law gives purports give tenant right terminate lease surrender possession property upon transfer landlords interest section signing documents tenant shall sign deliver instrument documents necessary appropriate evidence attornment subordination agreement provided agreement include nondisturbance provision favor tenant tenant fails within fifteen days written request tenant hereby makes constitutes irrevocably appoints landlord transferee successor landlord attorneyinfact tenant execute deliver instrument document long instrument complies provisions article eleven section estoppel certificates upon landlords written request tenant shall execute acknowledge deliver landlord written statement form attached hereto exhibit c form required landlords lender certifying none terms provisions lease changed changed stating changed ii lease cancelled terminated iii last date payment base rent charges time period covered payment iv landlord default lease landlord claimed default stating v representations information respect tenant lease landlord may reasonably request prospective purchaser encumbrancer property may require tenant shall deliver statement landlord within fifteen days landlords request landlord may give statement tenant prospective purchaser encumbrancer property purchaser encumbrancer may rely conclusively upon statement true correct b tenant deliver statement landlord within fifteen day period landlord prospective purchaser encumbrancer may conclusively presume rely upon following facts terms provisions lease changed except otherwise represented landlord ii lease cancelled terminated except otherwise represented landlord iii one months base rent charges paid advance iv landlord default lease event tenant shall estopped denying truth facts section c see addendum section tenants financial condition within ten days written request landlord tenant shall deliver landlord tenants existing financial statements verify net worth tenant assignee subtenant guarantor tenant addition tenant shall deliver lender designated landlord financial statements required lender facilitate financing refinancing property tenant represents warrants landlord financial statement true accurate statement date statement al financial statements shall confidential shall used purposes set forth lease see addendum section article twelve legal costs section legal proceedings tenant landlord shall breach default lease party defaulting party shall reimburse party nondefaulting party upon demand costs expenses nondefaulting party incurs connection breach default defaulting party lease whether suit commenced judgment entered costs shall include legal fees costs incurred negotiation settlement enforcement rights otherwise furthermore action breach enforce provisions lease commenced court action shall award party whose favor judgment entered reasonable sum attorneys fees costs losing party action shall pay attorneys fees costs tenant shall also indemnify landlord hold landlord harmless costs expenses demands liability landlord may incur landlord becomes made party claim action instituted tenant third party third party tenant person holding interest using property license agreement tenant b foreclosure lien labor material furnished tenant group c otherwise arising resulting act transaction tenant group necessary protect landlords interest lease bankruptcy proceeding proceeding title united states code amended tenant shall defend landlord claim action tenants expense counsel reasonably acceptable landlord landlords election tenant shall reimburse landlord legal fees costs landlord reasonably incurs claim action section landlords consent tenant shall pay landlords reasonable attorneys fees incurred connection tenants request landlords consent article nine assignment subletting connection act tenant proposes requires landlords consent article thirteen miscellaneous provisions section nondiscrimination tenant promises condition continuance lease discrimination segregation person group persons basis race color sex creed national origin ancestry leasing subleasing transferring occupancy tenure use property portion thereof section landlords liability certain duties used lease term landlord means current owner owners fee title property leasehold estate ground lease property time question landlord obligated perform obligations landlord lease time landlord owns interest title landlord transfers title interest relieved al liability respect obligations landlord lease performed date transfer provided transferee assumes landlords obligations date transfer however landlord shall deliver transferee funds tenant previously paid funds yet applied terms lease b tenant shall give written notice failure landlord perform obligations lease landlord ground lessor mortgagee beneficiary deed trust encumbering property whose name address furnished tenant writing landlord shall default lease unless landlord ground lessor mortgagee beneficiary fails cure nonperformance within thirty days receipt tenants notice however nonperformance reasonably requires thirty days cure landlord shall default cure commenced within thirty day period thereafter diligently pursued completion c notwithstanding term provision herein contrary liability landlord performance duties obligations lease limited landlords interest property neither landlord partners shareholders officers principals shall personal liability lease section severability determination court competent jurisdiction provision lease part thereof illegal unenforceable shall cancel invalidate remainder provision lease shall remain full force effect section interpretation captions articles sections lease assist parties reading lease part terms provisions lease whenever required context lease singular shall include plural plural shall include singular masculine feminine neuter genders shall include provision relating conduct acts omissions tenant term tenant shall include tenants agents employees contractors invitees successors others using property tenants expressed implied permission section incorporation prior agreements modifications lease agreement parties pertaining lease property agreements effective amendments lease shall writing singed parties attempted amendment shall void section notices notices required permitted lease shall writing shall personally delivered sent national overnight carrier certified mail return receipt requested postage prepaid notices tenant shall delivered address specified section notices landlord shall delivered address specified section notices shall effective upon delivery either party may change notice address upon written notice party section waivers waivers must writing signed waiving party landlords failure enforce provision lease acceptance rent shall waiver shall prevent landlord enforcing provision provision lease future statement payment check tenant letter accompanying payment check shall binding landlord landlord may without notice tenant negotiate check without bound conditions statement section recordation tenant shall record lease without prior written consent landlord however either landlord tenant may require short form memorandum lease executed parties recorded party requiring recording shall pay transfer taxes recording fees section binding effect choice law lease binds party legally acquires rights interest lease landlord tenant however landlord shall obligation tenants successor unless rights interests tenants successor acquired accordance terms lease laws state property located shall govern lease section corporate authority partnership authority tenant corporation corporation represents warrants person signing lease behalf tenant full authority lease binds corporation within thirty days lease signed tenant shall deliver landlord certified copy resolution tenants board directors authorizing execution lease evidence authority reasonably acceptable landlord tenant partnership person entity signing lease tenant represents warrants general partner partnership full authority sign partnership lease binds partnership general partners partnership tenant shall give written notice landlord general partners withdrawal addition within thirty days lease signed tenant shall deliver landlord copy tenants recorded statement partnership certificate limited partnership section joint several liability intentionally deleted section see addendum section section execution lease lease may executed counterparts counterpart documents executed counterparts shall constitute single binding instrument landlords delivery lease tenant shall deemed offer lease shall binding upon either party executed delivered parties section survival representations warranties landlord tenant shall survive termination lease article fourteen brokers section brokers fee lease signed delivered landlord tenant landlord shall pay real estate commission landlords broker named section provided written agreement landlord landlords broker sum stated section services rendered landlord landlords broker transaction landlord shall pay landlords broker commission tenant exercises option extend lease term buy property similar option right landlord may grant tenant landlords broker procuring cause lease sale entered landlord tenant covering property commission shall amount set forth landlords brokers commission schedule effect execution lease tenants broker named section landlords broker shall pay appropriate portion commission tenants broker provided agreement landlords broker tenants broker nothing contained lease shall impose obligation landlord pay commission fee party landlords broker section protection brokers landlord sells property assigns landlords interest lease buyer assignee shall accepting conveyance property assignment lease conclusively deemed agreed make payments landlords broker thereafter required landlord article fourteen landlords broker shall right bring legal action enforce declare rights provision prevailing party action shall entitled reasonably attorneys fees paid losing party attorneys fees shall fixed court action paragraph included lease benefit landlords broker section brokers disclosure agency landlords broker hereby discloses landlord tenant landlord tenant hereby consent landlords broker acting transaction agent check one cid landlord exclusively cid landlord tenant section brokers tenant represents warrants landlord brokers named section agents brokers finders parties tenant dealt may entitled commission fee respect lease property additional provisions may set forth rider riders attached hereto blank space additional provisions inserted please draw line space landlord tenant signed lease place dates specified adjacent signatures initialed riders attached incorporated reference lease landlord majesticmapa properties llc signed california limited liability company majestic realty co california corporation manager david wheeler president jay h bradford executive vice president chief financial officer tenant signed gilead sciences inc delaware corporation anthony caracciolo mark l perry executive vice president operations real estate transaction recommended consult professional civil engineer industrial hygienist person experience evaluating condition property including possible presence asbestos hazardous materials underground storage tanks printed form lease drafted legal counsel direction southern california chapter society industrial office realtors inc representation recommendation made southern california chapter society industrial office realtors inc legal counsel real estate brokers named herein employees agents legal sufficiency legal effect tax consequences lease transaction landlord tenant retain legal counsel advise matters rely upon advice legal counsel exhibit southern california chapter society industrial office realtors inc industrial real estate lease singletenant facility article one basic terms article one contains basic terms lease landlord tenant named articles sections paragraphs lease referred article one explain define basic terms read conjunction basic terms section date lease february section landlord include legal entity majesticmapa properties llc california limited liability company address landlord crossroads parkway north th floor city industry ca section tenant include legal entity gilead sciences inc delaware corporation address tenant lakeside drive foster city ca section property includes street address approximate square footage description approximately square foot building commonly known cliffside drive san dimas california outlined red exhibit subject nonexclusive use area outlined green section lease term years months beginning june date specified lease ending november section permitted uses see article five general office laboratory warehousing manufacturing pharmaceutical products section tenants guarantor none state none section brokers see article fourteen none state landlords broker majestic realty co tenants broker none section commission payable landlords broker see article fourteen per separate agreement section initial security deposit see section section vehicle parking spaces allocated tenant per exhibit section rent charges payable tenant southern california chapter society industrial nd office realtors inc singletenant net form gilead sciences inc cliffside san dimas ca base rent fiftynine thousand two hundred twentyfive dollars per month first sixty months provided section shall increased first day sixtyfirst st months commencement date sixtyfive thousand one hundred fortyseven dollars b periodic payments real property taxes see section ii utilities see section iii insurance premium see section iv impounds insurance premiums property taxes see section v maintenance repairs alterations see article six section landlords share profit assignment sublease see section fifty percent profit landlords share section riders following riders attached made part lease none state addendum pages exhibits b c article two lease term section lease property lease term landlord leases property tenant tenant leases property landlord lease term lease term period stated section shall begin end dates specified section unless beginning end lease term changed provision lease commencement date shall date specified section beginning lease term unless advanced delayed provision lease section see addendum section section intentionally deleted section holding tenant shall vacate property upon expiration earlier termination lease tenant shall reimburse landlord indemnify landlord damages landlord incurs tenants delay vacating property tenant vacate property upon expiration earlier termination lease landlord thereafter accepts rent tenant tenants occupancy property shall monthtomonth tenancy subject terms lease applicable monthto month tenancy except base rent effect shall increased twentyfive percent section see addendum article three base rent section time manner payment upon execution lease tenant shall pay landlord base rent amount stated paragraph first month lease term first day second month lease term month thereafter tenant shall pay landlord base rent advance without offset deduction prior demand base rent shall payable landlords address place landlord may designate writing section intentionally deleted section security deposit increases upon execution lease tenant shall deposit landlord cash security deposit amount set forth section landlord may apply part security deposit unpaid rent charges due tenant cure defaults tenant landlord uses part security deposit tenant shall restore security deposit full amount within ten days landlords written request tenants failure shall material default lease interest shall paid security deposit landlord shall required keep security deposit separate accounts trust relationship created respect security deposit b time base rent increased tenant shall deposit additional funds landlord sufficient increase security deposit amount bears relationship adjusted base rent initial security deposit bore initial base rent section termination advance payments upon termination lease article seven damage destruction article eight condemnation termination resulting tenants default tenant vacated property manner required lease landlord shall within sixty days tenant delivering exclusive possession property landlord refund tenant tenants successor unused portion security deposit advance rent advance payments made tenant landlord amounts paid real property taxes reserves apply time periods termination lease article four charges payable tenant section additional rent charges payable tenant base rent called additional rent unless lease provides otherwise tenant shall pay additional rent due next monthly installment base rent term rent shall mean base rent additional rent section property taxes real property taxes tenant shall pay real property taxes property including fees taxes assessments result tenant improvements installed property benefit tenant lease term subject paragraph c section payment shall made least ten days prior delinquency date taxes within ten day period tenant shall furnish landlord satisfactory evidence real property taxes paid landlord shall reimburse tenant real property taxes paid tenant covering period time prior lease term tenant fails pay real property taxes due landlord may pay taxes tenant shall reimburse landlord amount tax payment additional rent b definition real property tax real property tax means fee license fee license tax business license fee commercial rental tax levy charge assessment penalty extent caused tenants acts omissions tax imposed taxing authority property ii tax landlords right receive receipt rent income property landlords business leasing property iii tax charge fire protection streets sidewalks road maintenance refuse services provided property governmental agency iv tax imposed upon transaction based upon reassessment property due change ownership defined applicable law transfer part landlords interest property v charge fee replacing tax previously included within definition real property tax real property tax however include landlords federal state income franchise inheritance estate taxes c joint assessment property separately assessed landlord shall reasonably determine tenants share real property tax payable tenant paragraph assessors worksheets reasonably available information tenant shall pay share landlord within fifteen days receipt landlords written statement personal property taxes tenant shall pay taxes charged trade fixtures furnishings equipment personal property belonging tenant tenant shall try personal property taxed separately property ii tenants personal property taxed property tenant shall pay landlord taxes personal property within fifteen days tenant receives written statement landlord personal property taxes e tenants right contest taxes tenant may attempt assessed valuation property reduced may initiate proceedings contest real property taxes required law landlord shall join proceedings brought tenant however tenant shall pay costs proceedings including costs fees incurred landlord upon final determination proceeding contest tenant shall immediately pay real property taxes due together costs charges interest penalties incidental proceedings tenant pay real property taxes due contests taxes tenant shall default lease nonpayment taxes tenant deposits funds landlord opens interestbearing account reasonably acceptable landlord joint names landlord tenant amount deposit shall sufficient pay real property taxes plus reasonable estimate interest costs charges penalties may accrue tenants action unsuccessful less applicable tax impounds previously paid tenant landlord deposit shall applied real property taxes due determined proceedings real property taxes shall paid protest deposit payment protest necessary prevent property sold tax sale similar enforcement proceeding section utilities tenant shall pay directly appropriate supplier cost natural gas heat light power sewer service telephone water refuse disposal utilities services supplied property however services utilities jointly metered property landlord shall make reasonable determination tenants proportionate share cost utilities services tenant shall pay share landlord within fifteen days receipt landlords written statement section insurance policies liability insurance lease term tenant shall maintain policy commercial general liability insurance sometimes known broad form comprehensive general liability insurance insuring tenant liability bodily injury property damage including loss use property personal injury arising operation use occupancy property tenant shall name landlord additional insured policy initial amount insurance shall three million dollars per occurrence shall subject periodic increase based upon industry standards similar facilities liability insurance obtained tenant paragraph shall primary noncontributing ii contain crossliability endorsements iii insure landlord tenants performance section matters giving rise indemnity section result negligence tenant amount coverage insurance shall limit tenants liability relieve tenant obligation lease landlord may also obtain comprehensive public liability insurance amount coverage determined landlord insuring landlord liability arising ownership operation use occupancy property policy obtained landlord shall contributory shall provide primary insurance b property rental income insurance lease term landlord shall maintain policies insurance covering loss damage property full amount replacement value policy shall provide protection loss damage due fire casualties covered within classification fire standard extended coverage vandalism malicious mischief sprinkler leakage perils landlord deems reasonably necessary landlord shall right obtain terrorism flood earthquake insurance forms insurance required lender holding security interest property landlord shall obtain insurance tenants fixtures equipment building improvements installed tenant property lease term landlord shall also maintain rental income insurance policy loss payable landlord amount equal one years base rent plus estimated real property taxes insurance premiums tenant shall liable payment deductible amount landlords tenants insurance policies maintained pursuant section provided however landlords insurance deductible shall exceed ten thousand dollars tenant shall permit anything done invalidates insurance policies upon tenants request landlord shall provide tenant certificate evidencing insurance c payment premiums subject section tenant shall pay premiums insurance policies described paragraphs b whether obtained landlord tenant within fifteen days tenants receipt copy premium statement evidence amount due except landlord shall pay premiums nonprimary comprehensive public liability insurance landlord elects obtain provided paragraph insurance policies maintained landlord cover improvements real property property landlord shall deliver tenant statement premium applicable property showing reasonable detail tenants share premium computed lease term expires expiration insurance policy maintained landlord tenant shall liable tenants prorated share insurance premiums commencement date tenant shall deliver landlord copy policy insurance tenant required maintain section least thirty days prior expiration policy tenant shall deliver landlord renewal policy alternative providing policy insurance tenant shall right provide landlord certificate insurance executed authorized officer insurance company showing insurance tenant required maintain section full force effect containing information landlord reasonably requires general insurance provisions insurance tenant required maintain lease shall include provision requires insurance carrier give landlord less thirty days written notice prior cancellation modification coverage ii tenant fails deliver policy certificate renewal landlord required lease within prescribed time period policy cancelled modified lease term without landlords consent landlord may obtain insurance case tenant shall reimburse landlord cost insurance within fifteen days receipt statement indicates cost insurance iii landlord tenant shall maintain insurance required lease companies holding general policy rating better set forth current issue best key rating guide landlord tenant acknowledge insurance markets rapidly changing insurance form amounts described section may available future tenant acknowledges insurance describe section primary benefit landlord time lease term tenant landlord unable maintain insurance required lease landlord tenant shall nevertheless maintain insurance coverage customary commercially reasonable insurance industry tenants type business coverage may change time time landlord makes representation adequacy insurance protect landlords tenants interests therefore tenant shall obtain additional property liability insurance tenant deems necessary protect landlord tenant iv landlord tenant hereby waive rights recovery officers employees agents representatives loss damage property property others control loss damage covered insurance policy force whether described lease time loss damage upon obtaining required policies insurance landlord tenant shall give notice insurance carriers mutual waiver subrogation landlords tenants insurance policies described section shall contain provision waiving carriers right subrogation section late charges tenants failure pay rent promptly may cause landlord incur unanticipated costs exact amount costs impractical extremely difficult ascertain costs may include limited processing accounting charges late charges may imposed landlord ground lease mortgage trust deed encumbering property therefore landlord receive rent payment within ten days becomes due provided landlord given tenant fortyeight hours written notice tenant still failed pay base rent fortyeight shall run concurrently ten day period tenant shall pay landlord late charge equal eight percent overdue amount parties agree late charge represents fair reasonable estimate costs landlord incur reason late payment section interest past due obligations amount owed one party hereunder paid due shall bear interest rate fifteen percent per annum due date amount however interest shall payable late charges paid tenant lease payment interest amounts shall excuse cure default lease interest rate specified lease higher rate permitted law interest rate hereby decreased maximum legal interest rate permitted law section impounds insurance premiums real property taxes tenant ten days late payment base rent twice consecutive twelve month period tenant shall pay landlord sum equal onetwelfth annual real property taxes insurance premiums payable tenant lease together payment base rent landlord shall hold payments noninterest bearing impound account unknown landlord shall reasonably estimate amount real property taxes insurance premiums due tenant shall pay deficiency funds impound account landlord upon written request tenant defaults lease landlord may apply funds impound account obligation due lease section see addendum article five use property section permitted uses tenant may use property permitted uses set forth section section manner use tenant shall cause permit property used way constitutes violation law ordinance governmental regulation order annoys interferes rights tenants landlord constitutes nuisance waste tenant shall obtain pay permits including certificate occupancy required tenants occupancy property shall promptly take actions necessary comply applicable statutes ordinances rules regulations orders requirements regulating use tenant property including occupational safety health act see addendum section section see addendum section section signs auctions tenant shall place signs property without landlords prior written consent tenant shall conduct permit auctions sheriffs sales property see addendum section section indemnity tenant shall indemnify landlord hold landlord harmless costs claims liability arising tenants use property b conduct tenants business anything else done permitted tenant done property c breach default performance tenants obligations lease misrepresentations breach warranty tenant lease e acts omissions tenant tenant shall defend landlord cost claim liability tenants expense counsel reasonably acceptable landlord landlords election tenant shall reimburse landlord legal fees costs incurred landlord connection claim material part consideration landlord tenant assumes risk damage property injury persons property arising cause tenant hereby waives claims respect thereof landlord except claim arising landlords landlords employees agents contractors active negligence willful misconduct used section term tenant shall include tenants employees agents contractors invitees applicable see addendum section section landlords access landlord agents may enter property reasonable times show property potential buyers investors tenants parties act inspect conduct tests order monitor tenants compliance applicable environmental laws laws governing presence use hazardous material purpose landlord deems necessary landlord shall give tenant hour prior notice entry except case emergency landlord agrees allow representative tenant accompany landlord agrees comply tenants reasonable security measures landlord may place customary sale lease signs property section quiet possession tenant pays rent complies terms lease tenant may occupy enjoy property full lease term subject provisions lease article six condition property maintenance repairs alterations section existing conditions subject provisions lease tenant accepts property condition execution lease subject recorded matters laws ordinances governmental regulations orders except provided herein tenant acknowledges neither landlord agent landlord made representation condition property suitability property tenants intended use tenant represents warrants tenant made inspection inquiry regarding condition property relying representations landlord broker respect thereto landlord landlords broker provided property information sheet disclosure statement regarding property copy attached exhibit lease section exemption landlord liability landlord shall liable damage injury person business loss income therefrom goods wares merchandise property tenant tenants employees invitees customers person property whether damage injury caused results fire steam electricity water gas rain b breakage leakage obstruction defects pipes sprinklers wires appliances plumbing air conditioning lighting fixtures cause c conditions arising property sources places act omission tenant landlord landlord shall liable damage injury even though cause means repairing damage injury accessible tenant provisions section shall however exempt landlord liability landlords landlords employees agents contractors active negligence willful misconduct section landlords obligations see addendum section section tenants obligations except provided section article seven damage destruction article eight condemnation tenant shall keep portions property including structural nonstructural interior exterior landscaped areas portions systems equipment good order condition repair including interior repainting refinishing needed portion property system equipment property tenant obligated repair fully repaired restored tenant shall promptly replace portion property system equipment property regardless whether benefit replacement extends beyond lease term benefit useful life replacement extends beyond lease term term may extended exercise options useful life replacement shall prorated remaining portion lease term extended tenant shall liable portion cost applicable lease term extended tenant shall maintain preventive maintenance contract providing regular inspection maintenance heating air conditioning system licensed heating air conditioning contractor subject provisions section div part property damaged act omission tenant tenant shall pay landlord cost repairing replacing damaged property whether landlord would otherwise obligated pay cost maintaining repairing property intention landlord tenant times tenant shall maintain portions property tenant obligated maintain attractive firstclass fully operative condition b tenant shall fulfill tenants obligations section tenants sole expense tenant fails maintain repair replace property required section using reasonable efforts landlord may upon ten days prior notice tenant except notice shall required case emergency enter property perform maintenance repair including replacement needed behalf tenant case tenant shall reimburse landlord costs incurred performing maintenance repair immediately upon demand section alterations additions improvements tenant shall make alterations additions improvements property without landlords prior written consent shall unreasonably withheld except nonstructural alterations exceed sixty thousand dollars cost per project visible outside building property part landlord may require tenant provide demolition andor lien completion bonds form amount satisfactory landlord tenant shall promptly remove alterations additions improvements constructed violation paragraph upon landlords written request alterations additions improvements shall done good workmanlike manner conformity applicable laws regulations contractor approved landlord shall unreasonably withheld upon completion work tenant shall provide landlord built plans copies construction contracts proof payment labor materials b tenant shall pay due claims labor material furnished tenant group property tenant shall give landlord least twenty days prior written notice commencement work property regardless whether landlords consent work required landlord may elect record post notices nonresponsibility property section condition upon termination upon termination lease tenant shall surrender property landlord broom clean condition received except ordinary wear tear tenant otherwise obligated remedy provision lease however tenant shall obligated repair damage landlord required repair accordance lease addition landlord may require tenant remove alterations additions improvements whether made landlords consent prior expiration lease restore property prior condition tenants expense alterations additions improvements landlord required tenant remove shall become landlords property shall surrendered landlord upon expiration earlier termination lease except tenant may remove tenants trade fixtures machinery equipment removed without material damage property tenant shall repair tenants expense damage property caused removal trade fixtures machinery equipment event however shall tenant remove following materials equipment shall deemed landlords property without landlords prior written consent power writing power panels lighting lighting fixtures wall coverings drapes blinds window coverings carpets floor coverings heaters air conditioners heating air conditioning equipment fencing security gates similar building operating equipment decorations see addendum section article seven damage destruction section partial damage property tenant shall notify landlord writing immediately upon occurrence damage property property partially damaged ie less fifty percent property untenantable result damage less fifty percent tenants operations materially impaired proceeds received landlord insurance policies described paragraph b sufficient pay necessary repairs lease shall remain effect landlord shall repair damage soon reasonably possible landlord may elect required repair damage tenants fixtures equipment improvements b landlord maintained insurance required maintained paragraph b insurance proceeds received landlord sufficient pay entire cost repair ii cause damage covered insurance policies iii holder mortgage property shall require insurance proceeds portion thereof used retire mortgage debt landlord may elect either repair damage soon reasonably possible case lease shall remain full force effect ii terminate lease date damage occurred landlord shall notify tenant within thirty days receipt notice occurrence damage whether landlord elects repair damage terminate lease landlord elects repair damage tenant shall pay landlord deductible amount landlords insurance policies damage due act omission tenant tenants employees agents contractors invitees difference actual cost repair insurance proceeds received landlord landlord elects terminate lease tenant may elect continue lease full force effect case tenant shall repair damage property building property located tenant shall pay cost repairs except upon satisfactory completion repairs landlord shall deliver tenant insurance proceeds received landlord damage repaired tenant tenant shall give landlord written notice election within ten days receiving landlords termination notice c damage property occurs last six months lease term damage require thirty days repair either landlord tenant may elect terminate lease date damage occurred regardless sufficiency insurance proceeds party electing terminate lease shall give written notification party election within thirty days tenants notice landlord occurrence damage section substantial total destruction property substantially totally destroyed cause whatsoever ie damage property greater partial damage described section regardless whether landlord receives insurance proceeds lease shall terminate later date destruction occurred ii date tenant ceases business property notwithstanding preceding sentence property rebuilt within six months date destruction landlord may elect rebuild property landlords expense case lease shall remain full force effect landlord shall notify tenant election within thirty days tenants notice occurrence total substantial destruction landlord elects landlord shall rebuild property landlords sole expense except destruction caused act omission tenant tenant shall pay landlord difference actual cost rebuilding insurance proceeds received landlord section temporary reduction rent property destroyed damaged landlord tenant repairs restores property pursuant provisions article seven rent payable period damage repair andor restoration shall reduced according degree tenants use property impaired except possible reduction base rent insurance premiums real property taxes tenant shall entitled compensation reduction reimbursement landlord result damage repair restoration property section waiver tenant waives protection statute code judicial decision grants tenant right terminate lease event substantial total destruction leased property tenant agrees provisions section shall govern rights obligations landlord tenant event substantial total destruction property article eight condemnation portion property taken power eminent domain sold threat power called condemnation lease shall terminate part taken sold date condemning authority takes title possession whichever occurs first twenty percent floor area building property located located property taken either landlord tenant may terminate lease date condemning authority takes title possession delivering written notice within ten days receipt written notice taking absence notice within ten days condemning authority takes title possession neither landlord tenant terminates lease lease shall remain effect portion property taken except base rent additional rent shall reduced proportion reduction floor area property condemnation award payment shall distributed following order first ground lessor mortgagee beneficiary deed trust encumbering property amount interest property b second tenant amount award specifically designated loss damage tenants trade fixtures removable personal property c third landlord remainder award whether compensation reduction value leasehold taking fee otherwise lease terminated landlord shall repair damage tenant reimbursed condemning authority severance damages received landlord sufficient pay repair landlord shall right either terminate lease make repair landlords expense article nine assignment subletting section landlords consent required portion property tenants interest lease may acquired person entity whether sale assignment mortgage sublease transfer operation law act tenant without landlords prior written consent except provided section landlord right grant withhold consent provided section attempted transfer without consent shall void shall constitute noncurable breach lease section tenant affiliate see addendum section section release tenant transfer permitted article nine whether without landlords consent shall release tenant change tenants primary liability pay rent perform obligations tenant lease landlords acceptance rent person waiver provision article nine consent one transfer consent subsequent transfer tenants transferee defaults lease landlord may proceed directly tenant without pursuing remedies transferee landlord may consent subsequent assignments modifications lease tenants transferee without notifying tenant obtaining consent action shall relieve tenants liability lease section offer terminate tenant desires assign lease sublease property landlord elects terminate lease pursuant section lease shall terminate commencement date new lease landlord proposed assignee subtenant terms provisions lease governing termination shall apply landlord elect lease shall continue effect otherwise terminated provisions section respect proposed transfer shall continue apply section landlords consent tenants request consent transfer described section shall set forth writing details proposed transfer including name business financial condition prospective transferee financial details proposed transfer eg term rent security deposit payable proposed assignment sublease information landlord reasonably deems relevant landlord shall right elect terminate lease withhold consent reasonable grant consent based following factors business proposed assignee subtenant proposed use property ii net worth financial reputation proposed assignee subtenant iii tenants compliance obligations lease landlord objects proposed assignment solely net worth andor financial reputation proposed assignee tenant may nonetheless sublease assign portion property proposed transferee terms proposed transfer b tenant assigns subleases following shall apply tenant assigns subleases seventy percent building located property aggregate tenant shall pay landlord additional rent lease landlords share stated section profit defined transaction received tenant unless landlord gives written notice tenant assignee subtenant landlords share shall paid assignee subtenant landlord directly profit means amounts paid tenant assignment sublease including key money monthly rent excess monthly rent payable lease fees consideration paid assignment sublease including fees collateral agreements less b costs expenses directly incurred tenant connection execution performance assignment sublease real estate brokers commissions costs renovation construction tenant improvements required assignment sublease tenant entitled recover costs expenses tenant obligated pay landlords share landlord profit case sublease less property rent allocable subleased space percentage square footage basis ii tenant shall provide landlord written statement certifying amounts paid assignment sublease property within thirty days transaction documentation signed landlord may inspect tenants relevant books records verify accuracy statement written request tenant shall promptly furnish landlord copies transaction documentation shall certified tenant complete true correct landlords receipt landlords share shall consent assignment subletting breach tenants obligation paragraph b shall material default lease section merger merger shall result tenants sublease property article nine tenants surrender lease termination lease manner event landlord may terminate subtenancies succeed interest tenant sublandlord subtenancies article ten defaults remedies section covenants conditions tenants landlords performance obligation lease condition well covenant tenants right continue possession property conditioned upon tenants performance time essence performance covenants conditions section defaults tenant shall material default lease tenant fails pay rent abandons property tenants vacation property results cancellation insurance described section b tenant fails pay rent due charge within ten days receipt bill statement landlord c tenant fails perform tenants nonmonetary obligations lease period thirty days written notice landlord provided thirty days required complete performance tenant shall default tenant commences performance within thirty day period thereafter diligently pursues completion notice required paragraph intended satisfy notice requirements imposed law landlord addition requirement tenant makes general assignment general arrangement benefit creditors ii petition adjudication bankruptcy reorganization rearrangement filed tenant dismissed within thirty days iii trustee receiver appointed take possession substantially tenants assets located property tenants interest lease possession restored tenant within thirty days iv substantially tenants assets located property tenants interest lease subjected attachment execution judicial seizure discharged within thirty days court competent jurisdiction determines acts described subparagraph default lease trustee appointed take possession tenant remains debtor possession trustee tenant transfers tenants interest hereunder landlord shall receive additional rent excess rent consideration paid connection assignment sublease rent payable tenant lease e guarantor lease revokes otherwise terminates purports revoke otherwise terminate guaranty portion tenants obligations lease unless otherwise expressly provided guaranty lease revocable section remedies occurrence material default tenant landlord may time thereafter following three days written notice demand may form three day notice pay rent quit time may run concurrently therewith without limiting landlord exercise right remedy landlord may terminate tenants right possession property lawful means case lease shall terminate tenant shall immediately surrender possession property landlord tenant shall served demand payment past due rent charge payments rendered thereafter cure default tenant shall made cashiers check event landlord shall entitled recover tenant damages incurred landlord reason tenants default including worth time award unpaid base rent additional rent charges landlord earned time termination ii worth time award amount unpaid base rent additional rent charges landlord would earned termination time award exceeds amount rental loss tenant proves landlord could reasonably avoided iii worth time award amount unpaid base rent additional rent charges tenant would paid balance lease term time award exceeds amount rental loss tenant proves landlord could reasonably avoided iv amount necessary compensate landlord detriment proximately caused tenants failure perform obligations lease ordinary course things would likely result therefrom including limited costs expenses landlord incurs maintaining preserving property default cost recovering possession property expenses reletting including necessary renovation alteration property landlords reasonable attorneys fees incurred connection therewith real estate commission paid payable used subparts ii worth time award computed allowing interest unpaid amounts rate fifteen percent per annum lesser amount may maximum lawful rate used subpart iii worth time award computed discounting amount discount rate federal reserve bank san francisco time award plus one percent tenant abandoned property landlord shall option retaking possession property recovering tenant amount specified paragraph andor ii proceeding paragraph b b maintain tenants right possession case lease shall continue effect whether tenant abandoned property event landlord shall entitled enforce landlords rights remedies lease including right recover rent becomes due landlord shall remedy described california civil code section lessor may continue lease effect lessees breach abandonment recover rent becomes due lessee right sublet assign subject reasonable limitations c pursue remedy hereafter available landlord laws judicial decisions state property located section automatic termination notwithstanding term provision hereof contrary lease shall terminate occurrence act affirms landlords intention terminate lease provided section hereof including filing unlawful detainer action tenant termination landlords damages default shall include costs fees including reasonable attorneys fees landlord incurs connection filing commencement pursuing andor defending action bankruptcy court court respect lease obtaining relief stay bankruptcy restraining action evict tenant pursuing action respect landlords right possession property damages suffered apart base rent rent payable hereunder shall constitute pecuniary damages must reimbursed landlord prior assumption lease tenant successor tenant bankruptcy proceeding section cumulative remedies landlords exercise right remedy shall prevent exercising right remedy section see addendum article eleven protection lenders section subordination landlord shall right subordinate lease ground lease deed trust mortgage encumbering property advances made security thereof renewals modifications consolidations replacements extensions thereof whenever made recorded tenant shall cooperate landlord lender acquiring security interest property lease tenant shall execute documents assurances lender may require form attached hereto exhibit b form required landlords lender provided agreement contains nondisturbance agreement favor tenant provided tenants obligations lease shall increased material way performance ministerial acts shall deemed material tenant shall deprived rights lease tenants right quiet possession property lease term shall disturbed tenant pays rent performs tenants obligations lease otherwise default ground lessor beneficiary mortgagee elects lease prior lien ground lease deed trust mortgage gives written notice thereof tenant lease shall deemed prior ground lease deed trust mortgage whether lease dated prior subsequent date said ground lease deed trust mortgage date recording thereof see addendum section section attornment landlords interest property acquired ground lessor beneficiary deed trust mortgagee purchaser foreclosure sale tenant shall attorn transferee successor landlords interest property recognize transferee successor landlord lease tenant waives protection current future statute rule law gives purports give tenant right terminate lease surrender possession property upon transfer landlords interest section signing documents tenant shall sign deliver instrument documents necessary appropriate evidence attornment subordination agreement provided agreement include nondisturbance provision favor tenant tenant fails within fifteen days written request tenant hereby makes constitutes irrevocably appoints landlord transferee successor landlord attorneyinfact tenant execute deliver instrument document long instrument complies provisions article eleven section estoppel certificates upon landlords written request tenant shall execute acknowledge deliver landlord written statement form attached hereto exhibit c form required landlords lender certifying none terms provisions lease changed changed stating changed ii lease cancelled terminated iii last date payment base rent charges time period covered payment iv landlord default lease landlord claimed default stating v representations information respect tenant lease landlord may reasonably request prospective purchaser encumbrancer property may require tenant shall deliver statement landlord within fifteen days landlords request landlord may give statement tenant prospective purchaser encumbrancer property purchaser encumbrancer may rely conclusively upon statement true correct b tenant deliver statement landlord within fifteen day period landlord prospective purchaser encumbrancer may conclusively presume rely upon following facts terms provisions lease changed except otherwise represented landlord ii lease cancelled terminated except otherwise represented landlord iii one months base rent charges paid advance iv landlord default lease event tenant shall estopped denying truth facts c see addendum section tenants financial condition within ten days written request landlord tenant shall deliver landlord tenants existing financial statements verify net worth tenant assignee subtenant guarantor tenant addition tenant shall deliver lender designated landlord financial statements required lender facilitate financing refinancing property tenant represents warrants landlord financial statement true accurate statement date statement financial statements shall confidential shall used purposes set forth lease see addendum section article twelve legal costs section legal proceedings tenant landlord shall breach default lease party defaulting party shall reimburse party nondefaulting party upon demand costs expenses nondefaulting party incurs connection breach default defaulting party lease whether suit commenced judgment entered costs shall include legal fees costs incurred negotiation settlement enforcement rights otherwise furthermore action breach enforce provisions lease commenced court action shall award party whose favor judgment entered reasonable sum attorneys fees costs losing party action shall pay attorneys fees costs tenant shall also indemnify landlord hold landlord harmless costs expenses demands liability landlord may incur landlord becomes made party claim action instituted tenant third party third party tenant person holding interest using property license agreement tenant b foreclosure lien labor material furnished tenant group c otherwise arising resulting act transaction tenant group necessary protect landlords interest lease bankruptcy proceeding proceeding title united states code amended tenant shall defend landlord claim action tenants expense counsel reasonably acceptable landlord landlords election tenant shall reimburse landlord legal fees costs landlord reasonably incurs claim action section landlords consent tenant shall pay landlords reasonable attorneys fees incurred connection tenants request landlords consent article nine assignment subletting connection act tenant proposes requires landlords consent article thirteen miscellaneous provisions section nondiscrimination tenant promises condition continuance lease discrimination segregation person group persons basis race color sex creed national origin ancestry leasing subleasing transferring occupancy tenure use property portion thereof section landlords liability certain duties used lease term landlord means current owner owners fee title property leasehold estate ground lease property time question landlord obligated perform obligations landlord lease time landlord owns interest title landlord transfers title interest relieved liability respect obligations landlord lease performed date transfer provided transferee assumes landlords obligations date transfer however landlord shall deliver transferee funds tenant previously paid funds yet applied terms lease b tenant shall give written notice failure landlord perform obligations lease landlord ground lessor mortgage beneficiary deed trust encumbering property whose name address furnished tenant writing landlord shall default lease unless landlord ground lessor mortgagee beneficiary fails cure nonperformance within thirty days receipt tenants notice however nonperformance reasonably requires thirty days cure landlord shall default cure commenced within thirty day period thereafter diligently pursued completion c notwithstanding term provision herein contrary liability landlord performance duties obligations lease limited landlords interest property neither landlord partners shareholders officers principals shall personal liability lease section severability determination court competent jurisdiction provision lease part thereof illegal unenforceable shall cancel invalidate remainder provision lease part thereof illegal unenforceable shall cancel invalidate remainder provision lease shall remain full force effect section interpretation captions articles sections lease assist parties reading lease part terms provisions lease whenever required context lease singular shall include plural plural shall include singular masculine feminine neuter genders shall include provisions relating conduct acts omissions tenant term tenant shall include tenants agents employees contractors invitees successors others using property tenants expressed implied permission section incorporation prior agreements modifications lease agreement parties pertaining lease property agreements effective amendments lease shall writing signed parties attempted amendment shall void section notices notices required permitted lease shall writing shall personally delivered sent national overnight carrier certified mail return receipt requested postage prepaid notices tenant shall delivered address specified section notices landlord shall delivered address specified section notices shall effective upon delivery either party may change notice address upon written notice party section waivers waivers must writing signed waiving party landlords failure enforce provision lease acceptance rent shall waiver shall prevent landlord enforcing provision provision lease future statement payment check tenant letter accompanying payment check shall binding landlord landlord may without notice tenant negotiate check without bound conditions statement section recordation tenant shall record lease without prior written consent landlord however either landlord tenant may require short form memorandum lease executed parties recorded party requiring recording shall pay transfer taxes recording fees section binding effect choice law lease binds party legally acquires rights interest lease landlord tenant however landlord shall obligation tenants successor unless rights interests tenants successor acquired accordance terms lease laws state property located shall govern lease section corporate authority partnership authority tenant corporation corporation represents warrants person signing lease behalf tenant full authority lease binds corporation within thirty days lease signed tenant shall deliver landlord certified copy resolution tenants board directors authorizing execution lease evidence authority reasonably acceptable landlord tenant partnership person entity signing lease tenant represents warrants general partner partnership full authority sign partnership lease binds partnership general partners partnership tenant shall give written notice landlord general partners withdrawal addition within thirty days lease signed tenant shall deliver landlord copy tenants recorded statement partnership certificate limited partnership section joint several liability section see addendum section section execution lease lease may executed counterparts counterpart documents executed counterparts shall constitute single binding instrument landlords delivery lease tenant shall deemed offer lease shall binding upon either party executed delivered parties section survival representations warranties landlord tenant shall survive termination lease article fourteen brokers section brokers fee lease signed delivered landlord tenant landlord shall pay real estate commission landlords broker named section provided written agreement landlord landlords broker sum stated section services rendered landlord landlords broker transaction landlord shall pay landlords broker commission tenant exercises option extend lease term buy property similar option right landlord may grant tenant landlords broker procuring cause lease sale entered landlord tenant covering property commission shall amount set forth landlords brokers commission schedule effect execution lease tenants broker named section landlords broker shall pay appropriate portion commission tenants broker provided agreement landlords broker tenants broker nothing contained lease shall impose obligation landlord pay commission fee party landlords broker section protection brokers landlord sells property assigns landlords interest lease buyer assignee shall accepting conveyance property assignment lease conclusively deemed agreed make payments landlords broker thereafter required landlord article fourteen landlords broker shall right bring legal action enforce declare rights provision prevailing party action shall entitled reasonable attorneys fees paid losing party attorneys fees shall fixed court action paragraph included lease benefit landlords broker section brokers disclosure agency landlords broker hereby discloses landlord tenant landlord tenant hereby consent landlords broker acting transaction agent check one cid landlord exclusively cid landlord tenant section brokers tenant represents warrants landlord brokers named section agents brokers finders parties tenant dealt may entitled commission fee respect lease property additional provisions may set forth rider riders attached hereto blank space additional provisions inserted please draw line space landlord tenant signed lease place dates specified adjacent signatures initialed riders attached incorporated reference lease signed landlord majesticmapa properties llc california limited liability company majestic realty co california corporation manager david wheeler president jay h bradford executive vice president chief financial officer signed tenant gilead sciences inc delaware corporation anthony caracciolo mark l perry executive vice president operations real estate transaction recommended consult professional civil engineer industrial hygienist person experience evaluating condition property including possible presence asbestos hazardous materials underground storage tanks printed form lease drafted legal counsel direction southern california chapter society industrial officer realtors inc representation recommendation made southern california chapter society industrial office realtors inc legal counsel real estate brokers named herein employees agents legal sufficiency legal effect tax consequences lease transaction landlord tenant retain legal counsel advise matters rely upon advice legal counsel exhibit southern california chapter society industrial office realtors inc industrial real estate lease singletenant facility article one basic terms article one contains basic terms lease landlord tenant named articles sections paragraphs lease referred article one explain define basic terms read conjunction basic terms section date lease july section landlord include legal entity majesticmapa properties llc california limited liability company majestic realty co california corporation address landlord crossroads parkway north th floor city industry ca section tenant include legal entity gilead sciences inc delaware corporation address tenant lakeside drive foster city california section property include street address approximate square footageand description approximately square foot building situated approximately acres land commonly known west covina boulevard san dimas california outlined red exhibit subject nonexclusive use area outlined green section lease term years months beginning date specified lease ending section permitted uses see article five general office laboratory warehousing manufacturing pharmaceutical products section tenants guarantor none state none section brokers see article fourteen none state landlords broker majestic realty co tenants broker julien j studley inc section commission payable landlords broker see article fourteen per separate agreement section initial security deposit see section sixty days later occur date existing tenant vacates property ii date landlord substantially completes landlords work fifth th anniversary lease commencement date southern california chapter society industrial nd office realtors inc singletenant net form gilead sciences inc west covina blvd san dimas ca section vehicle parking spaces allocated tenant per exhibit section rent charges payable tenant base rent twentythree thousand five hundred eightyfour dollars per month first twentyfour months provided section shall increased first day see addendum section months commencement date b periodic payments real property taxes see section ii utilities see section iii insurance premiums see section iv impounds insurance premiums property taxes see section v maintenance repairs alterations see article six section landlords share profit assignment sublease see section fifty percent profit landlords share section riders following riders attached made part lease none state addendum pages option extend term lease rider exhibits b c e article two lease term section lease property lease term landlord leases property tenant tenant leases property landlord lease term lease term period stated section shall begin end dates specified section unless beginning end lease term changed provision lease commencement date shall date specified section beginning lease term unless advanced delayed provision lease section delay commencement landlord shall liable tenant landlord deliver possession property landlords work substantially completed tenant april landlords nondelivery property tenant date shall affect lease obligations tenant lease except commencement date shall delayed landlord delivers possession property tenant lease term shall extended period equal delay delivery possession property landlords work substantially completed tenant plus number days necessary end lease term last day month landlord deliver possession property landlords work substantially completed tenant within one hundred eighty days tenant may elect cancel lease giving written notice landlord within ten days one hundred eighty day period ends tenant gives notice lease shall cancelled neither landlord tenant shall obligations tenant give notice tenants right cancel lease shall expire lease term shall commence upon delivery possession property landlords work substantially completed tenant delivery possession property tenant delayed landlord tenant shall upon delivery execute amendment lease setting forth actual commencement date expiration date lease failure execute amendment shall affect actual commencement date expiration date lease section early occupancy tenant occupies property purpose conducting business therein prior commencement date tenants occupancy property shall subject provisions lease early occupancy property shall advance expiration date lease tenant shall pay base rent charges specified lease early occupancy period section holding tenant shall vacate property upon expiration earlier termination lease tenant shall reimburse landlord indemnify landlord damages landlord incurs tenants delay vacating property tenant vacate property upon expiration earlier termination lease landlord thereafter accepts rent tenant tenants occupancy property shall monthtomonth tenancy subject terms lease applicable monthtomonth tenancy except base rent effect shall increased twentyfive percent article three base rent section time manner payment upon execution lease tenant shall pay landlord base rent amount stated paragraph first month lease term first day second month lease term month thereafter tenant shall pay landlord base rent advance without offset deduction prior demand base rent shall payable landlords address place landlord may designate writing section intentionally deleted section security deposit increases upon execution lease tenant shall deposit landlord cash security deposit amount set forth section landlord may apply part security deposit unpaid rent charges due tenant cure defaults tenant landlord uses part security deposit tenant shall restore security deposit full amount within ten days landlords written request tenants failure shall material default lease interest shall paid security deposit landlord shall required keep security deposit separate accounts trust relationship created respect security deposit b time base rent increased tenant shall deposit additional funds landlord sufficient increase security deposit amount bears relationship adjusted base rent initial security deposit bore initial base rent section termination advance payments upon termination lease article seven damage destruction article eight condemnation termination resulting tenants default tenant vacated property manner required lease landlord shall refund credit tenant tenants successor unused portion security deposit advance rent advance payments made tenant landlord amounts paid real property taxes reserves apply time periods termination lease article four charges payable tenant section additional rent charges payable tenant base rent called additional rent unless lease provides otherwise tenant shall pay additional rent due next monthly installment base rent term rent shall mean base rent additional rent section property taxes real property taxes tenant shall pay real property taxes property including fees taxes assessments result tenant improvements installed property benefit tenant lease term subject paragraph c section payment shall made least ten days prior delinquency date taxes within ten day period tenant shall furnish landlord satisfactory evidence real property taxes paid landlord shall reimburse tenant real property taxes paid tenant covering period time prior lease term tenant fails pay real property taxes due landlord may pay taxes tenant shall reimburse landlord amount tax payment additional rent alternatively landlord may elect bill tenant advance taxes tenant shall pay landlord amount taxes additional rent least ten days prior delinquency landlord shall pay taxes prior delinquency provided tenant timely made payments landlord penalty caused tenants failure timely make payments shall also additional rent owed tenant immediately upon demand b definition real property tax real property tax means fee license fee license tax business license fee commercial rental tax levy charge assessment penalty tax imposed taxing authority property ii tax landlords right receive receipt rent income property landlords business leasing property iii tax charge fire protection streets sidewalks road maintenance refuse services provided property governmental agency iv tax imposed upon transaction based upon reassessment property due change ownership defined applicable law transfer part landlords interest property v charge fee replacing tax previously included within definition real property tax real property tax however include landlords federal state income franchise inheritance estate taxes c joint assessment property separately assessed landlord shall reasonably determine tenants share real property tax payable tenant paragraph assessors worksheets reasonably available information tenant shall pay share landlord within fifteen days receipt landlords written statement personal property taxes tenant shall pay taxes charged trade fixtures furnishings equipment personal property belonging tenant tenant shall try personal property taxed separately property ii tenants personal property taxed property tenant shall pay landlord taxes personal property within fifteen days tenant receives written statement landlord personal property taxes e tenants right contest taxes tenant may attempt assessed valuation property reduced may initiate proceedings contest real property taxes required law landlord shall join proceedings brought tenant however tenant shall pay costs proceedings including costs fees incurred landlord upon final determination proceeding contest tenant shall immediately pay real property taxes due together costs charges interest penalties incidental proceedings tenant pay real property taxes due contests taxes tenant shall default lease nonpayment taxes tenant deposits funds landlord opens interestbearing account reasonably acceptable landlord joint names landlord tenant amount deposit shall sufficient pay real property taxes plus reasonable estimate interest costs charges penalties may accrue tenants action unsuccessful less applicable tax impounds previously paid tenant landlord deposit shall applied real property taxes due determined proceedings real property taxes shall paid protest deposit payment protest necessary prevent property sold tax sale similar enforcement proceeding section utilities tenant shall pay directly appropriate supplier cost natural gas heat light power sewer service telephone water refuse disposal utilities services supplied property however services utilities jointly metered property landlord shall make reasonable determination tenants proportionate share cost utilities services tenant shall pay share landlord within fifteen days receipt landlords written statement section insurance policies liability insurance lease term tenant shall maintain policy commercial general liability insurance sometimes known broad form comprehensive general liability insurance insuring tenant liability bodily injury property damage including loss use property personal injury arising operation use occupancy property tenant shall name landlord additional insured policy initial amount insurance shall three million dollars per occurrence shall subject periodic increase based upon industry standards similar facilities liability insurance obtained tenant paragraph shall primary noncontributing ii contain crossliability endorsements iii insure landlord tenants performance section matters giving rise indemnity section result negligence tenant amount coverage insurance shall limit tenants liability relieve tenant obligation lease landlord may also obtain comprehensive public liability insurance amount coverage determined landlord insuring landlord liability arising ownership operation use occupancy property policy obtained landlord shall contributory shall provide primary insurance b property rental income insurance lease term landlord shall maintain policies insurance covering loss damage property full amount replacement value policy shall contain inflation guard endorsement shall provide protection perils included within classification fire extended coverage vandalism malicious mischief special extended perils risk sprinkler leakage perils landlord deems reasonably necessary landlord shall right obtain flood earthquake insurance required lender holding security interest property landlord shall obtain insurance tenants fixtures equipment building improvements installed tenant property lease term landlord shall also maintain rental income insurance policy loss payable landlord amount equal one years base rent plus estimated real property taxes insurance premiums tenant shall liable payment deductible amount landlords tenants insurance policies maintained pursuant section provided however landlords insurance deductible shall exceed ten thousand dollars tenant shall permit anything done invalidates insurance policies upon tenants request landlord shall provide tenant certificate evidencing insurance c payment premiums subject section tenant shall pay premiums insurance policies described paragraphs b whether obtained landlord tenant within fifteen days tenants receipt copy premium statement evidence amount due except landlord shall pay premiums nonprimary comprehensive public liability insurance landlord elects obtain provided paragraph insurance policies maintained landlord cover improvements real property property landlord shall deliver tenant statement premium applicable property showing reasonable detail tenants share premium computed lease term expires expiration insurance policy maintained landlord tenant shall liable tenants prorated share insurance premiums commencement date tenant shall deliver landlord copy policy insurance tenant required maintain section least thirty days prior expiration policy tenant shall deliver landlord renewal policy alternative providing policy insurance tenant shall right provide landlord certificate insurance executed authorized officer insurance company showing insurance tenant required maintain section full force effect containing information landlord reasonably requires general insurance provisions insurance tenant required maintain lease shall include provision requires insurance carrier give landlord less thirty days written notice prior cancellation modification coverage ii tenant fails deliver policy certificate renewal landlord required lease within prescribed time period policy cancelled modified lease term without landlords consent landlord may obtain insurance case tenant shall reimburse landlord cost insurance within fifteen days receipt statement indicates cost insurance iii landlord tenant shall maintain insurance required lease companies holding general policy rating better set forth current issue best key rating guide landlord tenant acknowledge insurance markets rapidly changing insurance form amounts described section may available future tenant acknowledges insurance described section primary benefit landlord time lease term tenant landlord unable maintain insurance required lease landlord tenant shall nevertheless maintain insurance coverage customary commercially reasonable insurance industry tenants type business coverage may change time time landlord makes representation adequacy insurance protect landlords tenants interests therefore tenant shall obtain additional property liability insurance tenant deems necessary protect landlord tenant iv landlord tenant hereby waive rights recovery officers employees agents representatives loss damage property property others control loss damage covered insurance policy force whether described lease time loss damage upon obtaining required policies insurance landlord tenant shall give notice insurance carriers mutual waiver subrogation landlords tenants insurance policies described section shall contain provision waiving carriers right subrogation section late charges tenants failure pay rent promptly may cause landlord incur unanticipated costs exact amount costs impractical extremely difficult ascertain costs may include limited processing accounting charges late charges may imposed landlord ground lease mortgage trust deed encumbering property therefore landlord receive rent payment within ten days becomes due provided landlord given tenant forty eight hours written notice tenant still failed pay base rent fortyeight hours shall run concurrently ten day period tenant shall pay landlord late charge equal ten percent overdue amount parties agree late charge represents fair reasonable estimate costs landlord incur reason late payment section interest past due obligations amount owed one party hereunder paid due shall bear interest rate fifteen percent per annum due date amount however interest shall payable late charges paid tenant lease payment interest amounts shall excuse cure default lease interest rate specified lease higher rate permitted law interest rate hereby decreased maximum legal interest rate permitted law section impounds insurance premiums real property taxes tenant ten days late payment base rent twice consecutive twelve month period tenant shall pay landlord sum equal onetwelfth annual real property taxes insurance premiums payable tenant lease together payment base rent landlord shall hold payments noninterest bearing impound account unknown landlord shall reasonably estimate amount real property taxes insurance premiums due tenant shall pay deficiency funds impound account landlord upon written request tenant defaults lease landlord may apply funds impound account obligation due lease article five use property section permitted uses tenant may use property permitted uses set forth section section manner use tenant shall cause permit property used way constitutes violation law ordinance governmental regulation order annoys interferes rights tenants landlord constitutes nuisance waste tenant shall obtain pay permits including certificate occupancy required tenants occupancy property shall promptly take actions necessary comply applicable statutes ordinances rules regulations orders requirements regulating use tenant property including occupational safety health act see addendum section section intentionally deleted see addendum section section signs auctions tenant shall place signs property without landlords prior written consent tenant shall conduct permit auctions sheriffs sales property see addendum section section indemnity tenant shall indemnify landlord hold landlord harmless costs claims liability arising tenants use property b conduct tenants business anything else done permitted tenant done property c breach default performance tenants obligations lease misrepresentation breach warranty tenant lease e acts omissions tenant tenant shall defend landlord cost claim liability tenants expense counsel reasonably acceptable landlord landlords election tenant shall reimburse landlord legal fees costs incurred landlord connection claim material part consideration landlord tenant assumes risk damage property injury persons property arising cause tenant hereby waives claims respect thereof landlord except claim arising landlords landlords employees agents contractors active negligence willful misconduct used section term tenant shall include tenants employees agents contractors invitees applicable see addendum section section landlords access landlord agents may enter property reasonable times show property potential buyers investors tenants parties act inspect conduct tests order monitor tenants compliance applicable environmental laws laws governing presence use hazardous material purpose landlord deems necessary landlord shall give tenant hour prior notice entry except case emergency landlord agrees allow representative tenant accompany landlord agrees comply tenants reasonable security measures landlord may place customary sale lease signs property section quiet possession tenant pays rent complies terms lease tenant may occupy enjoy property full lease term subject provisions lease article six condition property maintenance repairs alterations section existing conditions subject provisions lease tenant accepts property condition execution lease subject recorded matters laws ordinances governmental regulations orders except provided herein tenant acknowledges neither landlord agent landlord made representation condition property suitability property tenants intended use tenant represents warrants tenant made inspection inquiry regarding condition property relying representations landlord broker respect thereto landlord landlords broker provided property information sheet disclosure statement regarding property copy attached exhibit lease section exemption landlord liability landlord shall liable damage injury person business loss income therefrom goods wares merchandise property tenant tenants employees invitees customers person property whether damage injury caused results fire steam electricity water gas rain b breakage leakage obstruction defects pipes sprinklers wires appliances plumbing air conditioning lighting fixtures cause c conditions arising property sources places act omission tenant landlord landlord shall liable damage injury even though cause means repairing damage injury accessible tenant provisions section shall however exempt landlord liability landlords landlords employees agents contractors active negligence willful misconduct section landlords obligations see addendum section section tenants obligations except provided section article seven damage destruction article eight condemnation tenant shall keep portions property including structural nonstructural interior exterior landscaped areas portions systems equipment good order condition repair including interior repainting refinishing needed portion property system equipment property tenant obligated repair fully repaired restored tenant shall promptly replace portion property system equipment property regardless whether benefit replacement extends beyond lease term benefit useful life replacement extends beyond lease term term may extended exercise options useful life replacement shall prorated remaining portion lease term extended tenant shall liable portion cost applicable lease term extended tenant shall maintain preventive maintenance contract providing regular inspection maintenance heating air conditioning system licensed heating air conditioning contractor subject provisions section div part property damaged act omission tenant tenant shall pay landlord cost repairing replacing damaged property whether landlord would otherwise obligated pay cost maintaining repairing property intention landlord tenant times tenant shall maintain portions property tenant obligated maintain attractive firstclass fully operative condition b tenant shall fulfill tenants obligations section tenants sole expense tenant fails maintain repair replace property required section using reasonable efforts landlord may upon ten days prior notice tenant except notice shall required case emergency enter property perform maintenance repair including replacement needed behalf tenant case tenant shall reimburse landlord costs incurred performing maintenance repair immediately upon demand section alterations additions improvements tenant shall make alterations additions improvements property without landlords prior written consent shall unreasonably withheld except nonstructural alterations exceed forty thousand dollars cost per project visible outside building property part landlord may require tenant provide demolition andor lien completion bonds form amount satisfactory landlord tenant shall promptly remove alterations additions improvements constructed violation paragraph upon landlords written request alterations additions improvements shall done good workmanlike manner conformity applicable laws regulations contractor approved landlord shall unreasonably withheld upon completion work tenant shall provide landlord built plans copies construction contracts proof payment labor materials b tenant shall pay due claims labor material furnished tenant group property tenant shall give landlord least twenty days prior written notice commencement work property regardless whether landlords consent work required landlord may elect record post notices nonresponsibility property section condition upon termination upon termination lease tenant shall surrender property landlord broom clean condition received except ordinary wear tear tenant otherwise obligated remedy provision lease however tenant shall obligated repair damage landlord required repair accordance lease addition landlord may require tenant remove alterations additions improvements whether made landlords consent prior expiration lease restore property prior condition tenants expense alterations additions improvements landlord required tenant remove shall become landlords property shall surrendered landlord upon expiration earlier termination lease except tenant may remove tenants machinery equipment removed without material damage property tenant shall repair tenants expense damage property caused removal machinery equipment event however shall tenant remove following materials equipment shall deemed landlords property without landlords prior written consent power wiring power panels lighting lighting fixtures wall coverings drapes blinds window coverings carpets floor coverings heaters air conditioners heating air conditioning equipment fencing security gates similar building operating equipment decorations see addendum section article seven damage destruction section partial damage property tenant shall notify landlord writing immediately upon occurrence damage property property partially damaged ie less fifty percent property untenantable result damage less fifty percent tenants operations materially impaired proceeds received landlord insurance policies described paragraph b sufficient pay necessary repairs lease shall remain effect landlord shall repair damage soon reasonably possible landlord may elect required repair damage tenants fixtures equipment improvements b landlord maintained insurance required maintained paragraph b insurance proceeds received landlord sufficient pay entire cost repair ii cause damage covered insurance policies iii holder mortgage property shall require insurance proceeds portion thereof used retire mortgage debt landlord may elect either repair damage soon reasonably possible case lease shall remain full force effect ii terminate lease date damage occurred landlord shall notify tenant within thirty days receipt notice occurrence damage whether landlord elects repair damage terminate lease landlord elects repair damage tenant shall pay landlord deductible amount landlords insurance policies damage due act omission tenant tenants employees agents contractors invitees difference actual cost repair insurance proceeds received landlord landlord elects terminate lease tenant may elect continue lease full force effect case tenant shall repair damage property building property located tenant shall pay cost repairs except upon satisfactory completion repairs landlord shall deliver tenant insurance proceeds received landlord damage repaired tenant tenant shall give landlord written notice election within ten days receiving landlords termination notice c damage property occurs last six months lease term damage require thirty days repair either landlord tenant may elect terminate lease date damage occurred regardless sufficiency insurance proceeds party electing terminate lease shall give written notification party election within thirty days tenants notice landlord occurrence damage section substantial total destruction property substantially totally destroyed cause whatsoever ie damage property greater partial damage described section regardless whether landlord receives insurance proceeds lease shall terminate later date destruction occurred ii date tenant ceases business property notwithstanding preceding sentence property rebuilt within six months date destruction landlord may elect rebuild property landlords expense case lease shall remain full force effect landlord shall notify tenant election within thirty days tenants notice occurrence total substantial destruction landlord elects landlord shall rebuild property landlords sole expense except destruction caused act omission tenant tenant shall pay landlord difference actual cost rebuilding insurance proceeds received landlord section temporary reduction rent property destroyed damaged landlord tenant repairs restores property pursuant provisions article seven rent payable period damage repair andor restoration shall reduced according degree tenants use property impaired except possible reduction base rent insurance premiums real property taxes tenant shall entitled compensation reduction reimbursement landlord result damage destruction repair restoration property section waiver tenant waives protection statute code judicial decision grants tenant right terminate lease event substantial total destruction leased property tenant agrees provisions section shall govern rights obligations landlord tenant event substantial total destruction property article eight condemnation portion property taken power eminent domain sold threat power called condemnation lease shall terminate part taken sold date condemning authority takes title possession whichever occurs first twenty percent floor area building property located located property taken either landlord tenant may terminate lease date condemning authority takes title possession delivering written notice within ten days receipt written notice taking absence notice within ten days condemning authority takes title possession neither landlord tenant terminates lease lease shall remain effect portion property taken except base rent additional rent shall reduced proportion reduction floor area property condemnation award payment shall distributed following order first ground lessor mortgagee beneficiary deed trust encumbering property amount interest property b second tenant amount award specifically designated loss damage tenants trade fixtures removable persona property c third landlord remainder award whether compensation reduction value leasehold taking fee otherwise lease terminated landlord shall repair damage property caused condemnation except landlord shall obligated repair damage tenant reimbursed condemning authority severance damages received landlord sufficient pay repair landlord shall right either terminate lease make repair landlords expense article nine assignment subletting section landlords consent required portion property tenants interest lease may acquired person entity whether sale assignment mortgage sublease transfer operation law act tenant without landlords prior written consent except provided section landlord right grant withhold consent provided section attempted transfer without consent shall void shall constitute noncurable breach lease section tenant affiliate see addendum section section release tenant transfer permitted article nine whether without landlords consent shall release tenant change tenants primary liability pay rent perform obligations tenant lease landlords acceptance rent person waiver provision article nine consent one transfer consent subsequent transfer tenants transferee defaults lease landlord may proceed directly tenant without pursuing remedies transferee landlord may consent subsequent assignments modifications lease tenants transferee without notifying tenant obtaining consent action shall relieve tenants liability lease section offer terminate tenant desires assign lease sublease property landlord elects writing terminate lease pursuant section lease shall terminate commencement date new lease landlord proposed assignee subtenant terms provisions lease governing termination shall apply landlord elect lease shall continue effect otherwise terminated provisions section respect proposed transfer shall continue apply section landlords consent tenants request consent transfer described section shall set forth writing details proposed transfer including name business financial condition prospective transferee financial details proposed transfer eg term rent security deposit payable proposed assignment sublease information landlord reasonably deems relevant landlord shall right elect terminate lease withhold consent reasonable grant consent based following factors business proposed assignee subtenant proposed use property ii net worth financial reputation proposed assignee subtenant iii tenants compliance obligations lease landlord objects proposed assignment solely net worth andor financial reputation proposed assignee tenant may nonetheless sublease assign portion property proposed transferee terms proposed transfer b tenant assigns subleases following shall apply tenant assigns subleases square feet property aggregate tenant shall pay landlord additional rent lease landlords share stated section profit defined transaction received tenant unless landlord gives written notice tenant assignee subtenant landlords share shall paid assignee subtenant landlord directly profit means amounts paid tenant assignment sublease including key money monthly rent excess monthly rent payable lease fees consideration paid assignment sublease including fees collateral agreements less b costs expenses directly incurred tenant connection execution performance assignment sublease real estate brokers commissions costs renovation construction tenant improvement required assignment sublease tenant entitled recover costs expenses tenant obligated pay landlords share landlord profit case sublease less property rent allocable subleased space percentage square footage basis ii tenant shall provide landlord written statement certifying amounts paid assignment sublease property within thirty days transaction documentation signed landlord may inspect tenants relevant books records verify accuracy statement written request tenant shall promptly furnish landlord copies transaction documentation shall certified tenant complete true correct landlords receipt landlords share shall consent assignment subletting breach tenants obligation paragraph b shall material default lease section merger merger shall result tenants sublease property article nine tenants surrender lease termination lease manner event landlord may terminate subtenancies succeed interest tenant sublandlord subtenancies article ten defaults remedies section covenants conditions tenants performance obligation lease condition well covenant tenants right continue possession property conditioned upon tenants performance time essence performance covenants conditions section defaults tenant shall material default lease tenant fails pay rent abandons property tenants vacation property results cancellation insurance described section b tenant fails pay rent due charge within ten days receipt bill statement landlord c tenant fails perform tenants nonmonetary obligations lease period thirty days written notice landlord provided thirty days required complete performance tenant shall default tenant commences performance within thirty day period thereafter diligently pursues completion notice required paragraph intended satisfy notice requirements imposed law landlord addition requirement tenant makes general assignment general arrangement benefit creditors ii petition adjudication bankruptcy reorganization rearrangement filed tenant dismissed within thirty days iii trustee receiver appointed take possession substantially tenants assets located property tenants interest lease possession restored tenant within thirty days iv substantially tenants assets located property tenants interest lease subjected attachment execution judicial seizure discharged within thirty days court competent jurisdiction determines acts described subparagraph default lease trustee appointed take possession tenant remains debtor possession trustee tenant transfers tenants interest hereunder landlord shall receive additional rent excess rent consideration paid connection assignment sublease rent payable tenant lease e guarantor lease revokes otherwise terminates purports revoke otherwise terminate guaranty portion tenants obligations lease unless otherwise expressly provided guaranty lease revocable section remedies occurrence material default tenant landlord may time thereafter following three days written notice demand may form three day notice pay rent quit time may run concurrently therewith without limiting landlord exercise right remedy landlord may terminate tenants right possession property lawful means case lease shall terminate tenant shall immediately surrender possession property landlord tenant shall served demand payment past due rent charge payments rendered thereafter cure default tenant shall made cashiers check event landlord shall entitled recover tenant damages incurred landlord reason tenants default including worth time award unpaid base rent additional rent charges landlord earned time termination ii worth time award amount unpaid base rent additional rent charges landlord would earned termination time award exceeds amount rental loss tenant proves landlord could reasonably avoided iii worth time award amount unpaid base rent additional rent charges tenant would paid balance lease term time award exceeds amount rental loss tenant proves landlord could reasonably avoided iv amount necessary compensate landlord detriment proximately caused tenants failure perform obligations lease ordinary course things would likely result therefrom including limited costs expenses landlord incurs maintaining preserving property default cost recovering possession property expenses reletting including necessary renovation alteration property landlords reasonable attorneys fees incurred connection therewith real estate commission paid payable used subparts ii worth time award computed allowing interest unpaid amounts rate fifteen percent per annum lesser amount may maximum lawful rate used subpart iii worth time award computed discounting amount discount rate federal reserve bank san francisco time award plus one percent tenant abandoned property landlord shall option retaking possession property recovering tenant amount specified paragraph andor ii proceeding paragraph b b maintain tenants right possession case lease shall continue effect whether tenant abandoned property event landlord shall entitled enforce landlords rights remedies lease including right recover rent becomes due landlord shall remedy described california civil code section lessor may continue lease effect lessees breach abandonment recover rent becomes due lessee right sublet assign subject reasonable limitations c pursue remedy hereafter available landlord laws judicial decisions state property located section intentionally deleted section automatic termination notwithstanding term provision hereof contrary lease shall terminate occurrence act affirms landlords intention terminate lease provided section hereof including filing unlawful detainer action tenant termination landlords damages default shall include costs fees including reasonable attorneys fees landlord incurs connection filing commencement pursuing andor defending action bankruptcy court court respect lease obtaining relief stay bankruptcy restraining action evict tenant pursuing action respect landlords right possession property damages suffered apart base rent rent payable hereunder shall constitute pecuniary damages must reimbursed landlord prior assumption lease tenant successor tenant bankruptcy proceeding section cumulative remedies landlords exercise right remedy shall prevent exercising right remedy section see addendum article eleven protection lenders section subordination landlord shall right subordinate lease ground lease deed trust mortgage encumbering property advances made security thereof renewals modifications consolidations replacements extensions thereof whenever made recorded tenant shall cooperate landlord lender acquiring security interest property lease tenant shall execute document assurances lender may require form attached hereto exhibit b form required landlords lender provided agreement contains nondisturbance agreement favor tenant provided tenants obligations lease shall increased material way performance ministerial acts shall deemed material tenant shall deprived rights lease tenants right quiet possession property lease term shall distributed tenant pays rent performs tenants obligations lease otherwise default ground lessor beneficiary mortgagee elects lease prior lien ground lease deed trust mortgage gives written notice thereof tenant lease shall deemed prior ground lease deed trust mortgage whether lease dated prior subsequent date said ground lease deed trust mortgage date recording thereof see addendum section section attornment landlords interest property acquired ground lessor beneficiary deed trust mortgagee purchaser foreclosure sale tenant shall attorn transferee successor landlords interest property recognize transferee successor landlord lease tenant waives protection current future statute rule law gives purports give tenant right terminate lease surrender possession property upon transfer landlords interest section signing documents tenant shall sign deliver instrument documents necessary appropriate evidence attornment subordination agreement provided agreement includes nondisturbance provision favor tenant tenant fails within fifteen days written request tenant hereby makes constitutes irrevocably appoints landlord transferee successor landlord attorneyinfact tenant execute deliver instrument document long instrument complies provisions article eleven section estoppel certificates upon landlords written request tenant shall execute acknowledge deliver landlord written statement form attached hereto exhibit c form required landlords lender certifying none terms provisions lease changed changed stating changed ii lease cancelled terminated iii last date payment base rent charges time period covered payment iv landlord default lease landlord claimed default stating v representations information respect tenant lease landlord may reasonably request prospective purchaser encumbrancer property may require tenant shall deliver statement landlord within fifteen days landlords request landlord may give statement tenant prospective purchaser encumbrancer property purchaser encumbrancer may rely conclusively upon statement true correct b tenant deliver statement landlord within fifteen day period landlord prospective purchaser encumbrancer may conclusively presume rely upon following facts terms provisions lease changed except otherwise represented landlord ii lease cancelled terminated except otherwise represented landlord iii one months base rent charges paid advance iv landlord default lease event tenant shall estopped denying truth facts section tenants financial condition within ten days written request landlord tenant shall deliver landlord tenants existing financial statements verify net worth tenant assignee subtenant guarantor tenant addition tenant shall deliver lender designated landlord financial statements required lender facilitate financing refinancing property tenant represents warrants landlord financial statement true accurate statement date statement financial statements shall confidential shall used purposes set forth lease article twelve legal costs section legal proceedings tenant landlord shall breach default lease party defaulting party shall reimburse party nondefaulting party upon demand costs expenses nondefaulting party incurs connection breach default defaulting party lease whether suit commenced judgment entered costs shall include legal fees costs incurred negotiation settlement enforcement rights otherwise furthermore action breach enforce provisions lease commenced court action shall award party whose favor judgment entered reasonable sum attorneys fees costs losing party action shall pay attorneys fees costs tenant shall also indemnify landlord hold landlord harmless costs expenses demands liability landlord may incur landlord becomes made party claim action instituted tenant third party third party tenant person holding interest using property license agreement tenant b foreclosure lien labor material furnished tenant group c otherwise arising resulting act transaction tenant group necessary protect landlords interest lease bankruptcy proceeding proceeding title united states code amended tenant shall defend landlord claim action tenants expense counsel reasonably acceptable landlord landlords election tenant shall reimburse landlord legal fees costs landlord reasonably incurs claim action section landlords consent tenant shall pay landlords reasonable attorneys fees incurred connection tenants request landlords consent article nine assignment subletting connection act tenant proposes requires landlords consent article thirteen miscellaneous provisions section nondiscrimination tenant promises condition continuance lease discrimination segregation person group persons basis race color sex creed national origin ancestry leasing subleasing transferring occupancy tenure use property portion thereof section landlords liability certain duties used lease term landlord means current owner owners fee title property leasehold estate ground lease property time question landlord obligated perform obligations landlord lease time landlord owns interest title landlord transfers title interest relieved liability respect obligations landlord lease performed date transfer provided transferee assumes landlords obligations date transfer however landlord shall deliver transferee funds tenant previously paid funds yet applied terms lease b tenant shall give written notice failure landlord perform obligations lease landlord ground lessor mortgagee beneficiary deed trust encumbering property whose name address furnished tenant writing landlord shall default lease unless landlord ground lessor mortgagee beneficiary fails cure nonperformance within thirty days receipt tenants notice however nonperformance reasonably requires thirty days cure landlord shall default cure commenced within thirty day period thereafter diligently pursued completion c notwithstanding term provision herein contrary liability landlord performance duties obligations lease limited landlords interest property neither landlord partners shareholders officers principals shall personal liability lease section severability determination court competent jurisdiction provision lease part thereof illegal unenforceable shall cancel invalidate remainder provision lease shall remain full force effect section interpretation captions articles sections lease assist parties reading lease part terms provisions lease whenever required context lease singular shall include plural plural shall include singular masculine feminine neuter genders shall include provision relating conduct acts omissions tenant term tenant shall include tenants agents employees contractors invitees successors others using property tenants expressed implied permission section incorporation prior agreements modifications lease agreement parties pertaining lease property agreements effective amendments lease shall writing signed parties attempted amendment shall void section notices notices required permitted lease shall writing shall personally delivered sent national overnight carrier certified mail return receipt requested postage prepaid notices tenant shall delivered address specified section notices landlord shall delivered address specified section notices shall effective upon delivery either party may change notice address upon written notice party section waivers waivers must writing signed waiving party landlords failure enforce provision lease acceptance rent shall waiver shall prevent landlord enforcing provision provision lease future statement payment check tenant letter accompanying payment check shall binding landlord landlord may without notice tenant negotiate check without bound conditions statement section recordation tenant shall record lease without prior written consent landlord however either landlord tenant may require short form memorandum lease executed parties recorded party requiring recording shall pay transfer taxes recording fees section binding effect choice law lease binds party legally acquires rights interest lease landlord tenant however landlord shall obligation tenants successor unless rights interests tenants successor acquired accordance terms lease laws state property located shall govern lease section corporate authority partnership authority tenant corporation corporation represents warrants person signing lease behalf tenant full authority lease binds corporation within thirty days lease signed tenant shall deliver landlord certified copy resolution tenants board directors authorizing execution lease evidence authority reasonably acceptable landlord tenant partnership person entity signing lease tenant represents warrants general partner partnership full authority sign partnership lease binds partnership general partners partnership tenant shall give written notice landlord general partners withdrawal addition within thirty days lease signed tenant shall deliver landlord copy tenants recorded statement partnership certificate limited partnership section joint several liability section see addendum section section execution lease lease may executed counterparts counterpart documents executed counterparts shall constitute single binding instrument landlords delivery lease tenant shall deemed offer lease shall binding upon either party executed delivered parties section survival representations warranties landlord tenant shall survive termination lease article fourteen brokers section brokers fee lease signed delivered landlord tenant landlord shall pay real estate commission landlords broker named section provided written agreement landlord landlords broker sum stated section services rendered landlord landlords broker transaction landlord shall pay landlords broker commission tenant exercises option extend lease term buy property similar option right landlord may grant tenant landlords broker procuring cause lease sale entered landlord tenant covering property commission shall amount set forth landlords brokers commission schedule effect execution lease tenants broker named section landlords broker shall pay appropriate portion commission tenants broker provided agreement landlords broker tenants broker nothing contained lease shall impose obligation landlord pay commission fee party landlords broker section protection brokers landlord sells property assigns landlords interest lease buyer assignee shall accepting conveyance property assignment lease conclusively deemed agreed make payments landlords broker thereafter required landlord article fourteen landlords broker shall right bring legal action enforce declare rights provision prevailing party action shall entitled reasonable attorneys fees paid losing party attorneys fees shall fixed court action paragraph included lease benefit landlords broker section brokers disclosure agency landlords broker hereby discloses landlord tenant landlord tenant hereby consent landlords broker acting transaction agent check one cid landlord exclusively cid landlord tenant section brokers tenant represents warrants landlord brokers named section agents brokers finders parties tenant dealt may entitled commission fee respect lease property additional provisions may set forth rider riders attached hereto blank space additional provisons inserted please draw line space landlord tenant signed lease place dates specified adjacent signatures initialed riders attached incorporated reference lease landlord igned majesticmapa properties llc california limited liability company majestic realty co majestic realty co california corporation california corporation manager edward p roski jr david wheeler executive vice president david wheeler edward p roski jr president tenant signed gilead sciences inc delaware corporation crispin gs eley vp pharmaceutical operations anthony caracciolo vp manufacturing real estate transaction recommended consult professional civil engineer industrial hygienist person experience evaluating condition property including possible presence asbestos hazardous materials underground storage tanks printed form lease drafted legal counsel direction southern california chapter society industrial office realtors inc representation recommendation made southern california chapter society industrial office realtors inc legal counsel real estate brokers named herein employees agents legal sufficiency legal effect tax consequences lease transaction landlord tenant retain legal counsel advise matters rely upon advice legal counsel addendum industrial real estate lease addendum addendum made entered majesticmapa properties llc california limited liability company majestic realty co california corporation collectively landlord gilead sciences inc delaware corporation tenant dated date set forth section industrial real estate lease landlord tenant lease addendum attached promises covenants agreements declarations made set forth herein intended shall force effect set forth length body lease extent provisions addendum inconsistent terms conditions lease terms conditions addendum shall control section base rent commencing twentyfifth th lease month term defined continuing thirtysixth th lease month monthly base rent shall amount equal twentyfour thousand six hundred fiftysix dollars commencing thirtyseventh th lease month continuing sixtieth th lease month monthly base rent shall equal twentyfive thousand seven hundred twentyeight dollars term lease month shall mean consecutive month lease term first lease month commencing lease commencement date section manner use section hereby amended adding following end thereof tenant shall anything suffer anything done property way conflict law statute ordinance governmental rule regulation requirement force may hereafter enacted promulgated collectively applicable laws tenant shall sole cost expense promptly comply applicable laws relate tenants specific use property ii alteration tenant improvements triggered alteration tenant improvement made tenant standard regulation hereafter imposed landlord tenant state federal local governmental body charged establishment regulation enforcement occupational health safety standards employers employees landlords tenants landlord tenant applicable agree sole cost expense comply promptly standards regulations judgment court competent jurisdiction admission tenant judicial action regardless whether landlord party thereto tenant violated said governmental measures shall conclusive fact landlord tenant landlord shall comply applicable laws relating property lease commencement date compliance applicable laws required governmental agency provided compliance applicable laws responsibility tenant lease provided landlords failure comply therewith would unreasonably materially affect safety tenants employees create significant health hazard tenants employees section hazardous materials definitions hazardous material means substance whether solid liquid gaseous nature presence requires investigation remediation federal state local statute regulation ordinance order action policy common law ii becomes defined hazardous waste hazardous substance pollutant contaminant federal state local statute regulation rule ordinance west covina blvd san dimas ca september gilead sciences inc amendments thereto including without limitation comprehensive environmental response compensation liability act usc section et seq andor resource conservation recovery act usc section et seq hazardous materials transportation act usc section et seq federal water pollution control act usc section et seq clean air act usc section et seq toxic substances control act amended usc section et seq occupational safety health act usc section et seq laws amended supplemented iii toxic explosive corrosive flammable infectious radioactive carcinogenic mutagenic otherwise hazardous becomes regulated governmental authority agency department commission board agency instrumentality united states state california political subdivision thereof iv presence property causes threatens cause nuisance upon property adjacent properties poses threatens pose hazard health safety persons property v presence adjacent properties could constitute trespass tenant vi without limitation contains gasoline diesel fuel petroleum hydrocarbons vii without limitation contains polychlorinated biphenyls pcbs asbestos urea formaldehyde foam insulation viii without limitation contains radon gas b environmental requirements means applicable present future statutes regulations rules ordinances codes licenses permits orders approvals plans authorizations concessions franchises similar items including limited pertaining reporting licensing permitting investigation remediation governmental agencies ii applicable judicial administrative regulatory decrees judgments orders relating protection human health environment including without limitation requirements pertaining emissions discharges releases threatened releases hazardous materials chemical substances air surface water groundwater land relating manufacture processing distribution use treatment storage disposal transport handling hazardous materials chemical substances c environmental damages means claims judgments damages losses penalties fines liabilities including strict liability encumbrances liens costs expenses including expense investigation defense claim whether claim ultimately defeated amount good faith settlement judgment arising claim whatever kind nature contingent otherwise matured unmatured foreseeable unforeseeable including without limitation reasonable attorneys fees disbursements consultants fees incurred time result existence hazardous material upon beneath property migrating threatening migrate property existence violation environmental requirements pertaining property activities thereon regardless whether existence hazardous material violation environmental requirements arose prior present ownership operation property environmental damages include without limitation damages personal injury injury property natural resources occurring upon property including without limitation lost profits consequential damages cost demolition rebuilding improvements real property interest penalties damages arising claims brought behalf employees tenant respect tenant waives right raise defense landlord immunity may entitled industrial workers compensation laws ii fees costs expenses incurred services attorneys consultants contractors experts laboratories costs incurred connection investigation remediation hazardous materials violation environmental requirements including limited preparation feasibility studies reports performance cleanup remediation removal response abatement containment closure restoration monitoring work required governmental agency reasonably necessary make full economic use property property manner consistent current use otherwise expended connection conditions including without limitation attorneys fees costs expenses incurred enforcing provisions lease collecting sums due hereunder iii liability third person governmental agency indemnify person governmental agency costs expended connection items referenced subparagraph ii iv diminution fair market value property including without limitation reduction fair market rental value life expectancy property improvements located thereon restriction use adverse impact marketing property portion thereof governmental agency means governmental agencies departments commissions boards bureaus instrumentalities united states states counties cities political subdivisions thereof e tenant group means tenant tenants successors assignees guarantors officers directors agents employees invitees permitees parties supervision control tenant entering property term lease permission knowledge tenant landlord agents employees prohibitions normal quantities general office supplies except specified exhibit attached hereto tenant shall cause permit suffer hazardous material brought upon treated kept stored disposed discharged released produced manufactured generated refined used upon beneath property tenant group person without prior written consent landlord time time term lease tenant may request landlords approval tenants use hazardous materials approval may withheld landlords sole discretion tenant shall prior commencement date provide landlord hazardous materials described exhibit description handling storage use disposal procedures b community right know plans disclosures andor emergency response plans tenant required supply local governmental agencies pursuant environmental requirements b tenant shall cause permit suffer existence commission tenant group person violation environmental requirements upon beneath property c tenant shall neither create suffer exist permit tenant group create suffer exist lien security interest charge encumbrance kind respect property including without limitation lien imposed pursuant section f superfund amendments reauthorization act usc section similar state statute tenant shall install operate maintain grade tank sump pit pond lagoon storage treatment vessel device property without landlords prior written consent indemnity tenant successors assigns guarantors agree indemnify defend reimburse hold harmless landlord ii person acquires portion property manner including purchase foreclosure sale becomes entitled exercise rights remedies landlord lease iii directors officers shareholders employees partners agents contractors subcontractors experts licensees affiliates lessees mortgagees trustees heirs devisees successors assigns invitees persons environmental damages exist result activities negligence tenant group exist result breach warranty covenant inaccuracy representation tenant contained lease tenants remediation property failure meet obligations contained lease b obligations contained section shall include limited burden expense defending claims suits administrative proceedings even claims suits proceedings groundless false fraudulent conducting negotiations description paying discharging become due judgments penalties sums due indemnified persons landlord sole expense may employ additional counsel choice associate counsel representing tenant c landlord shall right obligation join participate control elects legal proceedings actions initiated connection tenants hazardous material activities landlord may also negotiate defend approve appeal action taken issued applicable governmental authority regard contamination property hazardous material obligations tenant paragraph shall survive expiration termination lease e obligations tenant paragraph shall affected investigation behalf landlord information landlord may obtain respect thereto obligation remediate addition obligation tenant indemnify landlord pursuant lease tenant shall upon approval demand landlord sole cost expense using contractors approved landlord promptly take actions remediate property required governmental agency reasonably necessary mitigate environmental damages allow full economic use property remediation necessitated presence upon beneath property time upon termination lease hazardous material violation environmental requirements existing result activities negligence tenant group actions shall include limited investigation environmental condition property preparation feasibility studies reports remedial plans performance cleanup remediation containment operation maintenance monitoring restoration work whether property shall performed manner approved landlord tenant shall take actions necessary restore property condition existing prior tenant groups introduction hazardous material upon beneath property notwithstanding lesser standard remediation allowable applicable law governmental policies right inspect landlord shall right sole absolute discretion duty enter conduct inspection property including invasive tests reasonable time determine whether tenant complying terms lease including limited compliance property activities thereon environmental requirements existence environmental damages result condition property surrounding properties activities thereon landlord shall right duty retain independent professional consultant consultant enter property conduct inspection review report prepared tenant concerning compliance cost consultant shall paid landlord unless investigation discloses violation environmental requirement tenant group existence hazardous material property property caused activities negligence tenant group hazardous materials used compliance environmental requirements previously approved landlord case tenant shall pay cost consultant tenant hereby grants landlord agents employees consultants contractors landlord right enter property perform tests property reasonably necessary conduct reviews investigations landlord shall use commercially reasonable efforts minimize interference business tenant notification tenant shall become aware receive notice communication concerning actual alleged suspected threatened violation environmental requirements liability tenant environmental damages connection property pastor present activities person thereon including limited notice communication concerning actual threatened investigation inquiry lawsuit claim citation directive summons proceeding complaint notice order writ injunction relating tenant shall deliver landlord within ten days receipt notice communication tenant written description said violation liability actual threatened event condition together copies documents evidencing receipt notice shall deemed create obligation part landlord defend otherwise respond notification requested landlord tenant shall disclose landlord names amounts hazardous materials general office supplies referred section addendum used generated treated handled stored disposed property tenant intends use generate treat handle store dispose property foregoing way shall limit necessity tenant obtaining landlords consent pursuant section addendum surrender property ninety days prior expiration termination lease term ninety days tenant fully surrenders possession property landlord may environmental assessment property performed accordance section addendum tenant shall perform sole cost expense cleanup remedial work recommended consultant necessary remove mitigate remediate hazardous materials andor contamination property caused activities negligence tenant group assignment subletting event lease provides tenant may assign lease sublet property subject landlords consent andor certain conditions proposed assignees sublessees activities property involve use handling storage disposal hazardous materials general office supplies used tenant quantities processes similar tenants uses compliance addendum shall reasonable landlord withhold consent assignment sublease light risk contamination posed activities andor ii landlord may impose additional condition assignment sublease requires tenant reasonably establish assignees sublessees activities pose materially greater risk contamination property tenants permitted activities view quantities toxicity properties hazardous materials used assignee sublessee b precautions release hazardous materials assignee sublessee agrees implement c assignees sublessees financial condition relates ability fund major cleanup assignees sublessees policy historical record respecting willingness respond clean release hazardous materials survival hazardous materials obligation tenants breach covenants obligations addendum shall constitute material default lease obligations tenant addendum shall survive expiration earlier termination lease without limitation shall constitute obligations independent severable tenants covenants obligations pay rent lease landlords hazardous materials obligations landlord shall solely responsible remediate claims judgments damages penalties fines costs liabilities losses arise result contamination directly arising introduction hazardous materials property landlord agents employees contractors compliance applicable law notwithstanding foregoing landlord shall responsible liable consequential damages obligation landlord section shall survive expiration termination lease section signs notwithstanding foregoing subject landlords prior written approval shall unreasonably withheld delayed conditioned provided signs keeping quality design style industrial park within property located tenant sole cost expense may install identification signage limited one monument sign monument sign two property building signs building sign per street frontage collectively signs property provided however size color location materials design sign shall subject landlords prior written consent shall unreasonably withheld delayed conditioned ii sign shall comply applicable governmental rules regulations propertys covenants conditions restrictions iii sign shall personal original tenant named section lease assignee sublessee transferee tenants interest lease original tenant iv building sign shall painted directly building attached placed roof building v sign shall advertise gilead sciences pharmaceutical business vi consistent landlords signage program rules vii tenants continuing signage right shall contingent upon original tenant actually occupying entire property viii tenants continuing signage right shall contingent upon tenant maintaining sign firstclass condition tenant shall responsible costs incurred connection design construction installation repair maintenance tenants signs upon expiration earlier termination lease tenant shall cause tenants signs removed shall repair damage caused removal signs notices logos pictures names advertisements installed separately approved landlord may removed landlord without notice landlord tenant tenants sole cost expense section landlords indemnity landlord agrees indemnify hold harmless tenant claims costs reasonable attorneys fees liabilities incurred direct result claim action proceeding directly arising following except extent tenants actions omissions breach default performance obligation landlord hereunder ii active negligence willful misconduct landlord agents employees invitees licensees contractors notwithstanding anything contrary set forth lease either partys agreement indemnify party set forth section shall ineffective extent matters party agreed indemnify party covered insurance required carried nonindemnifying party pursuant lease tenants agreement indemnify landlord landlords agreement indemnify tenant pursuant section intended shall relieve insurance carrier obligations policies required carried pursuant provisions lease extent policies cover carried would covered matters subject parties respective indemnification obligations shall supersede inconsistent agreement parties set forth provision lease notwithstanding anything contrary contained lease nothing lease shall impose obligations tenant landlord responsible liable hereby releases liability consequential damages consequential damages incurred landlord connection holdover property tenant expiration earlier termination lease incurred landlord connection contamination property property resulting presence use hazardous materials caused permitted tenant group incurred landlord connection repair physical construction improvement work performed behalf tenant property either party breaches lease failure carry required insurance hereunder failure shall automatically deemed covenant agreement failing party selfinsure required coverage full waiver subrogation favor party section landlords obligations subject provisions article seven damage destruction article eight condemnation except damage caused act omission tenant tenants employees agents contractors invitees result tenants alterations landlord shall keep structural portions building foundation roof structure exterior walls property good order condition repair however landlord shall obligated maintain repair roof membrane windows doors plate glass surfaces walls landlord shall obligated make repairs section reasonable time receipt written notice tenant need repairs tenant waives benefit present future law might give tenant right repair property landlords expense terminate lease condition property landlord hereby assigns tenant warranties guaranties contractor constructed building tenant improvements located property tenant waives claims landlord relating thereto section condition upon termination section hereby amended adding following end thereof notwithstanding foregoing tenant may request time seeks landlords consent alterations additions improvements collectively alterations landlord state time grants approval whether removal required end lease term request shall specifically cite lease provision landlords obligation make statement section tenant affiliate notwithstanding anything contrary contained section lease assignment subletting portion property affiliate tenant entity controlled controls common control tenant corporation resulting merger consolidation acquisition tenant collectively tenant affiliate shall deemed transfer section consent required provided tenant notifies landlord assignment sublease ii promptly supplies landlord documents information requested landlord regarding assignment sublease affiliate iii requested landlord guaranty lease using landlords standard guaranty form iv tenant affiliate assumes tenants obligations lease v assignment sublease subterfuge tenant avoid obligations lease control used herein shall mean ownership directly indirectly least fiftyone percent voting securities possession right vote ordinary direction affairs least fiftyone percent voting interest person entity instance tenant shall obligated pay landlord increased base rent described section bi resulting profit derived tenants affiliate section arbitration general submittals arbitration submittal matters arbitration accordance terms section sole exclusive method means procedure resolve claims disputes disagreements arising lease including limited matter relating landlords failure approve assignment sublease transfer tenants interest lease terms lease defaults landlord default tenant except determination fair rental value determination shall made pursuant option extend term lease rider attached lease ii claims either party seek anything enforcement rights lease including without limitation claim constructive eviction b primarily founded upon matters fraud willful misconduct bad faith allegations tortious action seek award punitive exemplary damages iii landlords exercise unlawful detainer rights pursuant california law rights remedies used landlord gain possession property terminate tenants right possession property disputes relating thereto matters shall resolved suit filed superior court los angeles county california decision court shall subject appeal pursuant applicable law iv claims restraining orders injunctive relief parties hereby irrevocably waive rights contrary shall times conduct strict full complete timely accordance terms section attempts circumvent terms section shall absolutely null void force effect whatsoever matter submitted arbitration except respect payment money determine whether matter would passage time constitute default lease passage time shall commence run affirmative arbitrated determination long simultaneously determined arbitration challenge matter potential default tenant landlord case may made good faith matter submitted arbitration respect payment money determine whether matter would passage time constitute default lease passage time shall commence run event party obligated make payment fact make payment party payment made protest shall occur payment accompanied good faith notice stating reasons party elected make payment protest protest deemed waived unless subject matter identified protest submitted arbitration set forth section retired judges dispute arbitrated pursuant provisions section shall determined binding arbitration retired judge superior court state california retired judge california court appeal arbitrator arbitration shall initiated parties either within ten days either party sends written notice arbitration notice demand arbitrate registered certified mail party arbitration notice shall contain description subject matter arbitration dispute respect thereto amount involved remedy determination sought parties shall thereupon select retired judge either superior court california california court appeal serve arbitrator parties unable promptly agree identity arbitrator retired judge shall serve arbitrator shall selected presiding judge los angeles county superior court upon selection arbitrator parties dispute shall resolved binding arbitration commercial arbitration rules american arbitration association effect arbitration procedure predecision actions arbitrator shall schedule prehearing conference resolve procedural matters arrange exchange information obtain stipulations narrow issues parties submit proposed discovery schedules arbitrator prehearing conference scope duration discovery within sole discretion arbitrator arbitrator shall discretion order prehearing exchange information parties including without limitation production requested documents exchange summaries testimony proposed witnesses examination deposition parties thirdparty witnesses discretion shall exercised favor discovery reasonable circumstances decision arbitration shall conducted los angeles california party may represented counsel authorized representative rendering decisions arbitrator shall determine rights obligations parties according substantive procedural laws california terms provisions lease arbitrators decision shall based evidence introduced hearing including logical reasonable inferences therefrom arbitrator may make determination andor grant remedy relief equitable decision must based accompanied written statement decision explaining factual legal basis decision principal controverted issues decision shall conclusive binding may thereafter confirmed judgment superior court state california subject challenge grounds set forth california code civil procedure section validity enforceability arbitrators decision determined exclusively california courts pursuant provisions lease arbitrator may award costs including without limitation attorneys fees expert witness costs prevailing party determined arbitrator arbitrators discretion arbitrators fees costs shall paid nonprevailing party determined arbitrator arbitrators discretion party shall determined arbitrator prevailing party proposal resolution dispute closer adopted arbitrator section nondisturbance landlord shall use commercially reasonable efforts provide tenant nondisturbance agreement form attached hereto exhibit b landlords presently existing lender section force majeure landlord tenant perform obligations due events beyond applicable partys control except respect obligations imposed regard base rent additional rent charges paid tenant pursuant lease time provided performing obligations shall extended period time equal duration events events beyond landlords tenants control include limited acts god war civil commotion labor disputes strikes fire flood casualty shortages labor material government regulation restriction waiting periods obtaining governmental permits approval weather conditions article fifteen revenue expense accounting landlord tenant agree purposes including determination section internal revenue code rental income accrue landlord rental expenses accrue tenant amounts dates rent payable lease article sixteen landscape maintenance notwithstanding provisions sections landlord shall maintain tenants expense landscaping property applicable common areas maintenance shall include gardening tree trimming replacement repair landscaping landscape irrigation systems similar items maintenance shall also include sweeping cleaning asphalt concrete surfaces driveway parking areas yard areas loading areas paved covered surfaces connection landlords obligations article landlord may enter contract landscape contractor landlords choice provide necessarily maintenance services listed tenants monthly cost contract hereinafter referred landscape fee currently six hundred fifty dollars landlord shall use commercially reasonable efforts maintain competitive contracts shall promptly notify tenant increase landscape fee tenant agrees pay monthly landlord additional rent landscape fee tenant shall make payment together tenants monthly rental payment without necessity notice landlord understanding parties landscape fee pertains routine landscape maintenance property landlord may incur expenses addition landscape fee shall include landlords overhead landlords administrative expenses meeting obligations set forth tenant shall pay landlord additional rent within ten days demand therefore cost additional expenses article seventeen purchase option right first refusal landlord hereby grants original tenant whose name set forth section lease original tenant tenant affiliate onetime right first refusal purchase property accordance terms article landlord agrees provided tenant default lease landlord shall deliver written notice tenant landlords first refusal notice prior time landlord intends submit third party accept third party bona fide proposal purchase entire property purposes article third party shall include party affiliated related landlord landlord shall identify landlords first refusal notice economic terms upon landlord would sell property tenant including without limitation anticipated closing date purchase price paid property collectively economic terms section procedure acceptance date seven days tenants receipt landlords first refusal notice election day tenant shall deliver written notice landlord tenants election notice pursuant tenant shall onetime right elect either purchase property upon economic terms set forth first refusal notice ii refuse purchase property tenant respond writing landlords first refusal notice election date tenant shall deemed elected purchase property section tenants election purchase tenant elects deemed elected purchase property tenants first refusal rights set forth article shall terminate respect property landlord shall right sell property anyone landlord desires terms landlord desires provided however tenant sends notice accordance section ii tenants right first refusal may arise landlord intends sell property purchase price ten percent purchase price set forth landlord first refusal notice economic terms materially favorable set forth landlords first refusal notice section condition property tenant elects purchase property pursuant article landlord tenant shall promptly execute proper documents necessary memorialize tenants purchase property upon terms conditions set forth article tenant purchases property pursuant terms article tenant shall take property asis condition unless otherwise specified part economic terms landlords first refusal notice subject however tenants review approval preliminary title report within ten days receipt thereof section suspension right first refusal tenant shall right purchase property provided article date attempted exercise right first refusal tenant date escrow closes tenant default lease beyond applicable notice cure periods addition notwithstanding anything contrary contained article rights purchase property contained article shall personal original tenant tenant affiliate may exercised original tenant assignee sublessee transferee tenants interest lease tenant affiliate time attempted exercise right first refusal original tenant tenant affiliate occupies entire property section multiple building transactions notwithstanding anything contrary herein tenants right first refusal shall apply shall include reit transactions ii property part multiple properties included within package sale iii sale transfer property iv sale transfer party affiliate related landlord section exchange accommodation landlord tenant agrees cooperate landlord effectuating likekind exchange property pursuant section internal revenue code amended exchange including execution documents related thereto first amendment industrial real estate lease first amendment industrial real estate lease first amendment made entered march first amendment date majesticmapa properties llc california limited liability company landlord gilead sciences inc delaware corporation tenant r e c l tenant landlord entered certain industrial real estate lease lease dated july whereby landlord leased tenant tenant leased landlord approximately square feet space property commonly known west covina boulevard san dimas california b parties desire amend lease terms conditions set forth first amendment g r e e e n therefore consideration foregoing recitals mutual covenants contained herein good valuable consideration receipt sufficiency hereby acknowledged parties hereto hereby agree follows terms undefined terms used herein shall respective meanings given terms lease unless expressly provided otherwise first amendment lease term extended lease term lease term currently scheduled expire may lease expiration date first amendment date lease term extended november revised lease expiration date unless sooner terminated terms lease amended first amendment expire revised lease expiration date period time beginning day following lease expiration date continuing revised lease expiration date extended lease term termination right tenant shall onetime right terminate lease amended effective december termination date provided landlord receives written notice termination notice tenant date twelve months prior termination date stating tenant intends terminate lease amended pursuant terms conditions section b concurrent landlords receipt termination notice landlord receives tenant sum one hundred fiftyfive thousand six hundred fiftyfour dollars consideration condition precedent early termination c tenant default lease amended date west covina blvd san dimas ca april gilead sciences inc tenants delivery termination notice termination date provided tenant terminates lease amended pursuant terms section lease amended shall automatically terminate force effect termination date landlord tenant shall relieved respective obligations lease amended specifically including without limitation right tenant may audit review landlords books records contest tenants payment additional rent provided however notwithstanding anything contrary contained lease amended respect obligation tenant lease amended accrues prior termination date satisfied tenant prior termination date eg tenants payment rent tenants maintenance repair obligations tenants obligations survive termination lease amended including without limiting tenants obligation remediate environmental damages landlord shall rights remedies respect obligations set forth lease amended tenant shall vacate property pursuant lease amended surrender deliver exclusive possession thereof landlord termination date accordance provisions lease amended event tenant retains possession property part thereof termination date provisions section lease amended shall apply rights contained section shall personal tenant named summary assignee sublessee transferee tenants interest lease amended original tenant may exercised original tenant original tenant occupies entire property rent base rent commencing june continuing may tenant pay amount equal twentyfive thousand nine hundred fortytwo dollars per month base rent due lease amended first amendment commencing june continuing revised lease expiration date tenant pay amount equal twentyeight thousand five hundred thirtysix dollars per month base rent due lease amended first amendment security deposit termination advance payment section lease shall deleted replaced follows upon termination lease article seven damage destruction article eight condemnation termination resulting tenants default tenant vacated property manner required lease landlord shall within sixty days tenant delivering exclusive possession property landlord refund tenant tenants successor unused portion security deposit advance rent advance payments made tenant landlord amounts paid real property taxes reserves apply time periods termination lease real estate taxes tenant shall set forth section lease pay real property taxes directly respective taxing authority real property tax penalty section lease shall revised tenant shall responsible real property tax penalty extent penalty caused tenants acts omissions late charge effective commencement extended lease term late charge set forth section lease shall reduced eight percent landlords books records event tenant disputes amount statement statement delivered landlord within six months receipt statement tenant tenant shall right request receive landlord reasonable backup information landlords possession regarding statement hazardous material effective commencement extended lease term following revisions shall made section lease set forth section c lease shall deleted replaced follows landlord shall right obligation join participate control tenants commercially reasonable consent consent shall unreasonably withheld elects legal proceedings actions initiating connection tenants hazardous material activities property landlord may also negotiate defend approve appeal action taken issued applicable governmental authority regard contamination property hazardous material following shall added end section e lease landlord shall provide tenant copies information report related document landlord acquires within thirty days completion receipt said report first sentence section lease shall deleted replaced follows landlord shall right sole absolute discretion duty enter upon twentyfour hours notice except notice required landlord reasonable belief tenant creating environmental damage property conduct inspection property including invasive tests regular operative hours determine whether tenant complying terms lease including limited compliance property activities thereon environmental requirements existence environmental damages result condition property surrounding properties activities thereon first paragraph section lease shall deleted replaced follows tenant landlord shall become aware receive notice communication concerning actual alleged suspected threatened violation environmental requirements liability tenant landlord environmental damages connection property past present activities person thereon including limited notice communication concerning actual threatened investigation inquiry lawsuit claim citation directive summons proceeding complaint notice order writ injunction relating tenant landlord shall deliver party within ten days receipt notice communication written description said violation liability actual threatened event condition together copies documents evidencing receipt notice shall deemed create obligation part landlord defend otherwise respond notification following shall added end section lease tenant shall right observe landlords environmental assessment section lease shall deleted replaced follows landlord shall solely responsible remediate claims judgments damages penalties fines costs liabilities losses arise result contamination directly arising introduction hazardous materials property prior tenants occupancy landlord agents employees contractors compliance applicable law notwithstanding foregoing landlord shall responsible liable consequential damages obligation landlord section shall survive expiration termination lease alterations additions improvements effective commencement extended lease term first sentence section lease shall deleted replaced follows tenant shall make alterations additions improvements property without landlords prior written consent shall unreasonably withheld except nonstructural alterations exceed sixty thousand dollars cost per project visible outside building property part estoppel certificate effective commencement extended lease term following shall added section c lease upon tenants written request landlord shall execute estoppel certificate certifying landlords actual knowledge without duty investigate whether lease modified ii lease canceled iii tenant default lease tenants financial condition effective commencement extended lease term following shall added section lease original tenant monetary default lease landlords right request financial statements shall exceed one time per calendar year except financial statement requested landlords lender tenants acceptance property landlord tenant acknowledge tenant occupying property pursuant lease since april therefore tenant continues accept property presently existing condition landlord made representation warranty regard condition property suitability thereof tenants business shall landlord obligated provide pay improvement work services related improvement property deletions effective first amendment date option extend term lease rider attached lease hereby deleted shall force effect brokers parties recognize broker involved negotiation first amendment majestic realty co agree landlord shall solely responsible payment brokerage commission broker party represents warrants dealt broker connection negotiation consummation first amendment know real estate broker agent finder might entitled commission compensation connection first amendment party agrees indemnify defend party hold party harmless claims demands losses liabilities damages lawsuits judgments costs expenses including without limitation reasonable attorneys fees costs respect leasing commission equivalent compensation alleged owing account indemnifying partys dealings real estate broker agent modifications except otherwise provided herein terms provisions lease shall remain full force effect unmodified first amendment binding effect provisions first amendment shall binding upon inure benefit heirs representatives successors permitted assigns parties hereto authority parties represent warrant requisite authority bind entity whose behalf signing counterparts first amendment may executed number original counterparts counterpart executed shall constitute original first amendment counterparts together shall constitute one first amendment signatures next witness whereof parties entered first amendment date first set forth landlord tenant majesticmapa properties llc gilead sciences inc california limited liability company delaware corporation majestic realty co anthony caracciolo california corporation manager david wheeler president mark l perry b jay h bradford ts e xecutive vice president operations executive vice president chief financial officer exhibit certain confidential information contained document marked brackets omitted filed separately securities exchange commission pursuant rule b securities exchange act amended collaboration agreement among gilead sciences inc gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated december table contents section definitions section collaboration management general role joint executive committee joint development committee joint commercialization committee joint finance committee procedural rules operating committees alliance managers dispute resolution collaboration principles commercialization budgetplan deadlocks expenses section development activities general clinical development formulation cmc data regulatory matters performance subcontracting records updates development plan development budget development expenses reports new products publication certain inspections medical affairs medical communications section manufacturing supply clinical supply commercial supply section commercialization activities copromotion obligations distribution obligations pricing combination product national accounts performance subcontracting conflict avoidance marketing materials development use trademarks insurance records commercialization plan budget commercialization expenses reports section license grants technology licenses member parties jv licenses sublicenses jv member parties licenses rights reference member parties rights reference jv related matters sublicenses trademark licenses member parties jv trademark license jv gilead retained rights combination product sales outside territory canada europe combination product sales europe efv license agreement jv obligations sublicensee section payments third party royalties payments member parties royalty payments third parties authorized expenses mode timing payment taxes section financial records financial records audit records certain reports section adverse event information exchange pharmacovigilance material communications section product recall notification recall recall expenses section intellectual property rights ownership intellectual property prosecution patents enforcement patents infringement third party rights trademarks section confidentiality treatment confidential information permitted disclosure confidential information use name publicity terms agreement notification permitted uses remedies section warranties indemnities representations warranties covenants ii additional representations warranties covenants bms additional representations warranties covenants gilead disclaimer indemnification jv indemnification member parties general indemnification certain product liability related matters indemnification procedure limitation damages ancillary agreements employees section term termination term certain litigation termination nda filing delay material default termination upon generic launch consequences termination rights bankruptcy accrued rights surviving obligations section general provisions force majeure notice assurances successors assigns governing law arbitration waiver severability counterparts construction status parties standstill nonsolicitation employees entire agreement consent jurisdiction third parties iiiannexes annex initial committee members alliance managers annex b development plan development budget effective date annex c commercialization plan commercialization budget effective date annex bms patents annex e gilead patents annex f gilead licensed trademarks annex g bms licensed trademarks annex h quarterly detail report annex manner calculation net selling price annex j calculation cost goods annex k calculation transfer price annex l joint press release annex certain financial data annex n data provided independent accounting expert pursuant section annex jv obligations sublicensee annex p key terms services agreement annex q pricing annex r list countries comprising developing world ivthis collaboration agreement agreement made december effective date among gilead sciences inc corporation organized existing laws state delaware principal place business lakeside drive foster city ca gilead parent gilead holdings llc delaware limited liability company whollyowned subsidiary gilead parent gilead sub collectively gilead parent gilead bristolmyers squibb company corporation organized existing laws state delaware principal place business park avenue new york ny bms parent er squibb sons llc delaware limited liability company whollyowned subsidiary bms parent bms sub collectively bms parent bms bristolmyers squibb gilead sciences llc limited liability company organized existing laws state delaware principal place business lakeside drive foster city ca jv gilead bms jv collectively parties party recitals whereas gilead developed marketing proprietary nucleotide reverse transcriptase inhibitor viread known generic name tenofovir disoproxil fumarate tdf proprietary nucleoside reverse transcriptase inhibitor emtriva known generic name emtricitabine ftc fixeddose coformulated product containing tdf ftc active pharmaceutical ingredients truvada treatment hiv infection adults whereas bms developed marketing proprietary nonnucleoside reverse transcriptase inhibitor sustiva known generic name efavirenz efv treatment hiv infection adults whereas gilead bms desire develop commercialize united states joint venture entity fixed dose coformulated combination product containing tdf ftc efv active pharmaceutical ingredients whereas purpose gilead bms formed jv pursuant certain operating agreement entered effective date gilead sub bms sub operating agreement whereas parties wish allocate among certain rights duties relating development commercialization combination product upon terms conditions agreement operating agreement ancillary agreements defined whereas pursuant bms guarantee agreement gilead guarantee agreement terms defined dated effective date bms parent gilead parent guaranteeing performance obligations certain confidential information contained document marked brackets omitted filed separately securities exchange commission pursuant rule b securities exchange act amended bms sub gilead sub respectively agreement operating agreement ancillary agreements applicable affiliate defined becomes party therefore consideration mutual promises covenants set forth good valuable consideration receipt sufficiency hereby acknowledged parties agree follows section definitions act shall mean united states food drug cosmetic act amended actual bms percentage shall mean calendar year percentage applicable bms calendar year based historical data determined pursuant section b actual gilead percentage shall mean calendar year percentage applicable gilead calendar year based historical data determined pursuant section b actual percentage shall mean respect bms actual bms percentage respect gilead actual gilead percentage actual yield shall meaning set forth annex k affiliate person shall mean person directly indirectly one intermediaries controls controlled common control person purposes definition control correlative meanings terms controlled common control shall mean possession directly indirectly power direct management policies person whether ownership voting securities contract relating voting rights corporate governance b ownership directly indirectly fifty percent voting securities ownership interest person provided however local law restricts foreign ownership control shall established direct indirect ownership maximum ownership percentage may local law owned foreign interests purposes agreement operating agreement ancillary agreements jv shall deemed affiliate either gilead bms agreement shall meaning set forth first paragraph alliance manager shall meaning set forth section allocated costs shall meaning set forth section amp shall meaning set forth annex q ancillary agreements shall mean collectively bms supply agreement gilead supply agreement services agreement sdea shall meaning set forth section f applicable efv territory shall mean respect bms technology licensed bms efv licensor licensed efv licensor bms case efv license agreement efv license agreement territory b respect bms technology worldwide applicable law shall mean applicable laws rules regulations including without limitation rules regulations guidelines requirements regulatory authorities may effect time time territory approvals shall mean collectively approvals granted regulatory authorities manufacture marketing sale andor use combination product field territory including without limitation pricing reimbursement approvals approved marketing materials shall meaning set forth section representative shall meaning set forth section b authorized commercialization expenses shall meaning set forth section authorized development expenses shall meaning set forth section authorized expenses shall mean collectively authorized commercialization expenses authorized development expenses authorized expenses authorized expenses shall mean jv expenses expressly stated agreement operating agreement ancillary agreement authorized expenses agreed jec authorized expenses awp shall meaning set forth annex q bms shall meaning set forth first paragraph agreement bms core improvement shall mean improvement pertaining specifically bms core technology improvement conceived discovered developed otherwise made necessary establish authorship inventorship united states copyright patent law case may solely jointly behalf gilead affiliates jv course result connection project activities conducted pursuant development plan connection cofunded clinical trials provided however bms core improvements shall include dual improvements bms core technology shall mean bms proprietary technologies relating specifically exploitation efv bms guarantee agreement shall mean guarantee agreement executed bms parent favor gilead jv dated effective date agreement may amended time time bms indemnified party shall mean bms sub bms parent affiliates officers directors employees bms inventions shall mean information inventions whether patentable improvements thereto including gilead core improvements extent owned bms conceived discovered developed otherwise made necessary establish authorship inventorship united states copyright patent law case may solely case gilead core improvements solely jointly behalf bms affiliates course result connection project activities conducted pursuant development plan connection cofunded clinical trials excluding joint inventions bms knowhow shall mean information inventions control bms affiliates effective date time term agreement necessary reasonably useful exploitation combination product generally known excluding information inventions extent claimed bms patents b joint knowhow bms licensed trademarks shall meaning set forth section b bms parent shall meaning set forth first paragraph agreement bms patents shall mean patents bms affiliates control effective date time term agreement would absence license granted bms section b assuming efv active pharmaceutical ingredient therein purchased bms infringed exploitation combination product jv country world list bms patents territory effective date attached hereto annex bms regulatory documentation shall mean regulatory documentation applicable sustiva efv sustiva efv coformulation viread tdf emtriva ftc truvada tdf ftc developed behalf bms affiliates sublicensees prior effective date term agreement bms sub shall meaning set forth first paragraph agreement bms supply agreement shall mean supply agreement entered bms sub jv concurrently execution delivery agreement agreement may amended time time bms technology shall mean collectively bms knowhow bms patents bms transfer price shall meaning set forth section breaching member party shall meaning set forth section business day shall mean day saturday sunday day banking institutions new york new york san francisco california required law remain closed representative shall meaning set forth section b calendar quarter shall mean period three consecutive calendar months ending march june september december calendar year shall mean period twelve consecutive calendar months commencing january ending december change control shall mean respect person following transactions third party third party acquirer merger consolidation person third party acquirer results holders voting securities person outstanding immediately prior thereto third party acquirer affiliates associates terms used exchange act ceasing represent least fifty percent combined voting power surviving entity applicable parent company immediately merger consolidation b sale third party acquirer substantially business person agreement relates whether merger consolidation sale stock sale assets similar transaction c third party acquirer shall trustee fiduciary holding securities employee benefit plan person corporation owned directly indirectly stockholders person substantially proportion ownership stock person together third party acquirers affiliates associates terms used exchange act becoming beneficial owner fifty percent combined voting power outstanding securities person contract otherwise right control board directors equivalent governing body person ability cause direction management person clinical data shall mean data together results analysis thereof derived generated clinical trial pharmaceutical product testing analysis subjects samples clinical trial eg vitro testing tissue samples subjects enrolled clinical trial case clinical trial involves either single agent product double agent product whether alone combination product ii combination product whether alone combination product clinical trial registry shall meaning set forth section b clinical trial results database shall meaning set forth section b cmc data shall mean information contained well data supporting chemistry manufacturing control facilities sections sections corresponding thereto nda including without limitation drug master files referenced nda cofunded clinical trial shall meaning set forth section b collaboration principles shall meaning set forth section combination product shall mean fixeddose coformulated product developed pursuant agreement containing active pharmaceutical ingredients per single daily dose mg tdf mg ftc mg efv combination product regulatory documentation shall mean regulatory documentation applicable combination product developed behalf party pursuant term agreement excluding bms regulatory documentation gilead regulatory documentation combination product trademarks shall mean trademark trademarks selected jcc combination product packaging designs trade dress used connection combination product trademarks relating thereto registrations thereof pending applications relating thereto avoidance doubt following shall considered combination product trademarks bms licensed trademarks b gilead licensed trademarks c names logos trademarks member parties commercialization activities shall mean marketing activities commercialization combination product including set forth commercialization plan following conducted combination product execution product positioning preparation promotional marketing materials market research advertising activities promotion advocacy national accounts government relations activities pricing reimbursement patient assistance programs commercialization budget shall meaning set forth section b initial commercialization budget attached hereto annex c commercialization budget deadlock shall meaning set forth section commercialization plan shall mean plan marketing otherwise commercializing combination product described section b updated time time pursuant section c initial commercialization plan attached hereto annex c commercialization plan deadlock shall meaning set forth section commercially reasonable efforts shall mean respect development activities member party required perform respect combination product pursuant development plan b commercialization activities member party required perform respect combination product pursuant commercialization plan case may level effort would generally used member party conduct development commercialization activities manner consistent minimum level expenditure contemplated activities development budget commercialization budget case may product compound owned rights comparable market potential profit potential strategic value member party similar stage development product life taking account without limitation issues safety efficacy product profile proprietary position thencurrent competitive environment product compound individual agent comprising part product compound likely timing products compounds individual agents entry market thencurrent market penetration return investment potential product individual agent comprising part product regulatory environment status product individual agent comprising part product relevant scientific technical commercial factors case measured facts circumstances time efforts due commercial record request shall meaning set forth section b competing product shall mean case gilead assigning member party b case bms assigning member party confidential information shall meaning set forth section continuing member party shall mean member party designated pursuant section control controlled shall mean respect item information inventions patents intellectual property rights right whether ownership license otherwise grant license sublicense right item patent right provided agreement without violating terms agreement binding arrangement third party purposes section consent referred section shall deemed obtained effective date core technology shall mean bms core technology gilead core technology case may cost allocation proposal shall meaning set forth section cost goods shall meaning set forth annex j hereto court shall meaning set forth section detail shall mean inperson presentation health care provider specializing treatment hiv infection aids prescribing authority sales representative fully equipped knowledge subject section approved marketing materials product labels inserts respect combination product characteristics combination product described sales representative fair balanced manner consistent requirements applicable law agreement manner customary industry purpose promoting prescription pharmaceutical product without regard position presentation within call health care provider avoidance doubt promotional material drop product reminder shall constitute detail used verb detail shall mean engage detail detail equivalent amount shall mean calendar year calendar year successive calendar year thereafter amount adjusted calendar year developing world shall mean territory comprising countries listed annex r additional countries outside territory canada europe gilead includes gilead access program indicated website program wwwgileadaccessorg development activities shall mean activities set forth development plan updated time time pursuant section respect periods prior effective date activities pursuant mtta development budget shall mean budget respect expenses relating development activities combination product chargeable jv updated time time pursuant section initial development budget attached hereto annex b development plan shall mean plan regulatory clinical formulation manufacturing process cmc data development activities conducted combination product including phase iv clinical studies medical information medical education programs updated time time pursuant section initial development plan attached hereto annex b development record request shall meaning set forth section b disclosing party shall meaning set forth section shall meaning set forth annex q double agent product shall mean truvada coformulated product developed gilead containing active pharmaceutical ingredients tdf ftc dual improvement shall mean improvement constitutes improvement pertaining specifically gilead core technology improvement pertaining specifically bms core technology improvement conceived discovered developed otherwise made necessary establish authorship inventorship united states copyright patent law case may solely jointly behalf bms affiliates gilead affiliates jv jointly combination course result connection project activities conducted pursuant development plan connection co funded clinical trials dual improvement shall constitute joint invention effective date shall meaning set forth first paragraph agreement efv shall meaning set forth recitals agreement efv license agreement shall mean certain license agreement dated september amended efv licensor er squibb sons llc successor interest dupont pharmaceuticals company formerly named dupont merck pharmaceutical company efv license agreement territory shall mean bms territory efv license agreement effective date consists united states including territories possessions canada france continental area germany italy spain united kingdom republic ireland provided however efv license agreement amended expand bms territory efv license agreement territory shall forthwith mean bms territory expanded b efv license agreement terminated result bms acquisition rights efv licensor thereunder efv license agreement territory shall forthwith mean countries world efv licensor shall mean collectively merck co inc new jersey corporation merck company incorporated delaware corporation respective successors interest estimated net selling price shall meaning set forth section cii exchange act shall meaning set forth section b exploitation shall mean making made importation use sale offering sale disposition product process including without limitation research development registration modification enhancement improvement manufacturing storage formulation optimization import export transport distribution promotion marketing product process used verb exploit shall mean engage foregoing activities europe shall mean countries comprising european union may constituted time time fda shall mean united states food drug administration successor agency thereto field shall mean treatment hiv infection adult humans field force shall mean sales representatives regional subnational managers foregoing final invoice date shall meaning set forth section finished product manufacturing data shall mean data information necessary useful manufacture finished product packaged labeled active pharmaceutical ingredients thereof tablet capsule form expressly excluding manufacture active pharmaceutical ingredients included cmc data finished product customers shall meaning set forth annex q ftc shall meaning set forth recitals agreement gaap shall mean united states generally accepted accounting principles effect time time consistently applied generic version shall mean respect combination product single agent product double agent product product containing active pharmaceutical ingredients combination product single agent product double agent product case may active pharmaceutical ingredients product product approved united states abbreviated new drug application ie anda generic version launch shall meaning set forth section gilead shall meaning set forth first paragraph agreement gilead core improvement shall mean improvement pertaining specifically gilead core technology improvement conceived discovered developed otherwise made necessary establish authorship inventorship united states copyright patent law case may solely jointly behalf bms affiliates jv course result connection project activities conducted pursuant development plan connection cofunded clinical trials provided however gilead core improvements shall include dual improvements gilead core technology shall mean gilead proprietary technologies relating specifically exploitation ftc tdf combination ftc tdf including without limitation double agent product excluding combination product gilead guarantee agreement shall mean guarantee agreement executed gilead parent favor bms jv dated effective date agreement may amended time time gilead indemnified party shall mean gilead sub gilead parent affiliates officers directors employees gilead inventions shall mean information inventions whether patentable improvements thereto including bms core improvements extent owned gilead conceived discovered developed otherwise made necessary establish authorship inventorship united states copyright patent law case may solely case bms core improvements solely jointly behalf gilead affiliates course result connection project activities conducted pursuant development plan connection cofunded clinical trials excluding joint inventions gilead knowhow shall mean information inventions control gilead affiliates effective date time term agreement necessary reasonably useful exploitation combination product generally known excluding information inventions extent claimed gilead patents b joint knowhow gilead licensed trademarks shall meaning set forth section gilead parent shall meaning set forth first paragraph agreement gilead patents shall mean patents gilead affiliates control effective date time term agreement would absence license granted gilead section assuming tdf ftc active pharmaceutical ingredients therein purchased gilead infringed exploitation combination product jv country world list gilead patents territory effective date attached hereto annex e gilead regulatory documentation shall mean regulatory documentation applicable viread tdf emtriva ftc truvada tdf co formulation ftc viread tdf emtriva ftc truvada tdf ftc coformulation sustiva efv developed behalf gilead affiliates sublicensees prior effective date term agreement gilead sub shall meaning set forth first paragraph agreement gilead supply agreement shall mean supply agreement entered gilead parent jv concurrently execution delivery agreement agreement may amended time time gilead technology shall mean collectively gilead knowhow gilead patents gilead transfer price shall meaning set forth section shall meaning set forth shall meaning set forth section good clinical practice gcp shall mean thencurrent standards clinical trials pharmaceutical products set forth act applicable regulations promulgated thereunder may amended time time good laboratory practice glp shall mean thencurrent standards laboratory activities pharmaceutical products set forth act applicable regulations promulgated thereunder may amended time time good manufacturing practice gmp shall mean regulatory requirements current good manufacturing practices pharmaceutical products promulgated fda including set forth us food drug cosmetic act cfr parts may amended time time improvement shall mean modification compound composition product technology discovery device process formulation related compound composition product technology whether patented patentable including without limitation enhancement efficiency operation manufacture ingredients preparation presentation formulation means delivery packaging dosage compound composition product technology discovery device process formulation related thereto discovery development new expanded indications applications compound composition product technology discovery development improves stability safety efficacy compound composition product technology discovery development new dosage regimen product method use administration compound composition product technology ind shall mean investigational new drug application filed fda accordance applicable law indemnified party shall mean person seeking indemnification losses pursuant section indemnifying member party shall meaning set forth section indemnifying party shall mean party indemnification sought pursuant section independent accounting expert shall meaning set forth section information inventions shall mean technical scientific knowhow information trade secrets knowledge technology means methods processes practices formulas instructions skills techniques procedures experiences ideas technical assistance designs drawings assembly procedures computer programs apparatuses specifications data results material including without limitation preclinical clinical trial results manufacturing procedures test procedures purification isolation techniques whether confidential proprietary patented patentable written electronic form known hereafter developed improvements whether foregoing otherwise discoveries developments inventions whether confidential proprietary patented patentable tangible embodiments foregoing infringement shall meaning set forth section infringing combination product shall meaning set forth section initial launch period shall mean first commencing launch combination product territory initiating member shall meaning set forth section e interim bms unit transfer price shall meaning set forth section interim gilead unit transfer price shall meaning set forth section interim unit transfer price shall mean calendar year respect bms interim bms unit transfer price respect gilead interim gilead unit transfer price joint commercialization committee jcc shall meaning set forth section joint development committee jdc shall meaning set forth section joint executive committee jec shall meaning set forth section operating agreement joint finance committee jfc shall meaning set forth section joint inventions shall mean information inventions pertaining specifically combination product whether patentable improvements thereto conceived discovered developed otherwise made necessary establish authorship inventorship united states copyright patent law case may behalf bms affiliates gilead affiliates jv jointly combination course result connection project activities conducted pursuant development plan connection cofunded clinical trials b dual improvement joint knowhow means information inventions included joint inventions generally known excluding information inventions extent claimed joint patents avoidance doubt joint knowhow shall include clinical data proposed bioequivalence study contemplated development plan joint patents shall mean patents extent patents claim joint inventions joint technology shall mean collectively joint knowhow joint patents jv shall meaning set forth first paragraph agreement jv expenses shall mean direct outofpocket expenses gilead bms may incur cause affiliates incur performing project activities behalf jv avoidance doubt respect jv expenses incurred member party affiliates expenses chargeable jv member party expenses constitute authorized expenses key regulatory submissions shall meaning set forth section launch shall mean respect territory either date combination product first shipped behalf jv commercial sale third parties b generic version product referred section date first available commercial sale purchase case may losses shall mean judgments fines amounts paid settlement outofpocket expenses including reasonable attorneys fees reasonably incurred party indemnitee provided section proceeding shall meaning set forth annex q manufacture manufacturing means respect product compound manufacturing processing formulating packaging labeling holding quality control testing product compound manufacturing process shall mean process step thereof necessary useful manufacturing combination product bulk active pharmaceutical ingredients improvements thereto intermediate foregoing market marketing shall mean programs activities relating promotion sale commercialization combination product territory including without limitation detailing advertising well selling contracting sale distributing combination product material default shall meaning set forth section member parties shall mean collectively gilead bms members shall mean collectively gilead sub bms sub member vote shall meaning set forth section f shall meaning set forth section f shall meaning set forth section f mtta shall meaning set forth section nda shall mean new drug application filed fda accordance applicable law purpose obtaining marketing approval pharmaceutical product united states shall meaning set forth annex q net sales shall mean respect product period gross amount invoiced commercial sales product period behalf selling party third parties provided amounts invoiced product sold provided use developing world shall included less deductions normal customary quantity andor cash discounts sales returns allowances including without limitation granted account price adjustments billing errors rejected goods damaged goods returns rebates administrative fees reimbursements similar payments wholesalers distributors including without limitation pursuant inventory management agreements buying groups aids drug assistance programs pharmacy benefit management organizations health care insurance carriers institutions allowances rebates fees paid distributors chargebacks actually allowed given b freight postage shipping insurance expenses separately identified invoice c customs excise duties duties related sales making gross invoice amount separately identified invoice rebates similar payments accrued respect sales paid governmental regulatory authority way illustration limitation foregoing clause united states federal state medicaid medicare similar state program government imposed retroactive price reduction e sales taxes duties directly related sale extent items included gross invoice price including taxes assessed income derived sale deductions listed involves payment party shall taken deduction prior date accrued accordance gaap consistently applied partys audited financial statements purposes determining net sales pursuant section bii combination product shall deemed sold invoiced purposes calculating net sales sales among party andor affiliates shall excluded computation net sales sales party affiliates third parties shall included computation net sales net selling price shall mean price pharmaceutical product calculated accordance annex hereto nonbreaching member party shall meaning set forth section operating agreement shall meaning set forth recitals agreement operating committees shall mean collectively jcc jdc jfc optional update shall meaning set forth section paragraph iv certification shall meaning set forth section party parties shall meanings set forth first paragraph agreement patents shall mean patents patent applications including without limitation provisional applications b substitutions divisions continuations continuationsinpart reissues renewals registrations confirmations reexaminations extensions supplementary protection certificates like c foreign international equivalents foregoing pct shall mean patent cooperation treaty opened signature june ust permitted assignee shall meaning set forth section person shall mean individual sole proprietorship partnership limited partnership limited liability partnership corporation limited liability company business trust joint stock company trust unincorporated association joint venture similar entity organization including without limitation government political subdivision department agency government prescription drug marketing act pdma shall meaning set forth section pricing committee shall meaning set forth section b pricing information shall meaning set forth section h proceeding shall mean civil criminal administrative investigative proceeding brought demand made third party product detail period shall meaning set forth section e product efv yield shall meaning set forth annex k product ftc yield shall meaning set forth annex k product tdf yield shall meaning set forth annex k project activities shall mean activities undertaken performed behalf parties pursuant agreement mtta course result connection research development marketing sale use combination product including without limitation development activities commercialization activities provided however project activities shall include activities undertaken performed behalf either member party affiliates sublicensees extent arise course result connection exploitation combination product use outside territory including without limitation activities undertaken performed gilead exercise rights license granted section promotion shall mean conduct activities normally undertaken pharmaceutical companys field force implement plans strategies marketing commercialization aimed encouraging approved use pharmaceutical product including limited detailing used verb promote shall mean engage foregoing activities psur means periodic safety update report required submitted fda publication standards shall meaning set forth section shall meaning set forth section f recalculated transfer price shall meaning set forth section ciii receiving party shall meaning set forth section regulatory authorities shall mean applicable supranational federal national regional state provincial local regulatory agencies departments bureaus commissions councils government entities including without limitation fda entity exercising regulatory authority respect exploitation combination product territory regulatory documentation shall mean submissions regulatory authorities territory including without limitation inds ndas sndas cmc data drug master files correspondence regulatory agencies registrations licenses regulatory drug lists advertising promotion documents psurs adverse event files complaint files manufacturing records relevant experience information shall mean adverse experience reports reports based marketing data documentation relevant drug experience requesting member shall meaning set forth section g required update shall meaning set forth section b respective percentage shall mean respect gilead actual gilead percentage respect bms actual bms percentage provided however whenever agreement provides amount shall allocated member parties based respective percentages allocation shall first made basis member parties respective working percentages time relevant event allocation shall adjusted applicable determination member parties respective actual percentages calendar year relevant event occurs adjustments shall occur later april next calendar year unless otherwise provided agreement operating agreement otherwise agreed writing member parties right reference shall meaning set forth cfr b alternatively shall mean equivalents thereto jurisdictions outside territory avoidance doubt used agreement right reference shall refer right regulatory authorities rely upon otherwise use applicable information shall confer member party right reference granted right receive access information shall meaning set forth section sdea safety data exchange agreement shall meaning set forth section selected product liability claim shall meaning set forth section c services agreement shall mean distribution services agreement entered gilead parent jv effective date key terms outlined annex p hereto agreement may amended time time single agent product shall mean viread emtriva sustiva study shall mean clinical study initiated gilead prior effective date gileads clinical study protocol entitled phase randomized openlabel multicenter study treatment antiretroviralnave hivinfected subjects comparing tenofovir disoproxil fumarate emtricitabine combination efavirenz versus combivir lamivudinezidovudine efavirenz protocol may revised study may extended expanded time time case gilead avoidance doubt conduct study shall deemed development activity project activity purposes agreement clinical data derived generated study testing analysis subjects samples study shall gilead know joint knowhow subsequent launch period shall mean launch combination product territory supplier shall mean person selected commercial supplier combination product pursuant section supply agreements shall mean collectively bms supply agreement gilead supply agreement supply party shall mean respect supplier member party supplier member party b third party supplier member party designated pursuant section manage relationship supplier tdf shall meaning set forth recitals agreement technology shall mean bms technology gilead technology case may terminated member party shall mean member party designated pursuant section territory shall mean united states commonwealth puerto rico territories possessions united states third party shall mean person gilead bms jv respective affiliates third party acquirer shall meaning set forth section trademark shall include word name symbol color designation device combination thereof including without limitation trademark trade dress service mark service name brand mark trade name brand name logo business symbol transfer price shall mean bms transfer price gilead transfer price case may transferring member party shall meaning set forth section b shall meaning set forth section wac shall meaning set forth annex q working bms percentage shall mean calendar year preliminary percentage applicable bms calendar year determined pursuant section ci working gilead percentage shall mean calendar year preliminary percentage applicable gilead calendar year determined pursuant section ci working percentage shall mean respect bms working bms percentage respect gilead working gilead percentage section collaboration management general set forth agreement operating agreement member parties desire establish joint executive committee shall oversee member parties collaboration agreement facilitate communications member parties respect development approval manufacturing commercialization combination product territory subject foregoing member parties also desire establish specialized committees focus closely parties development activities commercialization activities finance activities hereunder committee shall responsibilities authority delegated vested committee section elsewhere agreement operating agreement role joint executive committee establishment composition governance powers limitations powers joint executive committee jec governed section operating agreement section initial jec members identified annex hereto jec shall overall authority responsibility respect development activities commercialization activities combination product except matters reserved member parties pursuant agreement operating agreement without limitation foregoing jec shall following powers duties oversee work operating committees possible resolve disputes referred alliance managers pursuant section ii oversee activities gilead keeping jvs books records pursuant section iii adopt guidelines compliance parties antitrust laws connection jv activities iv approve initial capital contributions defined operating agreement members approve capital contribution planning schedule issue certain requests additional capital contributions case pursuant section operating agreement v approve x annual update development plan development budget interim update development plan development budget case may jdc unable reach agreement vi approve x annual update commercialization plan commercialization budget interim update commercialization plan commercialization budget case may jcc unable reach agreement vii approve unit volume forecasts jcc unable reach agreement use preparation commercialization plans commercialization budgets regardless whether commercialization plan commercialization budget use planning manufacture combination product planning commercialization activities member parties financial planning purposes viii approve cost allocation proposals ix approve jfcs reports financial matters jec determines reasonably necessary appropriate implementation financial aspects jv x review recommendations jfc respect approve one means reconciling one internal reporting accounting standards member parties reasonably necessary methods charging costs expenses member parties xi review applicable recommend member parties changes pursuant section xii resolve disputes within jdc respect required approval publications presentations pursuant section b member partys obligation section b provide member party access certain member partys records documentation data xiii resolve disputes within jcc respect initially proposed marketing materials combination product territory thereafter updates approved marketing materials b member partys obligation pursuant section provide member party access certain member partys records documentation data c issues relating patient assistance programs arising section bvii issues relating suppliers alternate suppliers arising section bix xiv decide major strategic issues matters relating jv within purview operating committees ii reserved member parties pursuant agreement operating agreement xv take actions reserved jec agreement operating agreement parties may mutually agree writing except jec may amend take action would conflict provision agreement operating agreement ancillary agreement may resolve issue regarding termination agreement potential actual material default joint development committee member shall appoint four members joint development oversight management committee joint development committee jdc gilead sub shall appoint one members designated gilead sub serve chairperson jdc first anniversary effective date thereafter member designated bms sub member designated gilead sub shall serve alternately chairperson rotating annual basis anniversary effective date initial jdc members chairperson identified annex hereto b subject oversight jec jdc shall following powers duties x review propose jec approval annual update development plan development budget review approve interim update development plan development budget case proposed pursuant section ii oversee coordinate parties activities development plan iii oversee manage matters relating clinical supply combination product including without limitation manufacturing requirements inventory projections inventory control iv alliance managers x assist coordinating scientific interactions parties course implementing development plan facilitate exchange among parties data information materials results relating clinical manufacturing clinical trials communications filings regulatory authorities combination product case solely extent data information materials required exchanged among parties respect one member party right gain access member party jv pursuant agreement operating agreement v oversee regulatory matters jv including without limitation approving combination product regulatory documentation extent required pursuant section overseeing gileads activities jvs liaison regulatory authorities territory overseeing activities conducted pursuant sdea pharmacovigilance safety reporting vi oversee member parties activities pursuant respective supply agreements oversee coordinate jcc respect matters relating monitoring manufacturing capacity forecasts orders active pharmaceutical ingredients combination product vii resolve disputes member parties respect required approval publications presentations pursuant section b member partys obligation section b provide member party access certain member partys records documentation data viii oversee medical affairs medical communications activities ix review approve reject proposals phase iv clinical studies combination product x provide updates jdcs activities achievements jec calendar quarter xi perform functions member parties may mutually agree writing time time joint commercialization committee member shall appoint four members joint commercialization oversight management committee joint commercialization committee jcc bms sub shall appoint one members designated bms sub serve chairperson jcc first anniversary effective date thereafter member designated gilead sub member designated bms sub shall serve alternately chairperson rotating annual basis anniversary effective date initial jcc members chairperson identified annex hereto b subject oversight jec jcc shall following powers duties oversee coordinate parties activities commercialization plan ii x review propose jec approval annual update commercialization plan commercialization budget review approve interim update commercialization plan commercialization budget case proposed pursuant section c iii oversee gileads activities pursuant services agreement iv develop approve x initial marketing materials combination product territory updates materials time time may reasonably necessary appropriate accordance section v develop approve unit volume forecasts use preparation commercialization plans commercialization budgets regardless whether commercialization plan commercialization budget use planning manufacture combination product planning commercialization activities member parties financial planning purposes vi coordinate jdc respect manufacturing labeling matters vii x determine jv respond requests health care providers individual patients may obtain prescriptions combination product unable afford establish appropriate procedures response times shall apply responding requests case x accordance section viii make recommendations jec respect cost allocation proposals ix maintain one supplier one alternate suppliers pursuant section manufacture commercial supplies combination product x oversee coordinate jdc respect matters relating manufacturing labeling combination product commercial supply including case manufacturing respect quality control matters monitoring manufacturing capacity forecasts orders combination product ensure adequate commercial supply meet demand therefor territory projected jcc approved jec xi resolve disputes member parties respect member partys obligation pursuant section provide member party access certain member partys records documentation data xii provide updates jccs activities achievements jec calendar quarter xiii perform functions member parties may mutually agree writing time time joint finance committee member shall appoint two members joint finance committee support jec jdc jcc joint finance committee jfc gilead sub shall appoint one members designated gilead sub serve chairperson jfc first anniversary effective date thereafter member designated bms sub member designated gilead sub shall serve alternately chairperson rotating annual basis anniversary effective date initial jfc members chairperson identified annex hereto b subject oversight jec jfc shall following powers duties work jec operating committees assist financial budgeting planning matters required including assisting preparation budgets annual longterm plans ii recommend approval jec procedures formats timelines consistent agreement reporting financial data well additional alternative reporting procedures concerning financial aspects jv iii prepare reports financial matters approved jec implementation financial aspects jv iv coordinate audits financial data appropriate required allowed agreement v address issues implementation relating financial mechanics calculations agreement operating agreement vi recommend approval jec means reconciling one internal reporting accounting standards member parties necessary methods charging costs expenses member parties vii review appropriate allocation costs expenses respect authorized expenses viii calculate cause calculated case may matters expressly required calculated caused calculated jfc pursuant agreement including sections c pursuant operating agreement address issues implementation relating cash netting procedures set forth section c operating agreement ix develop recommend jec approval initial capital contributions defined operating agreement members capital contribution planning schedule recommend jec certain requests additional capital contributions case pursuant section operating agreement x provide updates jfcs activities achievements jec calendar quarter xi perform functions member parties may mutually agree writing time time procedural rules operating committees bms sub gilead sub shall designate representatives appropriate expertise serve members operating committee representative may serve one operating committee andor jec appropriate view individuals expertise members shall endeavor match respective representation operating committee terms functional areas management level b member operating committee may removed replaced time without cause member appointed committee member action shall accomplished written notice member member operating committee shall serve successor named member appointed committee member earlier resignation removal c jfc shall meet least one time per calendar quarter term agreement jdc shall meet least one time per calendar quarter first anniversary launch combination product thereafter least semiannually schedule may determined jdc jcc shall meet least one time per calendar quarter second anniversary launch combination product thereafter least semiannually schedule may determined jcc operating committee shall meet times places united states mutually agreed bms sub gilead sub respective operating committees shall meet discuss overall progress development activities development plan commercialization activities commercialization plan financial aspects jv case may problems arising course activities status development plan development budget commercialization plan commercialization budget financial aspects jv case may matter member operating committee may reasonably request operating committee shall keep accurate complete minutes meetings record proposals recommendations actions taken minutes records operating committee shall available member party chairperson shall organize committee meetings prepare meeting agenda based items submitted committee members take cause taken accurate minutes meetings circulate draft minutes within seven days meeting approval members committee members circulate final minutes committee members promptly following approval notice agenda meeting accompanying materials shall circulated members applicable operating committee sufficiently advance normal course materials received least five business days advance meeting provided however reasonable circumstances materials may circulated within lesser period time advance meeting long member agrees inclusion agenda items proposed consideration member member operating committee may waive notice meeting thereof shall deemed waive notice applicable right object inclusion particular agenda item items set forth proviso previous sentence attends meeting object meeting lack notice prior commencement e least two members appointed gilead sub two members appointed bms sub must attendance meeting operating committee establish quorum conduct business committee members may attend meetings person long attendee able hear others telephone video conference equipment provided however least two meetings per calendar year operating committee shall held person launch combination product thereafter least one meeting per calendar year operating committee shall held person operating committee may also act unanimous written consent members without meeting f meeting operating committee members designees operating committee shall collectively one vote matters acted upon member vote operating committee shall take action unanimous member vote operating committee unable reach agreement matter properly presented operating committee consideration matter shall resolved procedure set forth section except otherwise provided therein g operating committee may deems appropriate delegate decisionmaking authority specific matters types matters applicable case jdc jcc approval updates development plan commercialization plan development budget commercialization budget operating committee responsible provided section subcommittees specific groups representatives members shall make decisions consensus subcommittees groups reach consensus matter either member may refer matters back operating committee resolution h notwithstanding enumerated authority jec agreement operating agreement express reservation decisionmaking authority member parties certain matters herein therein event jec acting unanimous affirmative member votes defined operating agreement pursuant section operating agreement ii unanimous written consent pursuant section c operating agreement takes action matter relating exploitation combination product respect matter authority responsibility delegated vested jec member parties shall deemed waive objection effect jec acted beyond scope authority responsibility resolution matter shall binding member parties purposes agreement operating agreement alliance managers gilead bms shall designate within respective organizations alliance manager alliance manager responsibility facilitating interaction cooperation gilead bms respect jv exploitation combination product territory initial alliance managers identified annex hereto member party may change alliance manager time time upon written notice member party b alliance managers shall attend meetings jec operating committee jfc support chairpersons jec operating committee discharge responsibilities alliance managers shall nonvoting participants meetings unless also appointed members applicable committees alliance manager shall endeavor create maintain collaborative work environment within among jec operating committees addition alliance manager shall point first referral certain matters subject dispute resolution provided section ii shall coordinate relevant functional representatives member parties iii shall provide single point communication seeking consensus internally within respective member parties organizations member parties iv shall identify bring disputes attention jec operating committee appropriate timely manner v shall plan coordinate cooperative efforts internal external communications vi shall take responsibility ensuring governance activities conduct required jec operating committee meetings production meeting minutes occur set forth agreement operating agreement relevant action items agreed upon meetings appropriately carried otherwise addressed c notices given member party member party respect development activities combination product efv tdf ftc bulk active pharmaceutical ingredient manufacturing commercialization activities shall made member partys alliance manager operating committee jec member member party directly involved informed relevant activity except gilead bms selected supplier pursuant section shall required provide notice member partys alliance manager respect toll manufacturing activities dispute resolution disputes may referred jec resolution follows operating committee unable reach agreement matter properly presented operating committee decision operating committee shall refer matter alliance managers gilead bms alliance managers unable resolve dispute within referral matter shall referred jec ii either member party may refer jec issue arising agreement operating agreement otherwise covered clause b jec unable resolve dispute referred alliance managers member party pursuant section within referral event jec unable resolve dispute arising within jec dispute shall referred resolution chief executive officer gilead parent bms chief executive officer bms parent direct report designated chief executive officer bms parent shall member jec operating committee c chief executive officer gilead parent chief executive officer designee applicable bms parent unable reach agreement disputed matter referred pursuant section b within referral either gilead bms may refer disputed matter binding arbitration pursuant section extent disputed matter relates arises validity interpretation construction compliance breach agreement operating agreement ancillary agreement agreement contemplated agreement member party affiliates jv andor member party affiliates parties b disputed matter came jec pursuant section section provided dispute relating may submitted arbitration respect issue whether specific dispute relating pursuant may submitted arbitration respect issue dispute relating may submitted arbitration respect matters arising pursuant dispute relating may submitted arbitration respect matters arising pursuant c dispute whether satisfied respect matter avoidance doubt dispute resolution procedures set forth sections b c shall apply deadlock within jec operating committee resulting proposal one members committee members reverse modify decision jec operating committee respect matter previously presented decision approved unanimous member vote unanimous written consent members unless following conditions satisfied proposal applicable jec operating committee decision ii deadlock involves iii applicable jec operating committee decision reversed modified would pursuant agreement understood certain aspects applicable jec operating committee decision produce results shall subject dispute resolution procedures set forth sections b c balance decision shall remain effect provided however section shall apply deliberations decisions jcc pursuant sections deliberations decisions jec respect disputes arise within jcc respect thereto provided jccs jecs reconsideration prior decisions respect matters covered preceding proviso shall governed respectively event reconsideration dispute resolution arbitration connection therewith prior decision force time reconsideration shall remain force continue apply time modified position may agreed jcc jec adopted arbitrators case may e nothing section shall affect right member party exercise rights section respect material default member party concurrently exercise rights section event time prior completion dispute resolution procedures set forth section nonbreaching member party delivers notice material default breaching member party sixty day cure period referred section shall begin run upon receipt notice shall run concurrently procedures set forth section collaboration principles parties agree abide following principles collaboration principles conduct development activities commercialization activities cause representatives jec operating committees observe principles connection committeerelated activities subject sections b c purposes jv develop manufacture commercialize combination product use within territory ii optimize commercial potential combination product within commercialization plan subject commercialization budget avoidance doubt nothing agreement operating agreement shall deemed restrict prohibit either member party affiliates x commercializing single agent products andor double agent product applicable subject sections developing manufacturing commercializing combination products combination product treatment hiv infection otherwise including without limitation product containing partys single agent products andor double agent product z conducting clinical studies involving one efv ftc tdf combination thereof including combination product b subject section partys promotion combination product territory shall accordance approved marketing materials fdaapproved label package insert combination product provided however subject foregoing party shall right position combination product within hiv product portfolio sole discretion c except expressly provided otherwise agreement operating agreement ancillary agreement notwithstanding powers authority delegated party jec operating committee neither party shall obligation conduct activities support furtherance exploitation combination product unless mutually agreed writing parties expressly set forth agreement commercialization plan development plan ii make payments incur expenses liabilities support furtherance exploitation combination product unless mutually agreed writing parties expressly set forth commercialization budget development budget commercialization budgetplan deadlocks event commercialization budget deadlock commercialization plan deadlock terms defined respect portion period effective date end subsequent launch period lieu dispute resolution procedures set forth agreement operating agreement parties agree dispute shall conclusively resolved follows commercialization budget deadlock relates calendar year part thereof period effective date end initial launch period level aggregate expenditure calendar year part thereof dispute shall fixed upon notice given member party member party case disputes annual updates level calendar year dispute provided initial version commercialization budget included annex c hereto recently updated applicable ii case disputes interim updates level effect relevant part current calendar year b commercialization budget deadlock relates calendar year part thereof subsequent launch period level aggregate expenditure calendar year part thereof dispute shall fixed upon notice given member party member party case disputes annual updates level recently updated budgeted calendar year immediately preceding calendar year dispute unless members respective representatives jec proposed levels aggregate expenditure lower aforesaid level case level aggregate expenditure calendar year dispute shall instead fixed members respective representatives jec b case disputes interim updates level effect relevant part current calendar year ii dispute regarding level aggregate expenditure provided subsequent annual update commercialization budget covered foregoing clause level shall fixed upon notice given member party member party amount members respective representatives jec c commercialization plan deadlock relates calendar year part thereof initial launch period calendar year part thereof dispute shall fixed upon notice given member party member party case disputes annual updates level calendar year dispute provided initial version commercialization plan included annex c hereto recently updated applicable ii case disputes interim updates level effect relevant part current calendar year commercialization plan deadlock relates calendar year part thereof subsequent launch period calendar year part thereof dispute shall fixed upon notice given member party member party case disputes annual updates level recently updated effect calendar year immediately preceding calendar year dispute unless members respective representatives jec proposed lower aforesaid level case product year dispute shall instead fixed members respective representatives jec b case disputes interim updates level effect relevant part current calendar year ii dispute regarding provided subsequent annual update commercialization plan covered foregoing clause level shall fixed upon notice given member party member party amount members respective representatives jec calendar years part thereof commencing subsequent launch period aggregate expenditures commercialization budget commercialization plan shall decided mutual agreement writing member parties failure reach agreement thereon shall subject dispute resolution hereunder used agreement x commercialization budget deadlock shall mean jec unable reach agreement unanimous member vote defined operating agreement unanimous written consent members jec level aggregate expenditure annual case clause section vi interim update commercialization budget covering portion period effective date end initial launch period portion subsequent launch period commercialization plan deadlock shall mean jec unable reach agreement unanimous member vote unanimous written consent members jec conducted annual case clause section vi interim update commercialization plan covering portion initial launch period subsequent launch period expenses gilead bms shall bear expenses related management jv including without limitation expenses relating meetings jec operating committees participation members representatives meetings communications member connection meetings matters within authority committees travel meetings expenses shall deemed jv expenses authorized expenses section development activities general oversight jdc gilead bms shall perform cause affiliates perform behalf name jv development activities designated member party development plan case accordance timeline set forth development plan avoidance doubt gilead behalf name shall sole right sole discretion without oversight jdc jec shall respect clinical development without limitation section gilead oversight jdc shall primary responsibility development combination product conduct clinical trials bioequivalence studies required obtaining approval nda combination product territory field case set forth development plan otherwise mutually agreed upon member parties b event either member party desires conduct sponsor cause conducted sponsored jointly member party name jv clinical trial combination product whether clinical trial would involve combination product alone one products clinical trial contemplated development plan including without limitation expanded access program phase iiibiv study ii support jointly member party either behalf name jv clinical trial sponsored investigator member party shall notify member party member parties shall discuss particulars proposed clinical trial event member parties sole discretion agree conduct jointly sponsor jointly clinical trial either behalf name jv jdc representatives shall prepare agree upon trial protocol designate member party take lead conducting supervising clinical trial negotiating necessary clinical trial agreements case may external outof pocket costs member parties without markup relating clinical trial shall treated authorized development expenses event member parties sole discretion agree support jointly either behalf name jv investigatorsponsored clinical trial member parties shall coordinate investigator seeking conduct clinical trial agree upon appropriate grant support including without limitation support form funding contribution drug product external outofpocket costs member parties without mark respect clinical trial shall treated authorized development expenses clinical trial member parties shall determine conduct sponsor support jointly pursuant preceding two sentences shall referred cofunded clinical trial clinical data respect cofunded clinical trial shall deemed joint knowhow provided however case investigatorsponsored clinical trial clinical data resulting cofunded clinical trial shall deemed joint knowhow extent jv either member parties obtains right title interest clinical data avoidance doubt nothing contained section intended shall construed restrict prohibit either member party conducting independently together one third parties clinical trial combination product whether clinical trial would involve combination product alone one products prior member partys commencing clinical trial sponsored member party whether independently together one third parties applicable member party shall provide brief summary protocols member partys representatives jdc understood neither representatives jdc shall approval rights respect study protocols provided summary shall constitute confidential information disclosing member party extent information provided summary satisfies criteria set forth section b receiving member partys representatives shall use summary purpose providing comments thereon disclosing member party comments may accepted rejected disclosing member party sole discretion c receiving member partys representatives shall disclose summary persons employees member party obligation x disclose summary use summary solely order assist member partys representatives providing comments thereon avoidance doubt member partys providing summary respect clinical trial pursuant agreement shall construed effect causing activities respect clinical trial deemed project activities purposes agreement c event member parties determine conduct additional development activities alternative formulation presentation combination product conduct cause conducted additional activities external outofpocket costs member parties without markup respect activities shall treated authorized development expenses formulation cmc data without limitation section gilead oversight jdc shall primary responsibility formulation manufacturing process development preparation cmc data relating combination product contemplated development plan formulation development shall include without limitation conducting formulation screening optimization scaleup technology transfer combination product field regulatory matters without limitation section gilead oversight jdc participation bms described section shall primary responsibility preparing filing necessary regulatory documentation acting liaison behalf jv communications regulatory authorities territory relating obtaining approval combination product field nda separate respective ndas sustiva viread emtriva truvada gilead shall prepare file combination product regulatory documentation regulatory authorities territory name jv submissions combination product regulatory documentation consisting inds ndas sndas cmc data drug master files psurs collectively key regulatory submissions shall approved advance jdc shall delegate approval subcommittees groups referred section g permitted applicable law label combination product shall list agents following order b gilead shall notify bms early reasonably practicable advance meetings whether face face teleconference communications representatives regulatory authorities territory concerning combination product order provide bms opportunity present meetings review comment communications provided however event shall gilead using reasonable efforts provide bms opportunity present meeting review comment communications required postpone meeting ensure bms attends meeting postpone communication order ensure bms comments received gilead advance submission regulatory authorities case may order enhance efficiency member parties coordination regulatory matters concerning combination product increase likelihood bms meaningful opportunity participate activities term agreement bms cause one employees necessary regulatory expertise decisionmaking authority dedicated fulltime basis serving conduit bms participation activities gilead shall promptly forward bms advance meeting copies documents relevant information relating meeting notwithstanding anything contained agreement contrary meeting communication regulatory authorities territory concerning combination product bms gilead present member parties participate member party shall take lead matters relating respective single agent products double agent product ii meeting communication regulatory authorities concerning combination product one member party meets communication one member party participates without member partys presence participation member party shall engage substantive discussions pertaining member partys single agent products double agent product case may including without limitation respect api consisting efv tdf ftc case may relates combination product c member party shall promptly forward member party written communications received representatives regulatory authorities relating combination product bms shall provide gilead full access copies including electronic copies requested bms regulatory documentation including without limitation nda sustiva gilead may reasonably request connection solely purpose performance duties section nothing section shall prohibit restrict either member party communicating regulatory authorities matters relating exploitation respective single agent products double agent product pharmaceutical products member party shall promptly notify member party label change first member partys respective single agent products double agent product may result label change combination product communications regulatory authorities regarding potential label changes combination product reasonably expected lead label change member partys single agent product double agent product notwithstanding anything agreement contrary affected member party shall take lead dealing regulatory authorities matter performance subcontracting gilead bms shall perform respective development activities material compliance gcp glp gmp case extent applicable requirements applicable law long development plan effect shall use commercially reasonable efforts perform development activities development plan efficiently expeditiously subject development budget either member party may subcontract performance respective development activities provided however subcontracting member party shall oversee performance subcontractors subcontracted development activities manner would reasonably expected result timely successful completion shall remain responsible performance development activities accordance agreement development plan records maintenance records gilead bms shall severally accordance respective allocations responsibilities respect project activities maintain cause maintained combination product regulatory documentation final supporting records documentation therefor draft records documentation therefor except otherwise required applicable law sufficient detail material compliance gcp glp gmp case extent applicable records shall complete accurate shall fully properly reflect work done results achieved performance respective development activities manner appropriate regulatory purpose applicable use connection patent filings prosecution maintenance documentation records shall retained least three years ii longer period may required applicable law b access records member party shall right normal business hours upon reasonable notice inspect copy combination product regulatory documentation final supporting records documentation therefor generated maintained member party use receiving member party solely connection performance development activities manner consistent development plan subject terms conditions section b member party shall also right normal business hours upon reasonable notice obtain member party access copies scientific regulatory technical records documentation data solely extent relating combination product member partys single agent products andor double agent product case may solely extent necessary order receiving member party perform obligations respect development activities manner consistent development plan ii necessary receiving member party confirm compliance andor comply glp gcp gmp extent applicable applicable law relates project activities andor iii necessary enable receiving member party conduct reasonable diligence matters potentially giving rise liability part jv andor receiving member party conduct defense andor jv respect liability extent fact circumstance event arisen gives receiving member party reasonable basis believe jv may incur liability case use receiving member party purpose set forth clause ii iii case may clause iii immediately preceding sentence shall require party provide data documentation records event parties interests matter may case shall apply request shall made writing shall state reasons therefor development record request member party records documentation data requested shall right raise reasonable objections writing response development record request including without limitation based member partys interests protecting disclosure requesting member party trade secrets competitive business information upon objection asserted member parties shall promptly confer attempt address member partys concerns reach resolution respect matter event member parties unable agree upon mutually agreeable resolution either member party shall right refer matter jdc event dispute ultimately determine threshold matter whether extent one criteria set forth clauses ii andor iii satisfied requesting member party shall make determination respect whether extent disclosure information shall required making determination facts arguments set forth development record request member partys written response thereto shall right require receiving member party abide terms conditions handling use nondisclosure either within member partys organization andor third parties information may reasonable circumstances except provided section member party shall right obtain member party access copies member partys records documentation data described unless otherwise expressly permitted pursuant agreement member party gives consent sole discretion updates development plan development budget gilead shall prepare submit jdc jfc less prior start calendar year proposed update development plan development budget calendar year ii less prior start calendar year preliminary update development budget may address budget issues general level may incomplete subject change addition either member party directly representatives jdc may propose updates development plan development budget jdc time time appropriate light changed circumstances changes updates shall subject approval jdc set forth section f annual updates approved least prior start calendar year annual interim update development plan development budget approved jdc subject sections v applicable development plan development budget case may shall continue effect approved recently updated pursuant section updated development plans shall cover items included initial development plan unless mutually agreed member parties development expenses shall responsible costs incurs sole discretion connection b performance development activities set initial development plan parties agree jv shall bear jv expenses incurred gilead bms connection performance respective development activities extent meeting following criteria authorized development expenses development activities conducted pursuant development plan within area responsibility relevant member party listed development budget chargeable jv ii total expenses area responsibility member party relevant period extent exceed corresponding budgeted amount area period unless approved jdc iii expenses external ofpocket costs gilead bms without markup iv expenses costs referred reports gilead bms shall present meeting jdc least per calendar quarter first anniversary launch combination product thereafter meeting jdc least semiannually report oral written written report shall required contain detail typically included executive summary describing development activities performed caused performed since preceding meeting report presented case first meeting jdc prior meeting calendar yearto date basis evaluating work performed relation goals timeline development plan ii development activities process future activities expects initiate thencurrent calendar year compared development plan iii case written report authorized development expenses incurred expected incurred member party thencurrent calendar year compared development budget addition gilead bms shall report promptly jdc respective committee members material developments respect development activities responsible performing development plan notwithstanding anything contained section contrary member partys reporting obligations section shall automatically deemed terminate respect period effect development plan development budget new products period date agreement anniversary effective date member parties agree use commercially reasonable efforts evaluate pursue arrangement codevelopment cocommercialization product comprising provided however member parties may terminate efforts mutual written agreement determine proposed product commercially technically feasible agreement terminate unreasonably withheld furtherance foregoing notwithstanding anything agreement contrary period effective date anniversary effective date gilead shall shall cause affiliates within territory contains third party ii territory b bms shall shall cause affiliates within territory contains combination proprietary third party ii territory publication either member party shall right publish present data findings resulting project activities including without limitation cofunded clinical trials subject right objection demand modification member party interest protecting confidential information member party ii preserving intellectual property rights member party jv andor iii assuring publication presentation presents data findings fair accurate balanced manner accordance ethical medical andor scientific standards term agreement member party shall provide member partys representatives jdc review copies academic scientific medical publications presentations specifically relating combination product otherwise relating combined use efv ftc tdf member party proposes submit publication presentation result project activities provided however notwithstanding anything contained section contrary terms conditions section shall apply publications presentations resulting directly indirectly study review publications presentations shall conducted purposes considering compliance standards set forth clauses ii iii publication standards shall consider whether portion publication presentation modified deleted order conform publication standards addition case publication presentation resulting cofunded clinical trial member party proposes submit publication presentation shall right member party agrees publication presentation may modified conforms publication standards agreement shall unreasonably withheld delayed member party shall consider good faith comments provided member party respect publication presentation including without limitation comments scientific medical nature case publication presentation resulting project activities member party shall right comment publication presentation provided member party proposing publication presentation shall obligation accept comments except extent necessary preserve intellectual property rights member party jv shall free publish present case may written copies proposed publication presentation required provided review shall provided member partys representatives jdc later submission publication presentation except case abstract copy abstract shall provided soon reasonably practicable advance submission abstract third party period may less b deadline submission publication presentation less date completion publication presentation copies provided soon reasonably practicable advance submission deadline case proposed publication presentation member party required reviewed member party event member parties fail reach agreement applicable publication presentation conclusion applicable review period result dispute member parties respect publication presentation dispute may referred either member party jdc member parties shall comply publications made pursuant section standard academic practice regarding authorship scientific publications recognition contribution parties avoidance doubt nothing contained section shall alter affect member partys confidentiality obligations pursuant section b subject compliance section nothing agreement shall restrict either member party providing information cofunded clinical trials conducted member party clinical trials registry clinical trials results database accordance applicable law industry practice purposes section b clinical trial registry means listing clinical trials initiated whether maintained us federal government eg wwwclinicaltrialsorg independent organization eg phrma ii clinical trials results database means database provides access clinical trial results physicians patients general public whether maintained government regulatory authority independent organization eg phrma certain inspections member party shall involve member party extent feasible gcp glp gmp audit process facilities used performance development activities combination product including facilities subcontractors extent permitted pursuant terms applicable subcontract otherwise permitted applicable subcontractor shall consider good faith issues concerning compliance safety efficacy issues respect combination product active pharmaceutical ingredients member partys single agent products double agent product applicable raised member party reasonable basis result audits member party shall also right normal business hours upon reasonable notice inspect member partys facilities facilities subcontractor extent permitted pursuant terms applicable subcontract otherwise permitted applicable subcontractor used performance development activities combination product member party desiring inspection reasonable basis raise good faith compliance safety efficacy issues apart aforementioned audit inspections audit referred section shall subject reasonable restrictions access confidential information trade secrets inspecting member party extent confidential information trade secrets expressly required disclosed member party member party pursuant agreement medical affairs medical communications gilead bms shall determine independently utilize deploy respective medical science liaisons activities relating combination product jdc shall develop approve presentation materials use member partys medical science liaisons engaging activities support promotion combination product medical science liaisons shall use approved presentation materials activities jdc shall develop member parties shall implement procedures coordinate training member partys medical science liaisons approved presentation materials b jdc shall develop guidelines procedures determining providing appropriate responses medical inquiries combination product including assigning responsibilities medical communications parties shall develop set standard response documents member parties use responding medical inquiries combination product follows member party shall develop standard response documents relating respective single agent products double agent product incorporated combination product ii gilead shall develop draft standard response documents relating combination product whole substantially incorporating developed member party single agent products andor double agent product review comment approval jdc section manufacturing supply clinical supply gilead shall manufacture manufactured subcontractor behalf jv clinical supplies combination product quantities may needed clinical trials studies required obtain initial approvals nda connection manufacture gilead bms shall donate jv quantities ftc tdf case gilead efv case bms member partys cost goods supply well gileads cost goods manufacture clinical supplies combination product shall chargeable jv commercial supply initial development plan designates initial commercial supplier combination product supplier shall source combination product supply purposes nda filing launch territory within effective date jcc shall determine costefficient manner source commercial supply combination product including without limitation one alternate suppliers thereafter term agreement jcc shall review annually appropriate sources commercial supply combination product launch agree upon appropriate changes member party may propose interim changes respect thereto time time reviews changes jcc shall adopt failure would likely material adverse effect combination product business gilead bms desires considered possible supplier combination product shall submit confidential written proposal jv consideration jcc alongside written proposals submitted recognized reliable sufficiently capitalized third parties andor supply terms pertaining initial supplier proposal submitted possible supplier shall include offer perform required tableting blistering packaging labeling analytical testing storage activities respect commercial supplies combination product jcc shall select person supply jv commercial supplies combination product basis price quality reliability gmp compliance security supply relevant commercial considerations third party selected supplier jcc shall designate member party manage relationship supplier supply contract jv gilead bms supplier shall negotiated armslength basis shall contain terms conditions customary pharmaceutical industry modified appropriate combination product b jcc directly designated member party coordination jdc shall monitor manufacturing capacity forecasts orders combination product submitted relevant suppliers ensure adequate commercial supplies combination product available meet demand therefor projected jcc commercial unit volume forecasts jcc shall prepare rolling unit volume forecasts least commencement forecast period shall update unit volume forecasts basis jcc deems necessary appropriate c connection manufacture supplier commercial supply combination product jv gilead bms shall supply jv quantities ftc tdf case gilead efv case bms case form bulk active pharmaceutical ingredient pursuant accordance respective supply agreements consideration supply jv shall pay gilead bms respectively gilead transfer price bms transfer price jdc shall monitor orders respective supply agreements assure consistency quantities ftc tdf efv ordered jv thereunder section commercialization activities copromotion obligations gilead bms shall use commercially reasonable efforts perform territory commercialization activities member party required perform commercialization plan accordance commercialization budget applicable activities long commercialization plan effect member party shall required initial launch period extent applicable thereto subsequent launch period per calendar quarter take actions applicable specified commercialization plan subject section shall apply subsequent launch period unless approved jec jcc applicable part commercialization plan update pursuant section c ii subsequent launch period unless approved member parties member party shall free engage engage longer commercialization plan effect case sole discretion b gilead bms shall select independently target prescribers shall promote combination product c accordance section b gilead bms shall cause field force use fda approved product labels inserts subject section approved marketing materials promoting combination product make statements claims regarding combination product consistent applicable law fdaapproved product labels inserts gilead bms shall provide give access samples combination product health care practitioners patients connection promotion combination product gilead bms shall detail combination product perform promotional activities agreement territory strict adherence regulatory professional requirements applicable law including extent applicable act fda guidance industrysupported scientific educational activities pharmaceutical research manufacturers america code interactions healthcare professionals office inspector general compliance program guidance pharmaceutical manufacturers american medical association guidelines gifts physicians industry pharmaceutical marketing research group guidelines market research activities prescription drug marketing act amended pdma federal state local fraud abuse consumer protection false claims statutes regulations including limited medicare state health programs antifraud abuse amendments social security act safe harbor regulations found cfr et seq among parties member party shall treat sales representatives engaged detailing combination product affiliates employees purposes including without limitation federal state local tax employment laws e within end calendar quarter part thereof falling within initial launch period ii extent applicable thereto subsequent launch period iii period commencing subsequent launch period mutually agreed member parties pursuant section clauses ii iii referred herein collectively product detail period gilead bms shall furnish parties written report form set forth annex h attached hereto setting number details conducted calendar quarter part thereof territory number reported shall determined accordance applicable selfreporting procedures details customarily employed member party territory similarly detailed similarly reported hiv products target health care audience consistently applied f calendar year part thereof falling within product detail period subject terms section f member party shall conduct x calendar quarter part thereof specified commercialization plan calendar year part thereof specified commercialization plan ie extent product detail period includes part calendar quarter calendar quarter shall calendar quarter applicable calendar year details conducted member party calendar quarter member party may details conducts case order subject section g calendar year details conducted member party calendar year notwithstanding anything agreement contrary member party shall ii failure member comply section f results shall subject g calendar quarter member party expects experience succeeding calendar quarter part thereof shall inform member party anticipated written notice promptly practicable later due date report referred section e member party shall right succeeding calendar quarter part thereof anticipated succeeding calendar quarter part thereof giving notice first member party intent within receiving notice avoidance doubt member party gives notice first member party shall member party amount equal product multiplied multiplied case shall distribution obligations gilead shall sole responsibility right fill orders respect combination product behalf jv reason bms receives sales orders combination product shall promptly forward order gilead order combination product may rejected gilead rejection commercially reasonable circumstances jcc shall determine jv shall respond requests individual patients may obtain prescriptions combination product may unable afford health care providers behalf patients including without limitation establishing appropriate procedures response times shall apply responding requests provided however jcc shall structure applicable program manner make evident health care providers patients participation jv appropriate member parties program shall ensure procedures response times less favorable patients favorable either member partys patient assistance programs single agent products andor double agent product effective date jcc shall review arrangements patient assistance program annually agree upon appropriate changes member party may propose interim changes respect thereto time time reviews changes jcc shall adopt failure would likely material adverse effect combination product business b without limitation foregoing gilead shall perform functions distributor respect sales combination product behalf jv including without limitation inventory management control warehousing distribution invoicing collection sales proceeds preparation sales records reports customer relations services handling returns accordance customary practice biopharmaceutical industry pursuant separate services agreement entered parties within effective date substantially terms outlined annex p c gileads relationships wholesale distributors combination product shall governed inventory management agreements reduce inventory fluctuations extent commercially feasible agreements also cover gileads products field shall commercially reasonable respect relating thereto gilead shall ensure either ii basis among gilead shall use commercially reasonable efforts keep inventory levels combination product wholesale distributors subject fluctuations expected launch period combination product pricing combination product gilead shall sole responsibility act agent selling combination product behalf jv prices defined made pursuant provisions section set forth annex q b gilead bms shall appoint two members pricing committee jv pricing committee one representative member party representative shall employee member party time appointment time service pricing committee otherwise involved directly indirectly member partys affiliates provided purposes section duties solely respect accounts receivable analysis bookkeeping accounting shall without deemed involvement representatives shall skills reasonably appropriate responsibilities functions members pricing committee representative member party representative shall member party furthermore member party covenants immediately individuals service pricing committee shorter period employed member party affiliate assigned function position involves directly indirectly pricing member partys affiliates products member party shall right approve member partys proposed representative representative pricing committee replacement therefor approval shall unreasonably withheld subject preceding sentence member party shall right replace representative andor representative time time term agreement provided composition pricing committee changed meets requirements set forth section b avoidance doubt pricing committee operating committee jv accordingly references agreement operating agreement applicable ancillary agreement operating committee shall apply pricing committee pricing committee may determine sole discretion retain independent legal counsel case expenses counsel shall deemed authorized expenses c gilead bms shall responsible performance representatives pricing committee compliance terms section issue regarding pricing committee shall reviewed gilead bms shall bear expenses related pricing committee including without limitation expenses relating meetings pricing committee participation member parties representatives meetings communications member party connection meetings matters within authority pricing committee travel meetings expenses shall deemed jv expenses authorized expenses pricing committee shall responsible ongoing basis gilead agent jv accordance section ii according respect defined jv pricing committee shall meet least quarterly meeting may conducted telephone videoconference equipment long attendee able hear others otherwise required time time serve applicable gilead agent jv gilead agent jv shall authority case may e interpretation become necessary representatives pricing committee shall discuss matter representatives attempt resolve matter consensus event consensus reached respect gilead agent jv shall f functional role representative pricing committee shall limited coordinating gilead agent jv ascertain ii asneeded basis providing pricing committee case may iii asneeded basis specifically requested respect providing pricing committee specifically limited pertinent representatives shall agree necessary appropriate iv applying respect v ensuring combination product case may g either member party requesting member may upon written notice member party cause independent accounting expert selected pursuant section confirm accuracy respect andor ii pricing committee including without limitation case may case member party pricing committee shall cooperate independent accounting expert upon independent accounting experts entry appropriate confidentiality agreement provide data necessary make requisite calculations upon written request either member party calculations independent accounting expert shall audited second third party mutually agreed member parties independent accounting expert third party auditor shall notify jec respective determinations notifications shall contain information provided independent accounting expert andor third party auditor either member party calculations made independent accounting expert pursuant section g shall binding upon pricing committee parties provided however event third party auditor identifies discrepancy independent accounting experts calculations member parties shall cause independent accounting expert third party auditor confer agree upon final calculations advise member parties writing whereupon final agreed calculations shall binding parties requesting member shall bear fees costs independent accounting expert connection confirmation accuracy determination andor information unless independent accounting expert finds discrepancy equal greater therein case jv case discrepancy member party case discrepancy shall bear fees costs nothing section g shall deemed limit remedy available either member party event breach provisions section member party notwithstanding anything agreement contrary breach shall subject cure provisions set forth section h information provided pricing committee pricing information shall considered confidential information disclosing member party shall used solely purpose purpose avoidance doubt exceptions confidentiality set forth section sections b shall apply pricing information except expressly permitted pricing information shall disclosed pricing committee representatives except counsel independent accounting expert third party auditor selected pursuant section g pricing information shall maintained pricing committee shall accessible persons members pricing committee without limiting foregoing bms gilead shall cause representatives pricing committee disclose person ii reference use directly indirectly information pricing committee prior launch combination product thereafter annually jec shall review recently modified pursuant section applicable light thenprevailing market conditions jv marketing sales strategies appropriate jec shall recommend member parties changes jecs action inaction section shall subject arbitration gilead bms mutually agree changes proposed jec changed shall deemed hereunder j gilead bms shall retain sole discretion respect pricesetting discounts respective single agent products double agent product notwithstanding foregoing member party covenants shall shall directly indirectly solely primarily purpose national accounts gilead shall sole responsibility act agent conducting pricing activities behalf jv relating governmental organizations aids drug assistance programs correctional facilities systems managed care organizations national accounts payor segments territory including without limitation contract strategy contract creation activities shall defined commercialization plan shall comply section except respect pricing activities bms shall share commercialization activities correctional facilities systems national accounts performance subcontracting gilead bms shall comply shall cause affiliates comply applicable laws regulations approvals conducting respective commercialization activities either member party may subcontract performance commercialization activities allocated commercialization plan provided however subcontracting member party shall oversee performance subcontractors subcontracted commercialization activities manner would reasonably expected result timely successful completion shall remain responsible performance commercialization activities accordance agreement commercialization plan provided neither gilead bms may engage subcontractor including without limitation contract sales organization perform details combination product conflict avoidance gilead bms agrees ensure initial launch period none field force employees engages marketing combination product shall also market territory territory marketing materials jcc shall develop approve initial set advertising promotional materials combination product jcc reach agreement respect materials jec shall attempt resolve disputed issues relating materials event jcc following dispute within jcc jec shall reach agreement respect materials modified time time pursuant section approved marketing materials subject subparagraph b member party shall use approved marketing materials approved marketing materials together fdaapproved product label package insert promoting combination product territory least first twelve months following launch jcc jec unable reach agreement materials member parties shall promote combination product territory using fdaapproved product label package insert combination product b member party may propose interim updates approved marketing materials time time independent annual reviews conducted pursuant section c jcc shall required consider shall adopt updates satisfy following conditions update based relevant new scientific medical clinical data relevant new regulatory legal developments changes fdaapproved label package insert combination product ii absence update use approved marketing materials would comply applicable law update satisfying conditions required update c approximately launch jcc shall review appropriate update approved marketing materials updates shall include minimum required updates jcc reach agreement required update proposed member party matter shall subject dispute resolution section event neither jcc jec able reach agreement proposed required update relating required updates member party may elect upon written notice member party promote combination product territory using either fdaapproved product label package insert ii approved marketing materials modified reflect required updates connection review conducted pursuant section c jcc may make appropriate changes arising business considerations optional update proposed member party event jcc reach agreement proposed optional update dispute shall subject dispute resolution section provided however event neither jcc jec able reach agreement proposed optional update member party may elect upon written notice member party promote combination product territory using either fdaapproved product label package insert ii approved marketing materials without optional update e review conducted pursuant section c jcc shall review recent revised marketing materials annual basis shall make required updates consider optional updates proposed member party disputes within jcc relating updates shall resolved using procedures set forth sections c f jv shall rights title interest approved marketing materials notwithstanding anything agreement contrary neither member party shall use promotion combination product territory materials fdaapproved product label inserts approved marketing materials jcc shall select marketing combination product advertising agency agencies jv shall retain agency agencies commercially reasonable terms jcc shall also develop implement oversee orderly systematic process involving representatives legal medical regulatory functions respective member parties review approval advertising promotional materials interactions fda allocation member parties rights responsibilities shall set forth section development use trademarks jcc shall select combination product trademarks shall owned jv subject applicable law jv shall include trademark name gilead parent bms parent labeling packaging advertising materials combination product territory jv shall comply notice marking requirements applicable intellectual property law protection enforcement trademarks jv gilead bms unless notice marking requirements commercially reasonable circumstances insurance member parties agree jv neither member party shall obligation event either member party elects arising exploitation combination product member party shall sole right avoidance doubt nothing contained section intended shall construed limit member partys jvs indemnity obligations pursuant section records maintenance records gilead bms shall severally accordance respective allocations responsibility respect project activities maintain retain cause maintained retained final records draft records documents except otherwise required applicable law respective commercialization activities covered commercialization plan least three years ii longer period may required applicable law b access records subject section b member party shall right respect records maintained member party member partys commercialization activities covered commercialization plan normal business hours upon reasonable notice inspect copy records solely extent relating combination product solely extent necessary order receiving member party perform obligations respect commercialization activities manner consistent commercialization plan ii necessary receiving member party confirm compliance andor comply glp gcp gmp extent applicable applicable law relates project activities andor iii necessary enable receiving member party conduct reasonable diligence matters potentially giving rise liability part jv andor receiving member party conduct defense andor jv respect liability extent fact circumstance event arisen gives receiving member party reasonable basis believe jv may incur liability case use receiving member party purpose set forth clause ii iii case may clause iii immediately preceding sentence shall require party provide data documentation records event parties interests matter may case shall apply request shall made writing shall state reasons therefore commercial record request member party records documentation data requested shall right raise reasonable objections writing response commercial record request including without limitation based member partys interests protecting disclosure requesting member party trade secrets competitive business information upon objection asserted member parties shall promptly confer attempt address member partys concerns reach resolution respect matter event member parties unable agree upon mutually agreeable resolution either member party shall right refer matter jcc event dispute ultimately determine threshold matter whether extent one criteria set forth clauses ii andor iii satisfied requesting member party shall make determination respect whether extent disclosure information shall required making determination facts arguments set forth commercial record request member partys written response thereto right require receiving member party abide terms conditions handling use nondisclosure either within member partys organization andor third parties information may reasonable circumstances except provided section member party shall right obtain member party access copies member partys records documentation data described unless otherwise expressly permitted pursuant agreement member party gives consent sole discretion notwithstanding foregoing neither member party shall obligation respect pricing discounting matters set forth section neither member party shall provide member party information extent relates price setting discounting inventory management agreements first member party restricted disclosing pursuant applicable law confidentiality contractual arrangements third parties commercialization plan budget commercialization plan shall cover activities commercialization combination product territory shall conducted single member party must coordinated member parties activities shall conform collaboration principles provisions section b initial commercialization plan attached hereto annex c covers period effective date initial launch period commercialization plan update shall contain budget member partys outofpocket expenses member partys activities set forth therein commercialization budget initial commercialization plan covers member party territory initial launch period ii combination product initial launch period iii certain marketing commercialization activities combination product required conducted single member party must coordinated member parties provided however within effective date member parties shall x supplement initial commercialization plan order assign member parties respective responsibilities executing activities referred clause iii revise initial commercialization plan commercialization budget amounts set forth annex c respect period effective date commencement initial launch period reported calendar yearcalendar quarter basis reflecting timing amounts contemplated annex c updates commercialization plan shall cover include activities covered initial commercialization plan unless mutually agreed member parties c less prior proposed date filing approval nda combination product territory member parties shall revise thencurrent commercialization plan commercialization budget amounts set forth therein respect initial launch period reported calendar yearcalendar quarter basis reflecting timing amounts contemplated thencurrent commercialization plan commercialization budget responsible member party determined shall prepare submit jcc jfc less prior start calendar year proposed update commercialization plan commercialization budget calendar year ii less prior start calendar year preliminary update commercialization budget may address budget issues general level may incomplete subject change following review discussion revision proposed update jcc shall vote upon update least prior start applicable calendar year bms shall prepare first annual update thereafter responsibility shall rotate bms gilead yeartoyear basis annual schedule first update calendar year subsequent launch period ends longer period may agreed member parties addition either member party directly representatives jcc may propose interim updates commercialization plan commercialization budget jcc time time appropriate light changed circumstances annual interim updates periods commencing calendar years one containing end subsequent launch period shall approved jcc set forth section bii subject sections vi proposed update commercialization plan commercialization budget approved jec jcc applicable commercialization plan commercialization budget case may shall continue effect approved recently updated pursuant section c commercialization expenses parties agree jv shall bear jv expenses incurred gilead bms connection performance respective commercialization activities extent meet following criteria authorized commercialization expenses commercialization activities covered consistent commercialization plan within area responsibility relevant member party listed commercialization budget chargeable jv b total expenses member partys designated activities commercialization plan relevant period extent exceed aggregate amount set forth commercialization budget activities period c expenses external outofpocket costs gilead bms without markup internal costs including without limitation internal costs incurred relevant commercialization activities marketing combination product marketing proprietary products gilead bms notwithstanding limitation contained clause event either member party reasonably believes cost efficiencies jv reasonably expected achieve one member parties conducting commercialization activities respect combination product part coordination activities conducted one member parties respect single agent products andor double agent product member partyies may propose jcc members activities coordinated appropriate reasonable allocation related costs made combination product one hand product products hand amount allocated combination product treated authorized commercialization expenses proposal cost allocation proposal extent cost allocation proposal reviewed jfc jcc pursuant sections bvii bviii respectively approved jec pursuant section ix modifications made jec amount approved jec allocation combination product approved costs allocated costs shall constitute authorized commercialization expenses reports gilead bms shall present meeting jcc least per calendar quarter second anniversary launch combination product thereafter meeting jcc least semiannually report oral written written report shall required contain detail typically included executive summary describing commercialization activities performed caused performed since preceding meeting report presented case first meeting jcc prior meeting calendar yearto date basis evaluating work performed relation goals timeline commercialization plan ii commercialization activities process future activities expects initiate thencurrent calendar year compared commercialization plan iii case written report authorized commercialization expenses incurred expected incurred member party thencurrent calendar year compared commercialization budget applicable addition gilead bms shall report promptly jcc respective committee members material developments respect commercialization activities responsible performing commercialization plan notwithstanding anything contained section contrary member partys reporting obligations section shall automatically deemed terminate respect period effect commercialization plan andor commercialization budget section license grants technology licenses member parties jv subject terms conditions agreement gilead hereby grants jv sole royaltyfree license license shall exclusive bms affiliates third parties gilead affiliates right grant sublicenses solely set forth sections c pursuant section gilead technology exploit combination product make made active pharmaceutical ingredients thereof otherwise exploit active pharmaceutical ingredients thereof individually combination combination product worldwide b subject terms conditions agreement bms hereby grants jv sole royaltyfree license license shall exclusive gilead affiliates third parties bms affiliates right grant sublicenses solely set forth sections c pursuant section bms technology exploit combination product make made active pharmaceutical ingredients thereof otherwise exploit active pharmaceutical ingredients thereof individually combination combination product applicable efv territory licenses sublicenses jv member parties subject terms conditions agreement jv hereby grants following licenses sublicenses gilead nonexclusive royaltyfree sublicense without right grant sublicenses license granted jv section b nonexclusive royaltyfree license without right grant sublicenses joint technology joint inventions rights title interest jv may gilead core improvement patents claiming improvement additionally perpetual royaltyfree fully paidup irrevocable exclusive even jv license right grant sublicenses multiple tiers rights title interest jv may gilead core improvement patents claiming improvement case clauses exploit combination product exploit efv active pharmaceutical ingredient therein individually combination combination product territory ii conduct anywhere world development activities support approvals combination product territory iii make made import territory combination product make made efv active pharmaceutical ingredient therein exploitation territory case ii iii pursuant accordance agreement including without limitation performance gileads obligations development plan commercialization plan case clause exploit improvement worldwide respect products containing tdf ftc active pharmaceutical ingredient whether alone combination one active pharmaceutical ingredients excluding efv proprietary bms active pharmaceutical ingredients b bms nonexclusive royaltyfree sublicense without right grant sublicenses license granted jv section nonexclusive royaltyfree license without right grant sublicenses joint technology joint inventions rights title interest jv may bms core improvement patents claiming improvement additionally perpetual royaltyfree fully paidup irrevocable exclusive even jv license right grant sublicenses multiple tiers rights title interest jv may bms core improvement patents claiming improvement case clauses exploit combination product exploit tdf ftc active pharmaceutical ingredients therein individually combination combination product territory ii conduct anywhere world development activities support approvals combination product territory iii make made import territory combination product make made tdf ftc active pharmaceutical ingredients therein exploitation territory case ii iii pursuant accordance agreement including without limitation performance bms obligations development plan commercialization plan case clause exploit improvement efv license agreement territory respect products containing efv active pharmaceutical ingredient whether alone combination one active pharmaceutical ingredients excluding tdf ftc proprietary gilead pharmaceutical ingredients c gilead bms perpetual nonexclusive royaltyfree license right grant sublicenses multiple tiers joint technology joint inventions including without limitation joint knowhow consisting clinical data relevant experience information cmc data finished product manufacturing data exploit worldwide basis case gilead efv license agreement territory case bms member partys single agent products double agent product case may ii pharmaceutical compounds products combination product case ii whether alone combination agents gilead exclusive royaltyfree right grant sublicenses multiple tiers license granted jv sections b joint technology joint inventions including without limitation joint knowhow consisting clinical data relevant experience information cmc data finished product manufacturing data rights title interest jv may gilead core improvement patents claiming improvement exploit combination product exploit active pharmaceutical ingredients thereof individually combination combination product worldwide except territory canada europe conduct anywhere world development activities support approvals combination product worldwide approvals territory canada europe make made anywhere world import anywhere world combination product make made active pharmaceutical ingredients thereof individually combination combination product exploitation worldwide exploitation territory canada europe license continue effect long long gilead material breach conditions set forth following clauses v section subject last sentence section gilead shall use commercially reasonable efforts obtain bms appropriate legally permissible public recognition bms role enabling access combination product developing world may include following order preference inclusion bms licensor applicable manufacturer packaging label combination product sold provided use developing world b acknowledgement bms licensor applicable manufacturer supplier efv press releases public announcements relating provision combination product developing world c acknowledgement bms licensor applicable manufacturer supplier efv websites maintained cooperation gilead specifically promote enable provision combination product developing world provided however parties acknowledge gilead ensure required third party regulatory authority consents approvals recognition obtained ii except provided section gilead shall cause sale jv combination product use sale outside territory iii without bms prior written consent unreasonably withheld delayed gilead shall grant sublicenses license granted section utilize manufacture combination product person one contracted manufacture supply tableted combination product bms one affiliates joint venture similar entity bms ownership interest person acting behalf foregoing iv event gilead exploits combination product outside territory canada europe pursuant license granted section bms agrees perform administrative ministerial acts may reasonably necessary useful order enable gilead satisfy obligations clauses iii enable gilead exercise rights license granted section gilead agrees bms consent bms shall additional obligations including without limitation obligation incur additional expenses obligations result exploitation following bms obligations provided section bms obligations pursuant section last sentence section b last sentence section bms obligations pursuant applicable law separate agreements member parties including without limitation applicable bms supply agreement v gilead shall cause sublicensees section comply obligations gilead clauses iv failure part sublicensee comply material respect obligation gilead shall deemed failure part gilead comply respect obligation gilead material breach clauses v gileads license section shall terminate unless bms given notice gilead breach breach remains uncured sixty days gileads receipt notice longer period would reasonably required cure breach provided gilead using commercially reasonable efforts effect cure clarity material breach clauses v shall give rise rights cure termination agreement pursuant section agreement parties acknowledge agree remedy specific performance set forth section shall available respect material breach gilead obligations section material breach bms obligations section div section section licenses rights reference member parties subject terms conditions agreement gilead hereby grants bms nonexclusive right reference efv license agreement territory respect gilead knowhow consists clinical data relevant experience information b nonexclusive royaltyfree fully paidup irrevocable license right grant sublicenses multiple tiers use gilead knowhow efv license agreement territory case b solely extent reasonably necessary enable bms exploit single agent product whether alone combination agents gileads single agent products double agent product efv license agreement territory manner consistent labeling approved marketing materials combination product perpetual royaltyfree fully paidup irrevocable exclusive even gilead affiliates license right grant sublicenses multiple tiers rights title interest gilead affiliates may bms core improvement patents claiming improvement exploit improvement efv license agreement territory respect products containing efv active pharmaceutical ingredient whether alone combination one active pharmaceutical ingredients excluding tdf ftc proprietary gilead pharmaceutical ingredients clarity gilead shall required transfer gilead knowhow bms pursuant section b subject terms conditions agreement bms hereby grants gilead worldwide nonexclusive right reference respect bms knowhow consists clinical data relevant experience information b worldwide nonexclusive royaltyfree fully paidup irrevocable license right grant sublicenses multiple tiers use bms knowhow case b solely extent reasonably necessary enable gilead exploit single agent products double agent product applicable whether alone combination agents bms single agent product manner consistent labeling approved marketing materials combination product perpetual worldwide royalty free fully paidup irrevocable exclusive even bms affiliates license right grant sublicenses multiple tiers rights title interest bms affiliates may gilead core improvement patents claiming improvement exploit improvement respect products containing tdf ftc active pharmaceutical ingredient whether alone combination one active pharmaceutical ingredients excluding efv proprietary bms active pharmaceutical ingredients clarity bms shall required transfer bms knowhow gilead pursuant section b rights reference jv related matters subject terms conditions agreement gilead bms hereby grants jv non exclusive right reference territory regard gilead regulatory documentation bms regulatory documentation respectively purpose jvs securing maintaining updating approvals agrees provide signed statement effect accordance cfr g b subject terms conditions agreement jv hereby grants bms nonexclusive right reference territory regard combination product regulatory documentation purpose bms securing maintaining updating ndas sustiva products containing efv combination product agrees provide signed statement effect accordance cfr g c subject terms conditions agreement jv hereby grants gilead nonexclusive right reference territory regard combination product regulatory documentation purpose gileads securing maintaining updating ndas viread emtriva truvada products containing either tdf ftc combination product agrees provide signed statement effect accordance cfr g long license granted gilead section remains effect jv shall members agree cause jv cooperate gilead make combination product regulatory documentation available gilead including potentially filing snda nda needed change combination product label applicable qualify different presentation combination product export granting right reference thereto use securing approvals fda export combination product securing approvals regulatory authorities use sale outside territory canada europe ii bms jv hereby grant gilead rights reference country worldwide outside territory canada europe solely purposes filing approvals combination product country rights reference shall continue long license granted gilead section remains effect agree perform administrative ministerial acts may reasonably necessary useful order enable gilead avail rights reference iii bms jv shall permit gilead designee provide copy combination product regulatory documentation data information therein regulatory authorities outside territory canada europe shall permit gilead obtain provide certificates pharmaceutical product combination product approved fda regulatory authorities submissions regulatory authorities outside territory canada europe shall provide documentation consents necessary effectuate rights reference permit gilead take foregoing actions clause ii combination product regulatory documentation combination product certificates pharmaceutical product clarity bms grants rights clauses ii iii shall construed bms granting right gilead bms technology anywhere outside applicable efv territory sublicenses supply agreements suppliers selected pursuant section jv shall right grant suppliers nonexclusive royaltyfree worldwide sublicense without right sublicense joint technology licenses granted jv sections b sole purpose manufacturing combination product active pharmaceutical ingredients thereof supply jv trademark licenses member parties jv subject terms conditions agreement gilead hereby grants jv nonexclusive royaltyfree fully paidup license right sublicense multiple tiers use territory trademarks listed annex f hereto gilead licensed trademarks sole purposes exploitation combination product exploit active pharmaceutical ingredients thereof individually combination combination product territory ii gilead parents name company logoidentifiers use name jv andor product labeling product packaging promotional materials combination product pursuant section b subject terms conditions agreement bms hereby grants jv nonexclusive royaltyfree fully paidup license without right sublicense use territory trademarks listed annex g hereto bms licensed trademarks sole purposes exploitation combination product exploit active pharmaceutical ingredients thereof individually combination combination product territory ii bms parents name company logoidentifiers use name jv andor product labeling product packaging promotional materials combination product pursuant section c member parties shall responsible determining thereafter monitoring steps needs take order satisfy jvs use trademarks ie gilead licensed trademarks bms licensed trademarks case may meets commercially reasonable high quality standards specifications instructions submitted approved gilead bms respectively connection agreement gilead jv hereby recognize bms right title interest bms licensed trademarks gilead jv recognize agreement use bms licensed trademarks connection agreement way confers gilead jv right title interest bms licensed trademarks trademarks intellectual property rights owned bms except may otherwise expressly provided agreement bms jv hereby recognize gileads right title interest gilead licensed trademarks bms jv recognize agreement use gilead licensed trademarks connection agreement way confers bms jv right title interest gilead licensed trademarks trademarks intellectual property rights owned gilead except may otherwise expressly provided agreement e jv acknowledges goodwill generated jvs use gilead licensed trademarks inure solely benefit gilead ii goodwill generated jvs use bms licensed trademarks inure solely benefit bms trademark license jv gilead subject terms conditions agreement jv hereby grants gilead nonexclusive royaltyfree fully paidup license countries territories world excluding territory canada europe right sublicense multiple tiers use combination product trademarks sole purpose exploitation combination product exploit active pharmaceutical ingredients thereof individually combination combination product countries territories provided however license shall remain effect long gileads license pursuant section remains effect b bms gilead hereby recognize jvs right title interest combination product trademarks bms gilead recognize agreement use combination product trademarks connection agreement way confers bms gilead right title interest combination product trademarks trademarks intellectual property rights owned jv except may otherwise expressly provided agreement c bms gilead acknowledge goodwill generated use combination product trademarks inure solely benefit jv retained rights license rights specifically granted section expressly reserved licensing party license granted section sublicensable may transferred assigned licensee party connection permitted assignment agreement party section combination product sales outside territory canada europe requested gilead either bms jv acting purposes bms representatives applicable shall negotiate good faith commercially reasonable arrangement taking account relevant economic market conditions relevant territories eg bms become supplier transfer price combination product territories would supplied enable supply efv active pharmaceutical ingredient manufacture combination product case bms either manufacturing enabling third party manufacture efv active pharmaceutical ingredient combination product case jv case sufficient allow gilead designee jv permitted section b sell provide combination product use developing world territories outside territory canada europe meet anticipated demand therefor countries b requested gilead permitted applicable laws rules regulations consented bms consent unreasonably withheld delayed parties shall cooperate enable cause jv make combination product available export use sale developing world including without limitation sales within territory combination product export use sale developing world part efforts parties shall negotiate good faith appropriate amendments agreement operating agreement consistent clauses v section section c c payments respect supply efv applicable combination product bms jv pursuant section bms jv shall entitled additional financial compensation whether form license fees milestone payments royalties otherwise either reason sales jv persons authorized gilead combination product use outside territory canada europe reason jvs grant license section combination product sales europe parties acknowledge agree combination product shall sold otherwise commercially distributed europe upon one applicable covering unless sale distribution commenced efv license agreement notwithstanding anything agreement contrary gilead agrees exercise rights granted sections territories outside efv license agreement territory reaching agreement efv licensor necessary gilead avoid infringing misappropriating intellectual property rights efv licensor territories requested gilead bms shall cooperate gilead efforts reach agreement jv obligations sublicensee jv shall comply provisions applicable sublicensees set forth efv license agreement form provided bms gilead pursuant section c license agreements delivered gilead bms pursuant third sentence section c form delivered respectively including without limitation provisions respect reporting information record keeping access records audit upstream licensor excluding payment obligations matters member party responsible section obligations effective date specifically identified annex respect referred annex shall use commercially reasonable efforts effective date grant sublicense jv agreement required shall form substance reasonably acceptable section payments third party royalties payments member parties consideration supply gilead bms jv quantities respective active pharmaceutical ingredients manufacture nonclinical supply combination product pursuant section c respective supply agreements consideration provision certain services hereunder subject adjustment pursuant section jv shall pay gilead gilead transfer price bms sub bms transfer price accordance section given calendar year pursuant section jfc shall calculate interim gilead transfer prices per kilogram tdf ftc bulk active pharmaceutical ingredient respectively ie applicable transfer price accordance annex k hereto per kilogram bulk active pharmaceutical ingredient interim gilead unit transfer price ii interim bms transfer price per kilogram efv active pharmaceutical ingredient ie applicable transfer price accordance annex k hereto per kilogram efv active pharmaceutical ingredient interim bms unit transfer price case based upon respective working percentages calculated pursuant section ci estimated net selling price combination product determined jfc respect calendar year pursuant section cii relevant target yield active pharmaceutical ingredient calculated pursuant annex k hereto jfc shall inform gilead bms respective interim unit transfer prices pursuant section ciii subject last sentence section c gilead bms sub shall use thencurrent interim unit transfer prices preparing invoice shipment bulk active pharmaceutical ingredients makes pursuant section c supply agreement b actual gilead percentage actual bms percentage particular calendar year shall equal one hundred percent multiplied fraction denominator sum net selling prices truvada sustiva territory relevant calendar year numerator actual gilead percentage net selling price truvada territory relevant calendar year ii actual bms percentage net selling price sustiva territory relevant calendar year provided however without limitation obligations member parties section j purposes calculating numerator denominator fraction actual gilead percentage actual bms percentage net selling price sustiva truvada relevant calendar year calendar year shall shall event termination agreement effective date falls date december calendar year determination actual percentages shall based period january calendar year effective date termination instead entire calendar year provisions agreement shall apply mutatis mutandis period c jfc shall determine member parties interim unit transfer prices calendar year using member parties respective working percentages estimated net selling price target yield follows bms gilead shall agree writing working bms percentage working gilead percentage calendar year shall equal respective actual percentages calendar year using relevant data calendar year inclusive subsequent calendar year respective working percentages shall equal actual bms percentage actual gilead percentage respectively immediately preceding calendar year provided however respect calendar year pending determination actual percentages immediately preceding calendar year working percentages immediately preceding calendar year shall remain effect time actual percentages immediately preceding calendar year determined bms gilead shall agree writing target yields efv tdf ftc calendar year subsequent calendar year relevant target yields efv tdf ftc shall calculated pursuant section dii annex k ii later subsequent calendar year jfc shall determine estimated net selling price combination product calendar year using historical data amount calendar year estimated net selling price iii using member parties respective working percentages estimated net selling price target yield calendar year jfc shall calculate member partys interim unit transfer prices accordance annex k shall notify member parties writing later days first day applicable calendar year date member party receives notice jfc respect member partys respective interim unit transfer prices respect calendar year amounts shall used member parties invoicing jv transfer price shipments bulk active pharmaceutical ingredients pursuant section c applicable supply agreement calendar year notwithstanding foregoing calendar quarter basis jfc shall recalculate respective interim unit transfer prices recalculated transfer price accordance annex k within end recalculation shall made using working percentages target yield updated net selling prices determined annex event particular interim unit transfer price less recalculated transfer price jv shall deliver reconciliation statement applicable member party setting forth difference price multiplied quantity active pharmaceutical ingredient member party invoiced jv event particular interim unit transfer price greater recalculated transfer price jv shall deliver reconciliation statement applicable member party setting forth difference price multiplied quantity active pharmaceutical ingredient member party invoiced jv case relevant adjustment shall addressed part cash netting mechanism provided section operating agreement shall settled first cash netting day following recalculation interim unit transfer prices shall changed result recalculation mentioned iv following jv shall cause independent accounting expert calculate solely planning accounting bookkeeping purposes member parties actual percentages based data completed later respective percentages shall changed result recalculation mentioned following end calendar year jfc shall cause independent third party accounting firm consultant mutually agreed member parties agreed third party independent accounting expert calculate actual percentages calendar year recalculate transfer prices using product yields determined pursuant section dii actual net selling price combination product determined pursuant section diii respect shipments bulk active pharmaceutical ingredient made member parties calendar year pursuant section c respective supply agreements follows within following end calendar year member party shall provide independent accounting expert data necessary order make calculations required pursuant section data described annex n ii within following end calendar year jfc shall calculate product efv yield product ftc yield product tdf yield case based actual yield supply combination product b provide independent accounting expert written confirmation calculations within following first fullscale commercial manufacturing run jfc shall determine blended average product efv yield product ftc yield tdf product yield per weight per unit basis inform independent accounting expert thereof iii within following end calendar year jv shall cause independent accounting expert calculate actual net selling prices combination product truvada sustiva calendar year b calculate actual gilead percentage actual bms percentage pursuant section b using actual net selling prices combination product truvada sustiva calendar year c recalculate gilead transfer price bms transfer prices bulk active pharmaceutical ingredient shipments calendar year pursuant section accordance annex k iv within following end calendar year basis recalculated transfer prices notified jv independent accounting expert jfc shall recalculate amounts owed jv member parties respect shipments received jv calendar year pursuant section c respective supply agreements provide member parties notice recalculated amounts adjustments required pursuant section div aggregate amount invoiced member party transfer prices greater less aggregate amount owed member party jv transfer prices recalculated pursuant section relevant adjustment shall addressed part cash netting mechanism provided section operating agreement shall settled first cash netting day following recalculation e independent accounting expert shall bound commercially reasonable written confidentiality nonuse obligations member parties independent accounting expert shall upon written request either member party initiating member audit member party confirm accuracy data provided independent accounting expert member party upon written request either member party calculations independent accounting expert shall audited second third party mutually agreed member parties independent accounting expert third party auditor shall notify member parties respective determinations provided however neither independent accounting expert third party selected audit independent accounting expert shall share either member party information provided independent accounting expert andor third party member party calculations made independent accounting expert pursuant section e shall binding parties provided however event third party auditor identifies discrepancy independent accounting experts calculations member parties shall cause independent accounting expert third party confer agree upon final calculations advise member parties writing whereupon final agreed calculations shall binding parties initiating member shall bear fees costs independent accounting expert connection confirmation accuracy data unless independent accounting expert finds discrepancy equal greater therein case member party shall bear fees costs royalty payments third parties third partys patent would infringed third partys trade secrets would misappropriated solely direct result incorporation tdf ftc tdf ftc combination product gilead shall solely responsible losses royalty license fee payment obligation third party shall qualify jv expense authorized expense connection infringement misappropriation including without limitation obligations pursuant section third partys patent would infringed third partys trade secrets would misappropriated solely direct result incorporation efv combination product bms shall solely responsible losses royalty license fee payment obligation third party shall qualify jv expense authorized expense connection infringement misappropriation including without limitation obligations pursuant section royalty license fee payments gilead bms third parties connection licenses third party patents third party trade secrets reasonably necessary performance member parties obligations agreement shall qualify authorized commercialization expenses authorized expenses mode timing payment jv shall bear authorized expenses incurred gilead bms member party shall calculate invoice jv respective authorized expenses incurred calendar quarter sufficient time ensure applicable invoice received jv later last day next calendar quarter final invoice date jv shall obligation make payments gilead bms account expenses incurred given calendar quarter invoice received final invoice date b payments jv member parties pursuant sections bii payments made member parties agreement shall made wire transfer electronic funds transfer united states dollars requisite amount bank account member party may designate time time notice payor c member party shall calculate invoice jv time shipment transfer price shipment bulk active pharmaceutical ingredient pursuant section c applicable supply agreement using applicable interim unit transfer price jv shall pay member party amounts owed member party case bms bms sub pursuant section applicable cash netting day provided section operating agreement case shipment bulk active pharmaceutical ingredient pursuant applicable supply agreement first calendar quarter given calendar year prior jfc giving notice applicable interim unit transfer price member party providing shipment shall use interim unit transfer price immediately preceding calendar year purposes invoicing shipment provided upon jfcs determination new interim unit transfer price calendar year shipment occurs pursuant section annex k jv shall recalculate invoices using new interim transfer price calendar year time payment shall issue applicable member party reconciliation statement respect invoice reconcile differences original transfer price shipment transfer price shipment calculated using new interim unit transfer price interest shall accrue delinquent payments date payments due lesser prime rate interest published wall street journal eastern united states edition plus basis points ii maximum rate interest permissible applicable law taking consideration amounts deemed additional interest taxes jv shall responsible sales use excise value added similar taxes charges imposed respect acquisition product member party andor payments jv member party pursuant section provided member party shall responsible taxes including taxes imposed way withholding nature income franchise taxes based measured gross net income imposed respect income jv shall pay withholding taxes similar charges imposed governmental unit required withheld amounts due member party jv pursuant section proper taxing authority proof payment taxes charges shall secured sent member party evidence payment amounts paid jv pursuant immediately preceding sentence respect taxes member party responsible pursuant first sentence section shall paid account member party deducted amounts due jv member party pursuant section section financial records financial records gilead shall keep complete accurate books records behalf jv pertaining sales combination product including without limitation books records net sales combination product detail required calculation behalf jv amounts payable jv section identify purchase order details customer sells combination product pertaining authorized commercialization expenses authorized development expenses authorized expenses gilead shall retain books records least latest three years calendar quarter relevant sale made relevant expense reimbursed pursuant section b expiration applicable statute limitations tax purposes extension thereof c longer period may required applicable law gilead bms shall keep records authorized commercialization expenses authorized development expenses authorized expenses incurs least latest three years calendar quarter invoiced jv ii expiration applicable statute limitations tax purposes expiration thereof iii longer period may required applicable law gilead bms shall keep documentation supporting least x three years calendar quarter occurred longer period may required applicable law audit records request bms gilead case may member party shall permit independent certified public accountant reasonably acceptable member party reasonable times upon reasonable notice examine books records maintained member party applicable books records maintained gilead behalf jv pursuant section verify following accuracy amounts invoiced member party jv pursuant section b authorized commercialization expenses authorized development expenses authorized expenses charged member jv case period ending three years prior date request third party accountant shall bound written commercially reasonable confidentiality nonuse obligations member parties member party shall receive copy third party accountants report audit shall disclose whether amounts invoiced charged correct incorrect amounts underpayments overpayments report shall confidential information member parties discrepancy shall rectified reconciliation payment made underpaying party overpaid party case may within thirty days receipt notice thereof audit establishes either nonrequesting member party jv made error invoicing payment detriment requesting member party amount equal greater relevant amounts period audit outofpocket costs audit shall qualify authorized expense cases costs audit shall borne solely requesting member party shall qualify jv expense authorized expense bms gilead may make audit requests section behalf behalf jv certain reports bms may satisfy internal reporting needs gilead shall provide bms applicable times set forth annex financial data described annex section adverse event information exchange pharmacovigilance subject terms agreement bms gilead guidance respective pharmacovigilance departments equivalent thereof shall define finalize mutually acceptable guidelines procedures followed member parties respect receipt investigation recordation communication exchange member parties adverse event reports pregnancy reports information concerning safety combination product efv tdf ftc appropriate guidelines procedures shall included agreement hereafter referred safety data exchange agreement sdea entered member parties prior earlier occur anniversary effective date ii first dosing combination product patients shall accordance enable parties affiliates fulfill local international regulatory reporting obligations government authorities furthermore agreed procedures shall consistent relevant international council harmonization guidelines except said guidelines may conflict existing local regulatory safety reporting requirements case local reporting requirements shall prevail without limitation foregoing sdea shall include provisions stating gilead shall primarily responsible complying applicable laws collecting reporting regulatory authorities information adverse events associated use combination product ii gilead shall maintain global safety database combination product iii bms shall right review approve psurs prepared gilead approval unreasonably withheld material communications addition notifications required section sdea member party shall promptly provide notice member party material communications governmental agency concerning safety combination product including without limitation adverse drug reaction reports copies material communications shall attached applicable notice section product recall notification recall event governmental agency authority issues requests recall market withdrawal takes similar action connection combination product event either member party determines recall market withdrawal combination product may necessary advisable member party shall advise member party thereof telephone within member party shall also notify promptly event issuance fda field alert similar alert member party case member party issuing field alert shall notify member party time applicable governmental agency authority ii communication governmental agency authority regarding potential recall market withdrawal combination product member partys respective single agent product double agent product b within receipt notice given pursuant first sentence section member parties shall cause respective representatives business medical regulatory quality assurance legal functions others deemed necessary member party convene initial meeting consider whether jv conduct recall except case governmentmandated recall market withdrawal representatives shall thereafter make recommendation member parties respect determination recommendation recall combination product respect timing recall breadth extent level customer recall shall reach strategies notifications used related issues neither member party shall unreasonably object recall requested member party neither member party shall right object recall requested member party failure combination product meet specifications therefor ii reasonable basis conclude material harm patients may occur iii manufacture combination product manner comply act notwithstanding foregoing recall market withdrawal mandated governmental agency authority recall proposed member party account member partys single agent product double agent product member party may cause jv accordingly gilead shall take action behalf jv effectuate recall reasonable terms member party determines without meeting described first sentence section b without liability member party jv except expenses described section indemnity amounts payable party pursuant section c member parties may commercial reasons otherwise mutually determine withdraw combination product market reason market withdrawal relates efficacy safety withdrawal shall treated one mandated government agency authority dealt provided section b cases jv shall upon receiving fda approval cease selling combination product member parties shall mutually determine whether recall combination product already market nothing set forth section shall construed restricting right either member party make timely report matter government agency take action deems appropriate required applicable law recall expenses member parties shall bear expenses recall combination product proportion respective percentages respective external outofpocket costs recall without markup shall qualify authorized expense provided however member party shall bear expenses recall incurred reasonable manner extent recall caused member partys breach obligations agreement supply agreement supplier supply contract referred section gross negligence willful misconduct b otherwise occasioned solely member partys single agent product andor double agent product case may expenses recall shall include without limitation expenses notification destruction return recalled combination product refund consumers amounts paid recalled combination product section intellectual property rights ownership intellectual property gilead intellectual property except otherwise expressly provided sections among parties gilead shall right title interest gilead patents gilead knowhow gilead inventions gilead regulatory documentation gilead shall disclose shall cause affiliates disclose bms bms core improvement promptly conceived discovered developed otherwise made b bms intellectual property except otherwise expressly provided sections b b among parties bms shall right title interest bms patents bms knowhow bms inventions bms regulatory documentation bms shall disclose shall cause affiliates disclose gilead gilead core improvement promptly conceived discovered developed otherwise made c jv intellectual property except otherwise expressly provided sections b c among parties jv shall right title interest joint patents joint knowhow joint inventions combination product regulatory documentation except otherwise expressly permitted agreement party including without limitation jv shall license assign sell convey otherwise exploit rights joint patents joint knowhow joint inventions combination product regulatory documentation purpose member party shall disclose member party promptly writing joint inventions conceived discovered developed otherwise made behalf member party member parties hereby assigns agrees cause employees agents assign jv without payment additional consideration member partys rights title interest joint inventions prosecution patents gilead patents gilead shall sole right sole cost expense prepare file prosecute maintain gilead patents territory gilead shall sole discretion determine gilead patents shall listed orange book respect combination product b bms patents bms shall sole right sole cost expense prepare file prosecute maintain bms patents territory bms shall sole discretion determine bms patents shall listed orange book respect combination product c joint patents patent application joint patent claiming joint invention shall filed mutual written agreement member parties solely accordance section c event either member party desires filed patent application joint patent claiming joint invention member party shall propose filing member party representatives designated member party shall discuss consider matter event member parties fail reach written agreement patent application filed neither member party whether behalf jv third party may file cause filed patent application ii event member parties mutually agree writing pursuant section ci patent application joint patent claiming joint invention filed gilead shall sole right obligation prepare file prosecute maintain joint patents name jv countries member parties shall determine external outof pocket costs without markup respect thereto shall treated authorized expenses bms shall cooperate fully gileads preparation filing prosecution maintenance joint patents proceedings patent official office respect thereto cooperation shall include without limitation promptly executing papers instruments requiring employees execute papers instruments reasonable appropriate enable gilead prepare file prosecute maintain joint patents country b promptly informing gilead matters may affect preparation filing prosecution maintenance joint patent including without limitation providing copy official correspondence received bms patent office country respect joint patents gilead shall keep bms advised status joint patent filings upon request bms shall provide copies official correspondence documentation respect official actions submissions relating prosecution maintenance joint patents iii member parties shall sole discretion determine mutual agreement joint patents shall listed orange book respect combination product enforcement patents gilead patents among parties gilead shall sole right option sole cost expense respond infringement defined respect gilead patent appropriate steps including without limitation filing infringement suit taking similar action gilead shall also sole right option take action respond infringement event party shall right take action respond infringement respect gilead patent gileads request bms jv shall partys expense provide reasonable assistance gilead connection action respond infringement including without limitation providing access relevant documents evidence making employees available reasonable business hours joining jv join action extent necessary allow gilead maintain action purposes section infringement shall mean infringement potential infringement one gilead patents andor one bms patents case may actions third party connection product infringing combination product containing among active pharmaceutical ingredients tdf ftc efv ii similar action shall include without limitation responses paragraph iv certification drug price competition patent restoration act also known hatchwaxman act resulting attempt market generic version combination product paragraph iv certification avoidance doubt parties acknowledge agree infringement gilead patent bms patent case may infringing combination product outside scope agreement shall create rights impose obligations parties hereunder including right obligation take actions respond infringement b bms patents among parties bms shall sole right option sole cost expense respond infringement respect bms patent appropriate steps including without limitation filing infringement suit taking similar action bms shall also sole right option take action respond infringement event party shall right take action respond infringement respect bms patent request bms gilead jv shall partys expense provide reasonable assistance bms efv licensor applicable connection action respond infringement including without limitation providing access relevant documents evidence making employees available reasonable business hours joining jv join action extent necessary allow bms efv licensor maintain action c joint patents either member party determines joint patent infringed third partys activities shall notify member party writing provide evidence infringement reasonably available gilead behalf name jv shall first right option respond infringement respect joint patent appropriate steps including without limitation filing infringement suit taking similar action shall notify bms consult bms time time regarding suit action gilead elects sole discretion take action respond infringement bms behalf name jv shall right option respond infringement appropriate steps including without limitation filing infringement suit taking similar action shall notify gilead consult gilead time time regarding suit action without limiting foregoing event gilead behalf jv receives paragraph iv certification respect combination product gilead shall notify bms within receipt paragraph iv certification whether gilead made election described preceding sentence gilead elects take action respond infringement fails notify bms within period bms shall rights described immediately preceding sentence member party taking action respond infringement shall provide reasonable assistance member party taking action including without limitation providing access relevant documents evidence making employees available reasonable business hours joining action extent necessary allow member party taking action maintain action amounts recovered member party pursuant section c whether settlement judgment shall deemed recovered behalf shall paid jv reasonable outofpocket costs including reasonable attorneys fees without markup incurred member parties making recovery shall treated authorized expenses paragraph iv certifications member party shall notify member party writing within receiving paragraph iv certification respect combination product case bms sustiva case gilead viread emtriva truvada applicable infringement third party rights third party initiates proceeding jv member party alleging conduct project activities infringes infringe third partys patent misappropriates misappropriate third partys trade secrets proceeding arises direct result tdf ftc tdf ftc incorporated combination product case without reference efv gilead shall defend hold jv bms harmless proceeding losses resulting proceeding shall sole right obligation defend proceeding settle eg obtaining license third party gileads sole cost shall deemed jv expense authorized expense bms shall reasonably cooperate gileads request expense defense andor settlement b claim arises direct result efv incorporated combination product case without reference tdf ftc bms shall defend hold jv gilead harmless proceeding losses resulting proceeding shall sole right obligation defend proceeding settle eg obtaining license third party bms sole cost shall deemed jv expense authorized expense gilead shall reasonably cooperate bms request expense defense andor settlement c event neither clause b applies jec shall determine whether defend claim obtain license third party terms conditions outofpocket costs without markup shall deemed authorized expenses member party shall take actions behalf jv procedures set forth section shall apply indemnification member parties section trademarks gilead licensed trademarks gilead shall sole right sole cost expense search clear file register prosecute maintain enforce gilead licensed trademarks territory gilead shall sole right option sole cost expense respond infringement respect gilead licensed trademark appropriate steps including without limitation filing infringement suit taking similar action gilead shall also sole right option prosecute maintain enforce gilead licensed trademarks take action respond infringement b bms licensed trademarks bms shall sole right sole cost expense search clear file register prosecute maintain enforce bms licensed trademarks territory bms shall sole right option sole cost expense respond infringement respect bms licensed trademark appropriate steps including without limitation filing infringement suit taking similar action bms shall also sole right option prosecute maintain enforce bms licensed trademarks take action respond infringement c combination product trademarks except otherwise expressly provided section parties agree among jv shall right title interest combination product trademarks gilead shall solely responsible searching clearing filing registering prosecuting maintaining combination product trademarks territory name jv external outofpocket costs without markup shall treated authorized expenses either member party reasonable basis believe third party may engaging commercially significant infringement combination product trademark member party shall notify member party writing provide evidence infringement reasonably available gilead shall first right option respond infringement potential infringement respect combination product trademark appropriate steps including without limitation filing infringement suit taking similar action shall notify bms consult bms time time regarding suit action gilead elects sole discretion take action respond infringement potential infringement within thirty days gileads becoming aware infringement potential infringement bms shall right option respond infringement potential infringement appropriate steps including without limitation filing infringement suit taking similar action shall notify gilead consult gilead time time regarding suit action member party taking action respond infringement potential infringement shall provide reasonable assistance member party taking action including without limitation providing access relevant documents evidence making employees available reasonable business hours joining action extent necessary allow member party taking action maintain action amounts recovered member party pursuant section c whether settlement judgment shall deemed recovered behalf shall paid jv reasonable outofpocket costs including reasonable attorneys fees without markup incurred member parties making recovery shall treated authorized expenses section confidentiality treatment confidential information except provided section term agreement five years agreements expiration termination party receiving party shall hold strict confidence shall publish otherwise disclose directly indirectly third party confidential information another party affiliates collectively disclosing party b except permitted pursuant section shall directly indirectly use confidential information disclosing party purpose performance obligations exercise rights agreement otherwise permitted agreement operating agreement ancillary agreement c shall use level effort maintain confidentiality confidential information disclosing party uses confidential proprietary information event least commercially reasonable efforts permitted disclosure party may disclose confidential information disclosing party extent disclosure made required specific persons entities applicable laws rules regulations orders court competent jurisdiction supranational federal national regional state provincial local governmental regulatory body competent jurisdiction provided however receiving party shall first given notice disclosing party given disclosing party reasonable opportunity seek available limitations exemptions protections available disclosure requirement reasonably cooperate efforts disclosing party provided exemption disclosure requirement obtained confidential information disclosed response requirement shall limited information legally required disclosed b otherwise required law opinion legal counsel receiving party expressed opinion letter form substance reasonably satisfactory disclosing party shall provided disclosing party least two business days prior receiving partys disclosure confidential information pursuant section b c made required applicable laws regulations including without limitation regulation fd relating securities rules national association securities dealers new york stock exchange applicable association governing stock exchange member partys stock listed including without limitation filing reports forms k q k us securities exchange commission case procedures set forth section shall apply section also applicable filing ii procedures set forth proviso section b shall apply made form filing copy agreement gilead bms case may us securities exchange commission comply applicable law provided member party requests confidential treatment least commercial terms material terms hereof extent confidential treatment reasonably available member party ii solicits member partys comments request confidential treatment case filing member party shall use commercially reasonable efforts take account member partys reasonable comments request e subject section made receiving party regulatory authorities required connection filing application request regulatory approvals otherwise comply requirements applicable law provided however reasonable measures shall taken assure confidential treatment information f made receiving party necessary file prosecute patent applications prosecute defend litigation otherwise establish rights enforce obligations agreement g made receiving party employees affiliates independent contractors legal counsel consultants auditors advisors bound confidentiality nonuse obligations less protective section reasonably require confidential information performance member partys obligations enforcement member partys rights agreement including without limitation matters described sections j provided however receiving party shall remain responsible failure person treat confidential information required section h made receiving party licensors respective technology pursuant contractual obligations licensors existing effective date obligations confidentiality nonuse less protective section provided however receiving party shall remain responsible failure person treat confidential information required section made receiving party necessary filing tax returns pursuant audit thereof j otherwise permitted pursuant section section confidential information defined confidential information party shall mean terms agreement information inventions provided behalf party another party case section pricing committee either connection discussions negotiations pertaining agreement including mutual confidential disclosure agreement entered bristolmyers squibb company gilead sciences inc december course performing agreement mtta including without limitation material terms agreement data knowledge practices processes ideas research plans engineering designs drawings research data manufacturing processes techniques scientific manufacturing marketing business plans financial personnel matters relating disclosing party present future products sales suppliers customers employees investors business avoidance doubt confidential information shall include information provided one party another party relating combination product first mentioned partys single agent products double agent product applicable provided however information provided one party another party relating improvements core technology party shall deemed confidential information party b exclusions notwithstanding foregoing information inventions disclosing party shall deemed confidential information respect receiving party purposes agreement already known receiving party affiliates obligation confidentiality nonuse time disclosure receiving party ii generally available known otherwise part public domain time disclosure receiving party iii became generally available known otherwise became part public domain disclosure receiving party fault receiving party affiliates iv disclosed receiving party affiliates obligation confidentiality nonuse third party obligation disclosing party disclose information inventions others v independently discovered developed receiving party affiliates evidenced written records without use confidential information belonging disclosing party specific aspects details confidential information shall deemed within public domain possession party merely confidential information embraced general information public domain possession party combination confidential information shall considered public domain possession party merely individual elements confidential information public domain possession party unless combination principles public domain possession party use name subject sections member party shall mention otherwise use name insignia symbol trademark trade name logotype another party abbreviation adaptation thereof publication press release promotional material form publicity without prior written approval member party instance purposes section approved marketing materials shall deemed approved member parties restrictions imposed section shall prohibit member party making disclosure identifying another party required applicable law publicity terms agreement parties shall make joint public announcement execution delivery agreement substantially form joint press release attached annex l hereto upon execution agreement b public disclosure joint press release pursuant section either member party desires make public announcement press release concerning material terms agreement member party shall give reasonable prior advance notice proposed text announcement member party prior review approval except otherwise provided section b approval unreasonably withheld member party commenting proposed announcement shall provide comments soon reasonably practicable event within three business days receiving proposed announcement review either member party shall right make press release announcing receipt approvals subject review procedure set forth preceding sentence neither member party shall required seek permission member party repeat information terms agreement already publicly disclosed member party accordance section section event legally required press release public announcement disclosure member party question shall provide member party copy proposed text much notice practicable shall less three business days prior proposed disclosure member party shall respond comments promptly practicable less one business day prior proposed disclosure member party question shall take due consideration reasonable comments member party may provide timely manner provided however member party determines must make legally required disclosure regulation fd shall right make disclosure time necessary comply regulation fd shall provide member party much notice opportunity review comment practicable circumstances notification receiving party shall notify disclosing party immediately cooperate disclosing party disclosing party may reasonably request upon receiving partys discovery loss compromise disclosing partys confidential information permitted uses notwithstanding provision agreement contrary regardless member party disclosing party extent confidential information relates specifically combination product including confidential information consisting combination product regulatory documentation member party shall right use confidential information connection exploitation combination product extent permitted terms conditions agreement including without limitation use accordance license grants made jv member parties section rights reference granted jv member parties sections b c case may b connection preparation andor submission regulatory authorities required connection filing application request regulatory approval combination product anywhere world remedies party agrees unauthorized use disclosure material confidential information receiving party violation agreement may cause severe irreparable damage disclosing party money damages represent insufficient remedy event violation section notwithstanding anything agreement contrary disclosing party shall authorized entitled seek court competent jurisdiction injunctive relief whether preliminary permanent respect violation well relief permitted applicable law may obtain relief without making showing insufficiency money damages irreparable harm receiving party agrees waive requirement disclosing party post bond condition obtaining relief section warranties indemnities representations warranties covenants member party hereby represents warrants covenants member party effective date follows member party applicable power authority legal right enter agreement operating agreement ancillary agreements party perform obligations hereunder thereunder ii taken necessary action part required authorize execution delivery agreement operating agreement ancillary agreements party agreement operating agreement case ancillary agreements member party party executed delivered duly executed delivered behalf member party constitutes case ancillary agreements member party party duly executed delivered shall constitute legal valid binding obligation member party case ancillary agreements member party party duly executed delivered shall enforceable accordance terms subject effects bankruptcy insolvency laws general application affecting enforcement creditor rights judicial principles affecting availability specific performance general principles equity whether enforceability considered proceeding law equity b member party aware pending threatened litigation received communication alleges member partys activities related agreement violated conducting activities contemplated agreement party would violate intellectual property rights person giving effect license grants agreement effective date member party delivered member party list setting forth extent member partys knowledge products liability litigation ii intellectual property litigation reasonably likely material adverse effect member partys single agent products double agent product combination product applicable rights licenses granted member party member party jv hereunder respect product iii litigation investigations initiated warning letters received regulatory authorities including form letters case respect manufacturing case ii iii relates member partys single agent products double agent product b litigation investigation currently pending pending warning letter received time c necessary consents approvals authorizations regulatory governmental authorities persons required obtained member party connection execution delivery agreement performance obligations agreement obtained respect member party applicable execution delivery agreement operating agreement ancillary agreements party performance member partys obligations hereunder thereunder conflict violate material way requirement applicable law ii conflict violate provision articles incorporation bylaws limited partnership agreement similar instrument member party applicable ii conflict violate breach constitute default require consent contractual obligation court administrative order member party bound additional representations warranties covenants bms bms represents warrants covenants gilead bms parent bms sub corporation limited liability company case may duly organized good standing laws state delaware ii full power authority legal right operate property assets carry business conducted contemplated conducted agreement b neither bms affiliates debarred subject debarment neither bms affiliates shall use capacity connection services performed agreement person debarred pursuant section act subject conviction described section bms agrees inform gilead writing immediately person performing services agreement debarred subject conviction described section action suit claim investigation legal administrative proceeding pending knowledge bms threatened relating debarment conviction bms person performing services agreement c bms right grant license bms patents set forth section b prior effective date made grant third party right license respect bms patents would conflict grant rights licenses gilead jv hereunder bms patents subject encumbrance lien third party except encumbrances liens would aggregate material adverse effect license rights granted jv gilead agreement prior effective date bms delivered gilead copy financial terms redacted license similar grant rights bms one hand third party hand pursuant bms obtained third party license rights respect bms patents ii pursuant bms grants third party license rights respect bms patents exploitation territory bms covenants agrees except agreements referred preceding sentence including extensions amendments renewals thereof shall effective date throughout term agreement grant third party right license respect bms patents would conflict grant gilead jv hereunder judgments settlements amounts respect thereto owed bms relating bms patents knowledge bms received written notice proceeding alleged bms patents invalid unenforceable ii exploitation efv whether alone combination either tdf ftc infringes third party patent e knowledge bms information contained bms single agent product label nda bms single agent product represents material respects complete accurate reflection safety efficacy profile bms single agent product effective date bms shall use commercially reasonable efforts maintain single agent product label bms regulatory documentation updates needed ensure information continues represent complete accurate reflection material respects safety efficacy profile single agent product understood agreed bms makes representation covenant gilead set forth section e solely purposes member parties collaboration pursuant agreement purpose f quantities efv provided bms pursuant section manufactured using reasonable care ii conform applicable efv bulk specifications defined bms supply agreement applicable certificate analysis time delivery iii conveyed bms good title free lawful security interest lien encumbrance bms affiliates third party suppliers applicable obtained approvals required applicable regulatory authorities manufacture efv use sustiva additional representations warranties covenants gilead gilead represents warrants covenants bms gilead parent gilead sub corporation limited liability company case may duly organized validly existing good standing laws state delaware full power authority legal right operate property assets carry business conducted contemplated conducted agreement b neither gilead affiliates debarred subject debarment neither gilead affiliates shall use capacity connection services performed agreement person debarred pursuant section act subject conviction described section gilead agrees inform bms writing immediately person performing services agreement debarred subject conviction described section action suit claim investigation legal administrative proceeding pending knowledge gilead threatened relating debarment conviction gilead person performing services agreement c gilead right grant license gilead patents set forth section prior effective date made grant third party right license respect gilead patents would conflict grant rights licenses bms jv hereunder gilead patents subject encumbrance lien third party except encumbrances liens would aggregate material adverse effect license rights granted jv bms agreement prior effective date gilead delivered bms copy financial terms redacted license similar grant rights gilead one hand third party hand pursuant gilead obtained third party license rights respect gilead patents ii pursuant gilead grants third party license rights respect gilead patents exploitation territory gilead covenants agrees except agreements referred preceding sentence including extensions amendments renewals thereof shall effective date throughout term agreement grant third party right license respect gilead patents would conflict grant gilead jv hereunder judgments settlements amounts respect thereto owed gilead relating gilead patents knowledge gilead received written notice proceeding alleged gilead patents invalid unenforceable ii exploitation either tdf ftc whether alone together whether combination efv infringes third party patent e knowledge gilead information contained labels gileads single agent products double agent product ndas gileads single agent products double agent product represents material respects complete accurate reflection safety efficacy profile gileads single agent products double agent product effective date gilead shall use commercially reasonable efforts maintain single double agent product labels gilead regulatory documentation updates needed ensure information continues represent complete accurate reflection material respects safety efficacy profile single double agent products understood agreed gilead makes representation covenant bms set forth section e solely purposes member parties collaboration pursuant agreement purpose f quantities ftc tdf provided gilead pursuant section manufactured using reasonable care ii conform applicable product specifications defined gilead supply agreement applicable certificate analysis time delivery iii conveyed gilead good title free lawful security interest lien encumbrance gilead affiliates third party suppliers applicable obtained approvals required applicable regulatory authorities manufacture ftc tdf use viread emtriva truvada applicable disclaimer except set forth sections party hereby disclaims warranties whether written oral express implied including without limitation respect single agent products double agent product combination product active pharmaceutical ingredients combination product supplied agreement technology licensed agreement including without limitation warranty quality performance merchantability fitness particular use purpose avoidance doubt nothing contained section shall operate limit invalidate warranty contained ancillary agreement indemnification jv jv shall indemnify member parties affiliates respective officers directors employees proceedings member party affiliate involved threatened involved arises exploitation combination product either member partys affiliates performance obligations compliance agreement operating agreement sdea mtta ii losses incurred indemnitee resulting proceedings b without limitation foregoing clause proceedings member party affiliate involved threatened involved arises content approved marketing materials extent approved marketing materials used member parties b performance member partys duties section respect formulation manufacturing process development related activities agreement c performance tax matters member duties operating agreement jvs use combination product trademarks gilead licensed trademarks andor bms licensed trademarks ii losses incurred indemnitee resulting proceedings except case b extent proceedings arise losses caused indemnitee member partys affiliates subcontractors gross negligence willful misconduct failure comply perform one covenants agreement operating agreement sdea mtta breach inaccuracy one representations warranties agreement operating agreement applicable sdea except case b extent member party obligation indemnity losses proceedings pursuant section section case may indemnification provided section shall deemed exclusive rights indemnified may entitled applicable statutes agreement vote jec otherwise except otherwise expressly provided agreement including without limitation section section losses incurred jv shall borne member parties accordance terms operating agreement indemnification member parties general member party indemnifying member party shall indemnify jv member party affiliates respective officers directors employees proceedings jv member party affiliate involved threatened involved arises indemnifying member partys affiliates subcontractors gross negligence willful misconduct failure comply perform one covenants agreement operating agreement sdea mtta breach inaccuracy one representations warranties agreement operating agreement applicable sdea ii content approved marketing materials used indemnifying member party accordance section following receipt notification member party accordance section member party elected use approved marketing materials promotion combination product territory provided member party use approved marketing materials promotion combination product territory b losses incurred indemnitee resulting proceedings except extent proceedings arise losses caused member partys affiliates subcontractors gross negligence willful misconduct failure comply perform one covenants agreement operating agreement sdea mtta breach inaccuracy one representations warranties agreement operating agreement applicable sdea except extent member party jv obligation indemnity losses proceedings pursuant section section section case may indemnification provided section shall deemed exclusive rights indemnified may entitled applicable statutes agreement vote jec otherwise indemnification certain product liability related matters gilead shall indemnify jv bms indemnified party proceedings jv bms indemnified party involved threatened involved arise personal injury death caused combination product due design defects manufacturing defects inherent characteristics thereof defects characteristics direct result incorporation combination product tdf ftc tdf ftc case without reference incorporation combination product efv selected product liability claims irrespective whether defects characteristics associated defects characteristics tdf andor ftc ii losses incurred jv bms indemnified party case may resulting proceedings except extent proceedings arise losses caused bms affiliates subcontractors gross negligence willful misconduct failure comply perform one covenants agreement operating agreement sdea mtta breach inaccuracy one representations warranties agreement operating agreement applicable sdea b bms shall indemnify jv gilead indemnified party proceedings jv gilead indemnified party involved threatened involved arise personal injury death caused combination product due design defects manufacturing defects inherent characteristics thereof defects characteristics direct result incorporation combination product efv case without reference incorporation combination product either tdf ftc selected product liability claims irrespective whether defects characteristics associated defects characteristics efv ii losses incurred jv gilead indemnified party case may resulting proceedings except extent proceedings arise losses caused gileads affiliates subcontractors gross negligence willful misconduct failure comply perform one covenants agreement operating agreement sdea mtta breach inaccuracy one representations warranties agreement operating agreement applicable sdea c jv shall indemnify gilead indemnified parties bms indemnified parties proceedings gilead indemnified party bms indemnified party case may involved threatened involved arise personal injury death caused combination product due design defects manufacturing defects inherent characteristics thereof defects characteristics direct result efv either tdf andor ftc incorporated combination product b ultimately determined whether defects characteristics direct result efv one hand either tdf ftc hand incorporated combination product c defects characteristics direct result aspect combination product active ingredients claim b c selected product liability claim ii losses incurred gilead indemnified party bms indemnified party case may resulting proceedings case except extent proceedings arise losses caused member partys affiliates subcontractors gross negligence willful misconduct failure comply perform one covenants agreement operating agreement sdea mtta breach inaccuracy one representations warranties agreement operating agreement applicable sdea except extent member party obligation indemnity losses proceedings pursuant section purposes sections b c shall deemed affiliate gilead provided however bms shall greater scope liability pursuant section lesser scope liability bms gilead pursuant section b ii scope liability gilead pursuant effective date indemnification procedure indemnified party agrees give indemnifying party prompt written notice losses discovery fact including proceeding upon indemnified party intends base request indemnification section case may understood agreed however failure give notice provided section shall relieve indemnifying party indemnification obligations except extent indemnifying party actually materially prejudiced result failure give notice b party shall furnish promptly parties copies papers official documents received respect proceedings indemnified party shall reasonably cooperate requested expense indemnifying party defense proceedings c respect losses relating solely payment money damages shall result indemnified partys becoming subject injunctive relief otherwise adversely affecting indemnified party manner indemnifying party shall acknowledged writing obligation indemnify indemnified party agreement indemnifying party shall sole right defend settle otherwise dispose proceeding terms indemnifying party shall deem appropriate respect losses addressed section c indemnifying party shall acknowledged writing obligation indemnify indemnified party agreement indemnifying party shall sole right control defense relevant proceeding provided indemnifying party shall obtain written consent indemnified party shall unreasonably withheld prior ceasing defend settling otherwise disposing proceeding result thereof indemnified party would become responsible payment money damages costs respect indemnifying party contested challenged may contest challenge obligation indemnify ii indemnified party would become subject injunctive equitable relief remedy payment money indemnifying party iii indemnified party would otherwise adversely affected e furthermore respect section c indemnifying party shall entitled control proceeding notifies indemnified party within thirty days delivery notice indemnified party section f indemnifying party shall liable losses resulting settlement disposition proceeding indemnified party reached without written consent indemnifying party g allocation among member parties jv liability loss proceeding otherwise determined court law shall considered jec jec reach agreement allocation unanimous member vote unanimous written consent members either member party shall right refer dispute arbitration pursuant section dispute resolution procedures section shall apply disputes arising section g h outofpocket expenses reasonably incurred indemnified party connection proceeding shall reimbursed calendar quarter basis indemnifying party without prejudice indemnifying partys right contest indemnified partys right indemnification subject refund event indemnifying party ultimately held obligated indemnify indemnified party limitation damages except breaches section parties shall liable special indirect incidental consequential damages including without limitation lost profits whether contract warranty negligence tort strict liability otherwise arising breach failure perform provisions agreement provided however parties shall liable provided parties shall liable provided breaches intentional arise acts omissions constituting gross negligence nothing section intended shall operate limit partys obligations indemnity respect losses awarded third parties proceeding sections ancillary agreements reference agreement ancillary agreement sdea obligation ancillary agreement shall construed include within scope indemnification obligations parties agreement liability arising ancillary agreement obligation ancillary agreement employees parties agree among parties actions taken omitted taken employee member party affiliates capacity member jec operating committee pricing committee actions taken omitted taken employee member party affiliates respect project activities shall attributed member party accordingly claims member party jv arising actions inactions shall asserted directly member party whose affiliate individuals employer member party jv case may hereby waives claims individual section term termination term term agreement shall commence effective date shall continue terminated mutual agreement parties otherwise accordance section certain litigation agreement shall terminate upon notice given either member party member party event us governmental authority seeks obtains temporary restraining order preliminary injunction enjoin transactions contemplated agreement institutes litigation seeking relief respect transactions applicable law territory termination nda filing delay either member party may terminate agreement notice member party either nda combination product field filed december b nda combination product field approved december material default member party breaching member party fails comply perform material respect material obligations contained agreement operating agreement act omission member party causes failure jv comply perform material respect material obligations contained agreement operating agreement default material default member party nonbreaching member party shall right give breaching member party notice specifying nature material default breaching member party shall period sixty days receipt notice fully cure material default manner reasonably acceptable nonbreaching member party within period member parties shall discuss good faith appropriate adjustments cancellation member parties respective obligations agreement permit continuation agreement jv mutually agreeable basis avoidance doubt nonbreaching member party may sole discretion deliver notice material default breaching member party prior completion dispute resolution procedures set forth section case sixty day cure period referred preceding sentence shall begin run upon receipt notice shall run concurrently procedures b breaching member party cure material default pursuant section member parties discussions pursuant last sentence section lead mutually agreeable restructuring agreement nonbreaching member party breaching member party mutually agree desirable practicable withdraw combination product market territory nonbreaching member party shall right terminate agreement upon notice breaching member party given within thirty days cessation member parties discussions pursuant last sentence section termination shall effective upon withdrawal member parties shall cooperate cause jv effect withdrawal promptly practicable applicable law c whether termination agreement pursuant section b nonbreaching member party shall right seek damages account material default arbitration pursuant section express remedies nonbreaching member party pursuant section shall addition remedies favor non breaching member party applicable jv provided agreement operating agreement applicable bms guarantee agreement gilead guarantee agreement applicable parties acknowledge member party entered agreement operating agreement reliance member partys continued compliance performance obligations agreement operating agreement accordingly member party agrees material default may cause severe irreparable damage nonbreaching member party jv applicable money damages would represent insufficient remedy event material default notwithstanding anything agreement contrary nonbreaching member party shall authorized entitled seek arbitrator section remedy specific performance respect material default well relief permitted applicable law may obtain relief without making showing insufficiency money damages breaching member party agrees waive requirement nonbreaching member party post bond condition obtaining relief termination upon generic launch either member party continuing member party may terminate agreement notice member party terminated member party event launch territory least one generic version single agent products double agent product terminated member party generic version launch continuing member party delivers notice termination within thirty days generic version launch termination shall effective last day calendar quarter notice given consequences termination termination pursuant sections b member party terminates agreement pursuant section b license sublicense grants rights reference section member parties jv shall terminate ii rights reference license grants section b shall survive solely extent necessary order licensee member party support labeling single agent products andor double agent product applicable approved effective date termination iii license grants section b shall survive iv license grants rights reference section jv member parties shall survive first date jv dissolved intangible property defined operating agreement distributed kind member parties pursuant section c operating agreement v unless gilead breaching member party licenses rights granted gilead sections respect combination product outside territory canada europe shall survive event licenses rights shall deemed granted bms directly gilead vi jv shall dissolved accordance operating agreement connection dissolution combination product trademark shall sold member bidding process vii operating agreement ancillary agreements shall terminate except expressly provided agreement viii member party shall promptly event within thirty days thereafter make arrangements return disposal member partys option confidential information tangible intangible form except x one copy may retained solely archival purposes confidential information relating surviving licenses rights described b termination pursuant section upon termination agreement pursuant section jv shall dissolved following terms conditions shall apply license grants rights reference section terminated member party jv shall survive except trademark license grants section shall survive extent necessary enable continuing member party identify terminated member party label combination product andor combination product regulatory documentation required applicable law b gilead terminated member party license grant section jv gilead shall terminate c license sublicense grants section jv terminated member party shall terminate section b applicable c gilead terminated member party sublicense grant section shall addressed set forth clause f license grants rights reference member party member party section shall survive e rights reference jv terminated member party section b c shall survive f gilead terminated member party sublicenses rights reference granted gilead sections respect combination product outside territory canada europe shall survive ii continuing member party shall pay cause jv pay terminated party manner set forth sections b subject mutatis mutandis section respect period effective date termination thereof amount determined pursuant following formula net sales net selling prices case determined applicable yearly period net sales combination product net selling price combination product net selling price continuing member partys single agent product double agent productnet selling price combination product multiplied following percentages following twelve month periods commencing effective date termination jv paying member party shall pay amounts owed member party pursuant section bii within sixty days end calendar quarter relevant net sales invoiced payment shall accompanied written report providing detailed breakdown calculation amounts paid relevant period iii terminated member party election shall promptly notify continuing member party writing shall pursuant license andor supply agreement containing following terms terms upon member parties mutually agree either enable continuing member party manufacture quantities efv tdf ftc case may bulk active pharmaceutical ingredient form use manufacture combination product use territory event terminated member party shall automatically deemed grant royaltyfree nonexclusive license continuing member party third party designee shall reasonably acceptable terminated member party terminated member partys patents covering manufacture information inventions used manufacture behalf terminated member party manufacture ingredients sole purpose using ingredients manufacture combination product territory provide reasonable technical assistance continuing member party third party designee choice recipient shall subject prior approval terminated member party approval unreasonably withheld delayed continuing member partys expense terminated member partys thencurrent standard terms conditions b continue supply jv designee nonexclusive basis quantities efv tdf ftc case may bulk active pharmaceutical ingredient form continuing member party may request manufacture combination product territory transfer price supply equal cost goods notwithstanding foregoing thereafter terminated member party may elect pursuant clause b continue supply applicable bulk active pharmaceutical ingredient determine cease manufacture ingredients otherwise desires terminate aforementioned supply arrangement continuing member party time continuing member party still manufacturing manufactured combination product event terminated member party elects cease manufacture ingredients otherwise desires terminate supply arrangement terminated member party shall x give continuing member party least written notice prior ceasing manufacture otherwise terminating agreement grant continuing member party license described clause z provide continuing member party technical assistance described clause event terminated member party jv continuing member party enter supply arrangement bulk active pharmaceutical ingredients pursuant first sentence section biii thereafter jv continuing member party case may desires terminate supply arrangement without receiving terminated member party license described clause technical assistance described clause jv continuing member party case may shall provide written notice thereof terminated member party jv continuing member party shall responsible third party royalties payable terminated member party respect supply provided terminated member party pursuant section biii iv name jv shall changed remove name terminated member party continuing member party shall shall cause jv include trademark name terminated member party labeling packaging advertising materials combination product otherwise connection jvs business respect combination product v terminated member party shall promptly event within thirty days thereafter make arrangements return disposal continuing member partys option confidential information tangible intangible form except x one copy may retained solely archival purposes confidential information relating surviving licenses rights pursuant section bi vi except otherwise expressly provided operating agreement andor ancillary agreement operating agreement ancillary agreements shall terminate vii jv shall immediately discontinue use terminated member partys trademarks license granted terminated member party jv use terminated member partys trademarks shall immediately revert terminated member party viii avoidance doubt pricing provisions contained section shall terminate rights bankruptcy rights licenses granted pursuant agreement jv bms gilead shall otherwise deemed purposes section n united states bankruptcy code licenses right intellectual property defined section united states bankruptcy code parties agree jv bms gilead licensees rights agreement shall retain may fully exercise rights elections united states bankruptcy code parties agree event commencement bankruptcy proceeding jv either member party united states bankruptcy code nonsubject parties shall entitled complete duplicate complete access nonsubject party deems appropriate intellectual property embodiments intellectual property already possession shall promptly delivered upon commencement bankruptcy proceeding upon non subject partys written request therefor unless party subject proceeding elects continue perform obligations agreement b delivered clause following rejection agreement behalf party subject proceeding upon written request therefor nonsubject party provisions section without prejudice rights non subject parties may arising us bankruptcy code applicable law accrued rights surviving obligations termination expiration agreement shall without prejudice rights shall accrued benefit party prior termination expiration termination expiration shall relieve party obligations expressly indicated survive termination expiration agreement b without limiting anything contained section sections provision shall implemented member parties modified payments pursuant section bii e second sentence thereof e second sentence thereof applies surviving provisions surviving rights licenses shall survive termination expiration agreement reason section general provisions force majeure party shall held liable responsible parties deemed defaulted breached agreement failure delay fulfilling performing term agreement except payment amounts agreement failure delay caused results causes beyond reasonable control non performing party including without limitation fires floods embargoes shortages epidemics quarantines war acts war whether war declared terrorism insurrections riots civil commotion acts god acts omissions delays acting governmental authority nonperforming party shall notify parties force majeure within five days occurrence giving written notice parties stating nature event anticipated duration action taken avoid minimize effect suspension performance shall greater scope longer duration necessary nonperforming party shall use throughout period suspension performance commercially reasonable efforts remedy inability perform provided however event suspension performance continues ninety days date force majeure commences parties shall meet discuss good faith proceed order accomplish collaboration principles purposes agreement force majeure shall include failure commit sufficient resources financial otherwise project activities general market economic conditions notice notices requests reports statements communications party specified section c shall writing shall refer specifically agreement shall delivered personally sent nationallyrecognized overnight courier sent registered certified mail postage prepaid return receipt requested following respective addresses address may specified notice time time relevant party gilead gilead sciences inc lakeside drive foster city ca attn evp cfo copies gilead sciences inc lakeside drive foster city ca attn vp general counsel covington burling one front street san francisco ca attn james c snipes esq bms bristolmyers squibb worldwide medicines group route province line road princeton nj attn vice president senior counsel corporate business development copy hughes hubbard reed llp one battery park plaza new york ny attn ellen friedenberg esq communication shall deemed given delivered personally delivered recipients normal business hours ii business day dispatch sent nationallyrecognized overnight courier proof delivery obtained iii third rd business day following date mailing sent mail understood agreed section intended govern daytoday business communications necessary parties performing duties due course terms agreement whenever agreement requires permits giving notice member party notice may given bms parent behalf bms sub gilead parent behalf gilead sub assurances party shall duly execute deliver cause duly executed delivered instruments cause done ministerial administrative similar acts things including without limitation filing assignments agreements documents instruments may necessary another party may reasonably request connection agreement carry effectively provisions purposes hereof better assure confirm unto party rights remedies agreement successors assigns terms provisions hereof shall inure benefit binding upon parties respective successors permitted assigns except expressly permitted pursuant sections member party may without prior written consent member party assign otherwise transfer rights interests subcontract otherwise delegate obligations agreement provided however either member party without consent may assign rights delegate duties agreement affiliate directly indirectly whollyowned subsidiary gilead parent bms parent case may provided however assigning member party shall remain primarily secondarily derivatively liable full timely performance affiliate obligations agreement provided except set forth clause ii assignment delegation shall terminate automatically time affiliate ceases whollyowned directly indirectly gilead parent bms parent case may ii either member party without consent may assign rights delegate duties agreement whether contract operation law third party acquirer event change control member party permitted successor assignee rights andor obligations hereunder permitted assignee shall writing delivered parties time assignment expressly assume performance rights andor obligations jv may assign agreement without prior written consent member parties purported assignment transfer subcontract delegation either member party jv violation terms section shall null void legal effect b event change control member party transferring member party transferring member party shall give member party written notice thereof within ten days identifying third party acquirer time change control third party acquirer marketing territory competing product commercially available effective date upon written notice member party election transferring member party within thirty days member partys receiving written notice change control third party acquirer shall third party acquirer fails performance obligations payment obligations member parties agreement shall terminate except extent minimum obligations reasonably required jv obtain maintain approval combination product territory b gilead act agent selling combination product behalf jv perform obligations respect pricing discounting combination product pursuant section c member party supply jv bulk active pharmaceutical ingredient pursuant section applicable supply agreement ii commercialization plan budget including minimum commercialization expenditures andor shall terminate iii member party shall right promote market otherwise commercialize combination product territory without coordination member party agreement including without obligation reach agreement form approved marketing materials governing law agreement shall governed construed accordance laws state delaware without reference rules conflict laws thereof arbitration disputes member parties member party jv relating arising validity interpretation construction compliance breach agreement operating agreement ancillary agreement agreement contemplated agreement member party affiliates jv andor member party affiliates parties shall except otherwise expressly provided agreement operating agreement ancillary agreement agreement referred initially jec provided section resolved provided section thereafter subject limitations section resolved exclusively binding arbitration accordance cpr institute dispute resolution rules nonadministered arbitration held washington dc proceeding member party jv member party shall act behalf name jv external outofpocket costs without markup incurred member party shall deemed jv expenses authorized expenses proceeding section shall one arbitrator except election either member party writing within ten business days receiving notice referral arbitration shall panel three arbitrators member parties shall appoint arbitrators mutual agreement member parties agree appointment arbitrators within thirty days receipt demand arbitration member parties shall relevant number arbitrators required qualifications appointed cpr institute dispute resolution provided either member party elected panel three arbitrators member party shall right appoint one arbitrator required qualifications third arbitrator shall appointed cpr institute dispute resolution arbitrator shall either least ten years significant management level experience biopharmaceutical industry including responsibility legal matters least ten years substantial experience attorney representing working biopharmaceutical clients either inhouse outside counsel commercial litigation transactional matters shall directly indirectly affiliated either member party either member partys affiliates shall direct indirect interest kind resolution relevant issue section shall also apply dispute properly referred arbitration accordance section section g hereof section operating agreement respect jec b fees expenses payable respect arbitration section together reasonable legal fees prevailing party shall borne nonprevailing party determined arbitrators arbitration rulings awards shall final binding parties c dispute referred binding arbitration pursuant section shall scheduled discovery briefing arguments arbitrators decision rendered within soon thereafter practicable referral member parties shall submit arbitrators comprehensive proposal resolution dispute including arbitration involves allegation breach member party obligations agreement operating agreement ancillary agreement agreement contemplated agreement member party affiliates jv andor member party affiliates parties proposal damages arbitrators shall decide favor one two proposals without making modifications thereto decision arbitrators shall based proposals complies nearly agreement relevant development plans commercialization plans relevant principles reflected plans including without limitation collaboration principles nothing agreement including without limitation section shall preclude either member party seeking interim provisional relief including temporary restraining order preliminary injunction interim equitable relief concerning dispute member party either prior dispute resolution procedures set forth section necessary protect interests member party section shall specifically enforceable waiver partys failure enforce time period time provision agreement exercise right remedy constitute waiver provision right remedy prevent party thereafter enforcing provisions exercising rights remedies exercise right remedy constitute election prevent exercise rights remedies rights remedies cumulative severability provision agreement obligation jv make payments pursuant section held invalid illegal unenforceable respect fullest extent permitted applicable law provisions hereof shall remain full force effect shall liberally construed order carry intent parties nearly may possible b parties agree use best efforts negotiate provision replacement provision held invalid illegal unenforceable consistent applicable law accomplishes nearly possible original intention parties respect thereto fullest extent permitted applicable law party hereby waives provision law would render provision hereof prohibited unenforceable respect counterparts agreement may executed number counterparts shall deemed original taken together shall constitute one instrument construction except context otherwise requires wherever used singular shall include plural plural singular use gender shall applicable genders words hereof hereunder words similar import shall construed refer agreement including annexes hereto entirety particular provision captions agreement convenience reference way define describe extend limit scope intent agreement intent provision contained agreement reference agreement matter action subject mutual agreement mutual consultation member parties words similar import shall construed agreement member parties shall agree matter action language agreement shall deemed language mutually chosen parties rule strict construction shall applied party status parties except set forth expressly agreement operating agreement party shall right enter agreements take action behalf party shall represent person right authority except status bms sub gilead sub members jv nothing agreement shall construed establishing partnership joint venture relationship parties member party shall made third party beneficiary ancillary agreements member party party purpose enforcing jvs rights thereunder standstill period commencing effective date continuing fifth anniversary effective date bms shall shall cause affiliates bms acquire offer agree acquire directly indirectly beneficial ownership equity securities gilead rights options acquire beneficial ownership otherwise act concert respect securities rights options person b make participate directly indirectly solicitation proxies vote terms used regulation promulgated united states securities exchange act amended exchange act become participant election contest terms defined rule promulgated exchange act initiate propose otherwise solicit stockholders gilead approval stockholder proposals c form join participate encourage formation group within meaning section exchange act respect voting securities gilead deposit securities gilead voting trust subject securities gilead agreement arrangement respect voting securities e make public announcement respect submit proposal offer without conditions extraordinary transaction involving gilead securities assets f seek encourage support effort influence control management board directors business policies gilead understood agreed section f shall apply exercise bms rights obligations agreement operating agreement ancillary agreements applicable g encourage assist person undertake foregoing actions h take action could reasonably expected require gilead make public announcement regarding possibility events described clauses g section provided however nothing sections e g shall deemed prohibit bms acquiring merger stock purchase fifty percent voting securities thereof third party beneficial ownership equity securities gilead rights options acquire beneficial ownership ii beneficial ownership five percent class equity securities gilead rights options acquire beneficial ownership employee benefit plan bms affiliates diversified mutual pension fund managed independent investment adviser pension plan established benefit employees bms affiliates stock portfolios controlled bms affiliates invest gilead affiliates among companies provided bms affiliates directly indirectly request trustee administrator investment adviser fund plan portfolio acquire gilead equity securities provided section shall effect shall bind bms manner time gilead shall make public announcement entered letter intent definitive agreement third party acquirer providing change control gilead nonsolicitation employees period commencing effective date continuing term agreement member party agrees neither affiliates participates responsible development commercialization combination product pursuant agreement shall recruit solicit induce employee member partys hivvirology sales force including managers terminate employment member party become employed consult member party whether employee fulltime employee member party whether employment pursuant written agreement atwill purposes foregoing recruit solicit induce shall deemed mean x general solicitations third party placement specialists firms eg headhunters general solicitations employment including responses general advertisements case x specifically targeted employees party affiliates entire agreement agreement including annexes hereto together operating agreement ancillary agreements agreements contemplated agreement including without limitation safety data exchange protocol constitutes effective date entire agreement parties respect subject matter hereof prior contemporaneous understandings agreements whether written oral parties respect subject matter including mutual technology transfer agreement entered bristolmyers squibb company gilead sciences inc february mtta mutual confidential disclosure agreement entered bristolmyers squibb company gilead sciences inc december amended hereby superseded entireties provided however rights obligations parties mtta mutual confidential disclosure agreement accrued effective date shall survive agreement shall amended respect whatsoever except agreement writing fully executed parties prior effective date gilead bms consent jurisdiction party purpose enforcing award section seeking injunctive equitable relief permitted section irrevocably submits nonexclusive jurisdiction united states district court district columbia court purposes action suit proceeding arising agreement operating agreement ancillary agreement b agrees raise objection time laying maintaining venue action suit proceeding court irrevocably waives claim action suit proceeding brought inconvenient forum irrevocably waives right object respect action suit proceeding court jurisdiction party party agrees service process summons notice document us registered mail partys notice address provided agreement shall effective service process action suit proceeding court respect matters submitted jurisdiction section third parties except set forth sections third parties expressly referred therein agreements covenants representations contained herein benefit parties benefit third parties signatures follow intentionally left blank intentionally left blank witness whereof parties caused collaboration agreement duly executed delivered date first written gilead sciences inc bristolmyers squibb company b john c martin b tamar howson john c martin phd tamar howson president chief executive senior vice president officer corporate business development gilead holdings llc er squibb sons llc b john f milligan b charles linzner john f milligan phd charles linzner president assistant secretary bristolmyers squibb gilead sciences llc gilead holdings llc member b john f milligan john f milligan phd president er squibb sons llc member b charles linzner charles linzner assistant secretary iannexes collaboration agreement annex initial committee members alliance managers annex b development plan development budget effective date annex c commercialization plan commercialization budget effective date annex bms patents annex e gilead patents annex f gilead licensed trademarks annex g bms licensed trademarks annex h quarterly detail report annex manner calculation net selling price annex j calculation cost goods annex k calculation transfer price annex l joint press release annex certain financial data annex n data provided independent accounting expert pursuant section annex jv obligations sublicensee annex p key terms services agreement annex q pricing annex r list countries comprising developing world iannex initial committee members alliance managers gilead sub bms sub joint executive committee jec j oint executive committee jec joint development committee jdc j oint development committee jdc joint commercialization committee jcc j oint commercialization committee jcc joint finance committee jfc j oint finance committee jfc alliance manager lliance manager denotes initial chairperson aannex b development plan development budget effective date bannex c commercialization plan commercialization budget effective date cannex bms patents patents exclusively licensed bms merck dannex e gilead patents eannex f gilead licensed trademarks country mark app reg filing reg date class usa truvada application filed usa viread usa emtriva fannex g bms licensed trademarks country mark app reg filing reg date class us sustiva puerto rico sustiva gannex h quarterly detail report illustrative purposes period ending detail activity report run date product fdc brand x hannex manner calculation net selling price net selling price product relevant period country shall expressed dollars per daily dose product shall equal quotient aggregate net sales country product period recognized revenue united states generally accepted accounting principles effect time time consistently applied divided ii number daily doses product units revenue may recognized united states generally accepted accounting principles effect time time consistently applied period may sold used country plus number daily doses product country shipped period provided however consistent definition net sales parties intent practices bms gilead calculation net sales shall harmonized process calculating net selling price deductions payments rebates compensations made given bms gilead connection respect sales products shall treated deduction gross amount invoiced calculation net sales b bms gilead make payments provide compensation similar purpose respect product one treats item accounting purposes deduction revenues purposes calculation net selling price annex item shall deduction gross amount invoiced calculation net sales parties example iannex j calculation cost goods cost goods means respect manufacture acquisition product amount equal calculation cost goods specific products mutually agreed writing members updated calendar year jannex k calculation transfer price k k k kannex l joint press release bristolmyers squibb contacts gilead sciences contacts david rosen media amy flood media john elicker investors susan hubbard investors bristolmyers squibb gilead sciences establish joint venture develop commercialize fixeddose combination three hiv medicines first collaboration develop oncedaily antiretroviral fixeddose regimen new york ny foster city ca date bristolmyers squibb company nyse bmy gilead sciences inc nasdaq cid gild today announced details joint venture develop commercialize fixeddose combination bristolmyers squibbs sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate united states approved new product would first complete highly active antiretroviral therapy haart treatment regimen hiv available fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together may help simplify hiv therapy patients providers joint venture established two companies first kind field hiv therapy work necessary coformulate sustiva truvada oncedaily combination product ongoing throughout continue joint venture bristolmyers squibb gilead sciences llc companies work partnership complete development us regulatory filings fixeddose regimen subject receiving marketing approval fixeddose regimen companies would share responsibility commercializing product united states companies provide funding fieldbased sales representatives support promotional efforts combination product bristolmyers squibb gilead receive revenues future net sales percentages relative contribution represented individual products comprise fixed dose combination guidelines issued us department health human services dhhs list combination emtricitabine tenofovir disoproxil fumarate efavirenz one preferred nonnucleoside reverse transcriptase inhibitor nnrtibased treatments use appropriate patients never taken antihiv medicines important patients aware individual hiv medications must taken part combination regimens cure hiv infection prevent passing hiv others gilead bristolmyers squibb share steadfast commitment addressing needs people living hivaids around world todays announcement signals significant progress toward lcommon goal commented john c martin phd president chief executive officer gilead sciences landmark partnership reflects dedication gilead bristolmyers squibb bring delivering simplified therapy physicians patients look forward working bristolmyers squibb team ensure novel therapeutic advancement reaches physicians people living hivaids rapidly possible decade bristolmyers squibb leader field hiv significant investments innovative scientific research unwavering commitment finding new better treatment options help improve lives people hiv said peter r dolan chairman chief executive officer bristolmyers squibb company pleased leveraging leadership hiv collaboration gilead help advance management disease development potentially convenient treatment options earlier us secretary health human services tommy thompson addressed need new products help advance simplify treatment people hivaids encouraging members industry work together create fixeddose combinations would help achieve goals additionally earlier year us food drug administration issued new guidelines expedite approval new combination products hiv availability simplified treatment regimens hivaids important ability make progress fight disease secretary thompson said pleased see collaboration efforts bristolmyers squibb gilead partnership create fixeddose combination three hiv medications represents important advance collective effort deliver simplified therapy people living hiv important safety information sustiva sustiva prescription medicine used combination medicines treat people infected human immunodeficiency virus type hiv sustiva cure hiv help prevent passing hiv others sustiva taken hismanal astemizole propulsid cisapride versed midazolam halcion triazolam ergot medicines example wigraine cafergot vfend voriconazole list medicines complete patients discuss prescription nonprescription medicines vitamin herbal supplements health preparations particularly st johns wort taking plan take healthcare provider patients taking sustiva tell doctor right away side effects conditions including severe depression strange thoughts angry behavior reported small number patients reports suicide made known sustiva cause patients tell doctor history mental illness using drugs alcohol dizziness trouble sleeping drowsiness trouble concentrating andor unusual dreams common feelings tend go away taking sustiva weeks women become pregnant breastfeed taking sustiva rash common side effect usually goes away without change treatment rash may serious problem children child develops rash doctor contacted right away patients tell doctor liver disease ever seizures taking medicine seizures tests check liver drug levels blood may needed changes body fat seen patients taking hiv medicines however cause longterm effects changes known time common side effects include tiredness upset stomach vomiting diarrhea taking sustiva food increases amount medicine body may increase frequency side leffects sustiva taken empty stomach preferably bedtime may make side effects less bothersome united states full prescribing information available wwwsustivacom truvada truvada combines emtriva emtricitabine viread tenofovir disoproxil fumarate one tablet taken day combination antiretroviral agents united states truvada indicated combination antiretroviral agents nonnucleoside reverse transcriptase inhibitors protease inhibitors treatment hiv infection adults safety efficacy studies using truvada tablets using emtriva viread combination ongoing components truvada studied individually part multidrug regimens found safe effective since emtriva lamivudine tc comparable structure resistance profiles efficacy safety part multidrug regimens existing data use lamivudine viread combination extrapolated support use truvada tablets treatment hiv infection adults therefore treatmentnave patients truvada considered alternative combination viread lamivudine patients might benefit oncedaily regimen treatmentexperienced patients use truvada guided laboratory testing treatment history study results demonstrating effect truvada clinical progression hiv recommended truvada used component triple nucleoside regimen truvada used emtriva viread drugs containing lamivudine including combivir epivir epivirhbv epzicom trizivir twohundred eightythree patients received combination therapy emtriva viread either non nucleoside reverse transcriptase inhibitor protease inhibitor weeks ongoing clinical studies based limited data new patterns adverse events identified increased frequency established toxicities additional safety information emtriva viread combination antiretroviral agents please see emtriva viread lactic acidosis severe hepatomegaly steatosis including fatal cases reported use nucleoside analogues alone combination antiretrovirals viread emtriva truvada indicated treatment chronic hepatitis b virus hbv infection safety efficacy drugs established patients coinfected hbv hiv severe acute exacerbations hepatitis b reported patients discontinued viread emtriva hepatic function monitored closely clinical laboratory followup least several months patients discontinue viread emtriva truvada coinfected hiv hbv appropriate initiation antihepatitis b therapy may warranted changes body fat observed patients taking viread emtriva truvada antihiv medicines cause long term health effect conditions unknown viread united states viread indicated combination antiretroviral agents treatment hiv infection indication based analyses plasma hiv rna levels cd cell counts controlled studies viread treatmentnave adults treatment experienced adults study results demonstrating effect viread clinical progression hiv use viread considered treating adult patients hiv strains expected susceptible tenofovir assessed laboratory testing treatment history ldrug interactions observed didanosine atazanavir lopinavirritonavir coadministered viread dose adjustments may necessary data available recommend dose adjustment didanosine patients weighing less kg patients atazanavir lopinavirritonavir plus viread monitored vireadassociated adverse events may require discontinuation coadministered viread recommended atazanavir mg given ritonavir mg atazanavir without ritonavir coadministered viread renal impairment including serious cases reported renal impairment occurred often patients underlying systemic renal disease patients taking concomitant nephrotoxic agents though cases appeared patients without identified risk factors decreases bone mineral density bmd lumbar spine hip seen use viread clinical significance changes bmd biochemical markers unknown followup continuing assess longterm impact common adverse events occurring percent patients receiving viread antiretroviral agents clinical trials include asthenia pain abdominal pain headache nausea diarrhea vomiting rash rash pruritis maculopapular rash urticaria vesiculobullous rash pustular rash flatulence dizziness depression less percent patients discontinued participation gastrointestinal events emtriva united states emtriva indicated combination antiretroviral agents treatment hiv infection adults indication based analyses plasma hiv rna levels cd cell counts controlled studies weeks duration antiretroviral nave patients antiretroviraltreatmentexperienced patients virologically suppressed hiv treatment regimen antiretroviraltreatmentexperienced patients use emtriva may considered adults hiv strains expected susceptible emtriva assessed genotypic phenotypic testing adverse events occurred percent patients receiving emtriva antiretroviral agents clinical trials include abdominal pain asthenia weakness headache diarrhea nausea vomiting dizziness rash rash pruritis maculopapular rash urticaria vesiculobullous rash pustular rash allergic reaction approximately percent patients discontinued participation events adverse events reported similar frequency emtriva control treatment groups exception skin discoloration reported higher frequency emtriva treated group skin discoloration manifested hyperpigmentation palms andor soles generally mild asymptomatic mechanism clinical significance unknown bristolmyers squibb bristolmyers squibb global pharmaceutical related healthcare products company whose mission extend enhance human life decade bristolmyers squibb company global leader science infectious diseases invested consistently innovative research leading development important treatments people hivaids visit bristolmyers squibb world wide web wwwbmscom gilead sciences gilead sciences biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases worldwide company seven marketed products focuses research clinical programs antiinfectives headquartered foster city ca gilead operations north america europe australia visit gilead world wide web wwwgileadcom lforwardlooking statements bristolmyers squibb forwardlooking statement press release contains forwardlooking statements term defined private securities litigation reform act regarding product development forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes results differ materially current expectations among risks guarantee combination product submitted regulatory approval receive regulatory approval approved commercially successful forwardlooking statement guaranteed forwardlooking statements press release evaluated together many uncertainties affect bristolmyers squibbs business particularly identified cautionary factors discussion bristolmyers squibbs annual report year ended december quarterly reports form q bristolmyers squibb undertakes obligation publicly update forwardlooking statement whether result new information future events otherwise gilead forwardlooking statement press release contains forwardlooking statements term defined private securities litigation reform act forwardlooking statements include statements regarding approval licensure combination product statements involve risks uncertainties may cause results differ materially set forth statements including risks related ability companies successfully complete ongoing studies support approval combination product willingness regulatory authorities grant regulatory approval combination product based data studies forwardlooking statement guaranteed actual results may differ materially projected gilead undertakes obligation publicly update forwardlooking statement whether result new information future events otherwise forwardlooking statements press release evaluated together many uncertainties affect gileads business particularly mentioned cautionary statements companys year ended december periodic reports form q form k lannex certain financial data annual budget reports quarterly projection reports later weekly sales reports actual reports times based mannex n data provided independent accounting expert pursuant section provided bms annual basis provided gilead annual basis provided jv designee annual basis nannex jv obligations sublicensee oannex p key terms services agreement term sheet focuses certain key aspects services agreement discuss terms conditions would included definitive services agreement entered jv gilead parent pursuant section collaboration agreement agreement distribution services agreement services agreement jv gilead parent pursuant gilead parent provide certain distribution services combination product territory behalf jv distribution services distribution services provided gilead parent behalf jv include without limitation inventory management control warehousing storage orders invoicing collection sales proceeds customer relations services returns jcc oversee gilead parents activities services agreement gilead parent provide distribution services accordance customary practice biopharmaceutical industry well gsp gmp applicable law compensation term services agreement continue term collaboration agreement unless earlier terminated accordance article collaboration agreement p miscellaneous services agreement contain additional provisions relating matters provisions consistent provisions collaboration agreement upon bms gilead parent mutually agree pannex q pricing qannex r list countries comprising developing world african countries algeria angola benin botswana burkina faso burundi cameroon cape verde central african republic chad comoros cte divoire democratic republic congo djibouti egypt equatorial guinea eritrea ethiopia gabon gambia ghana guinea guineabissau kenya lesotho liberia libya madagascar malawi mali mauritania mauritius morocco mozambique namibia niger nigeria republic congo rwanda tom prncipe senegal seychelles sierra leone somalia south africa sudan swaziland tanzania togo tunisia uganda zambia zimbabwe nonafrican countries united nations list least developed countries afghanistan antigua barbuda bahamas bangladesh barbados belize bhutanbolivia cambodia cuba dominica dominican republic el salvador fiji grenada guatemala guyana haiti honduras indonesia iran islamic rep iraq jamaica jordan kiribati laos lebanon maldives mongolia myanmar naura nepal nicaragua oman pakistan papua new guinea philippines saint kitts nevis saint lucia samoa saudia arabia solomon islands sri lanka st vincent grenadines suriname syrian arab republic timorleste trinidad tobago tonga tuvalu vanuatu vietnam yemen rexhibit fourth amendment license agreement fourth amendment license agreement fourth amendment effective th day april effective date among gilead sciences inc formerly triangle pharmaceuticals inc delaware corporation principal place business lakeside drive foster city ca company emory university notforprofit georgia corporation offices south oxford road ne atlanta georgia licensor amends certain terms certain license agreement dated april licensor company amended first amendment license agreement dated may first amendment amended second amendment license agreement dated july second amendment amended third amendment license agreement dated may license agreement amended first second third amendments referred herein agreement whereas licensor company wish clarify fair equitable formula net selling price licensed products contain active ingredients licensed compounds compounds licensed compounds whereas licensor company wish clarify definitions related expanded access program companys global access program therefore good valuable consideration receipt sufficiency acknowledged parties company licensor hereby agree follows definitions use existing definitions terms used fourth amendment otherwise defined herein shall meanings ascribed agreement amendment definitions agreement hereby amended provide sections deleted entirety replaced following net selling price product including licensed product shall mean respect particular fiscal quarter gross invoice price ie total invoiced price therefore prior deductions made pursuant clauses iv paid purchaser product including distributors company affiliate sublicensee company sublicensees party authorized company sell product shall include distributors collectively sellers plus applicable value properties services received consideration sale product less discounts including cash quantity discounts chargeback payments rebates granted managed health care organizations federal state local governments agencies purchasers reimbursers trade customers ii credits allowances actually granted upon claims damaged goods rejections returns licensed products including recalls iii freight postage shipping transportation insurance charges actually allowed paid delivery licensed products extent billed iv taxes income taxes duties governmental charges levied absorbed otherwise imposed sale licensed products including without limitation valueadded taxes governmental charges otherwise measured billing included billing adjusted rebates refunds notwithstanding foregoing section amounts received company affiliates sublicensees sale licensed products among company affiliates sublicensees resale shall included computation net selling price hereunder b purposes section distributor shall mean third party seller granted time term right sell distribute licensed product ii sells licensed products hospitals andor pharmacies sale use patients rather third parties resale hospitals andor pharmacies sale use patients iii make payments company company affiliate calculated basis percentage profit share third partys sales licensed products purposes calculating net selling price distributor shall deemed sublicensee company affiliates net selling price quantities license product sold distributors shall calculated based amount invoiced distributors company andor affiliates andor sublicensees affiliates company rather distributors customers c licensed product sold form combination product containing one active ingredients addition licensed compound combination product net selling price combination product purposes determining royalties payable agreement calculated multiplying actual net selling price combination product fraction aab net selling price stock keeping unit comparable formulation dosing used combination product licensed product containing relevant licensed compound sole active ingredient sold separately country relevant fiscal quarter b net selling price stock keeping unit comparable formulation dosing used combination product active ingredient sold separately country relevant fiscal quarter clarity three active ingredients including licensed compound additional b terms calculated manner shall included denominator fraction shall aab b countrybycountry basis one active ingredients combination product sold separately said country net selling price purpose determining royalties payable agreement combination product shall calculated multiplying actual net selling price combination product combination product licensed product containing relevant licensed compound sole active ingredient sold separately country relevant fiscal quarter c net selling price combination product country relevant fiscal quarter countrybycountry basis licensed product containing licensed compound sole active ingredient sold separately said country relevant fiscal quarter one active ingredients combination product sold separately said country relevant fiscal quarter net selling price combination product shall calculated multiplying actual net selling price combination product fraction dc net selling price stock keeping unit comparable formulation dosing used combination product product containing active ingredient sole active ingredient c net selling price combination product country relevant fiscal quarter countrybycountry basis licensed product containing licensed compound sole active ingredient sold separately one active ingredients combination product sold separately country relevant fiscal quarter net selling price purposes determining royalties combination product shall deemed net selling price combination product multiplied fraction numerator number licensed compounds combination product denominator number active ingredients combination product intentionally left blank sale sold shall mean sale transfer exchange disposition licensed products whether gift otherwise subsequent registration given country registration required seller make sale transfer exchange disposition party seller sales licensed products shall deemed consummated upon first occur receipt payment purchase b delivery licensed products purchaser common carrier c release licensed products consignment otherwise transferred exchanged disposed whether gift otherwise transfer exchange gift disposition occurs notwithstanding foregoing definition sale extent company distributes licensed product treatment ind expanded access program global access program extent actual net selling price exceeds fully absorbed costs therefor distribution considered sale actual net selling price exceeds fully absorbed costs distribution shall deemed sale deemed net selling price prior application section c purposes section difference actual net selling price fully absorbed cost therefor new sections hereby added global access program shall mean program company provides licensed products government agencies notforprofit nongovernmental organizations physicians pharmacies patients identified countries reduced costs countries identified exhibit c hereto exhibit may amended time time parties fully absorbed costs shall mean amount equal companys costs directly allocated production licensed products distributed treatment ind expanded access program global access program consisting direct labor including resources utilized support companys manufacturing operations ii materials iii reasonable allocation overhead facilities expense including depreciation expected life buildings equipment administrative costs directly support companys manufacturing operations treatment ind distribution program expanded access program global access program applicable calculated company accordance reasonable cost accounting methods consistent way company allocates costs products iv thirdparty costs amendment provisions agreement provisions agreement definitions hereby amended follows section deleted entirety replaced following commencing upon fda registration licensed product ending upon expiration second calendar year following year fda registration granted company may credit solely running royalties paid pursuant section reasonable costs incurred company date hereof including reimbursements licensor pursuant section inter partes patent prosecution activities defined therein connection litigation interference opposition inter partes action pertaining validity enforceability allowability subsistence licensed patents whether companys practice licensed patents infringes third party patent end second calendar year amount credits shall exceed year onehalf royalty payments due hereunder year commencing upon third calendar year following year fda registration granted credits shall exceed year onehalf annual minimum payments due year costs shall credited payments due licensor agreement section right audit first sentence insert including records reasonably necessary verify accuracy net selling prices fully absorbed costs prior required furnished company pursuant section agreement general terms unamended terms agreement remain effect except expressly amended hereby remaining terms agreement shall remain full force effect entire agreement agreement amended fourth amendment constitutes entire agreement licensor company regarding subject matters contained herein conflicts event conflict provisions agreement fourth amendment provisions fourth amendment shall govern control governing law fourth amendment shall governed construed accordance laws state georgia without regard conflicts laws principles counterparts fourth amendment may executed number counterparts shall deemed original shall constitute one instrument survival provisions provision fourth amendment reason held ineffective unenforceable illegal condition shall affect validity enforceability remaining portions hereof provided parties shall negotiate good faith replace ineffective unenforceable illegal provision effective replacement soon practical witness whereof licensor company executed fourth amendment authorized officer date first written emory university todd sherer asst vp director ott date gilead sciences inc john f milligan executive vp cfo date april e xhibit c global access program countries algeria kenya togo angola lesotho tunisia benin liberia uganda botswana libya zambia burkina faso madagascar z imbabwe burundi malawi cameroon mali cape verde mauritania afghanistan central african republic mauritius bahamas chad morocco bangladesh comoros mozambique bhutan congobrazzaville namibia cambodia cote divoire niger guyana democratic republic congo nigeria haiti djibouti rwanda kiribati egypt sao tome principe laos equatorial guinea senegal maldives eritrea seychelles myanmar ethiopia sierra leone nepal gabon somalia samoa gambia south africa solomon islands ghana sudan tuvalu guinea swaziland vanuatu guinea bissau tanzania yeman exhibit subsidiaries gilead sciences inc name subsidiary country incorporation avid corporation united states bristolmyers squibb gilead sciences llc united states gilead biopharmaceutics ireland corporation ireland gilead holdings llc united states gilead sciences holdings llc united states gilead sciences gmbh germany gilead sciences sarl france gilead sciences srl italy gilead sciences sl spain gilead sciences lda portugal gilead sciences limited ireland gilead sciences ltd united kingdom gilead sciences international ltd united kingdom gilead sciences pty limited australia gilead sciences nz new zealand gilead sciences bv netherlands gilead sciences canada inc canada gilead sciences hellas epe greece gilead sciences luxembourg sarl luxembourg gilead vintage park llc united states leaf shield insurance limited bermudaexhibit consent independent registered public accounting firm consent incorporation reference registration statements form nos pertaining stock option plan employee stock purchase plan nonemployee directors stock option plan equity incentive plan gilead sciences inc nexstar pharmaceuticals inc incentive stock plan nexstar pharmaceuticals inc director option plan vestar inc stock option plan triangle pharmaceuticals inc stock incentive plan option agreement dated august triangle pharmaceuticals inc daniel g welch registration statements form nos gilead sciences inc related prospectuses reports dated march respect consolidated financial statements schedule gilead sciences inc gilead sciences inc managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting gilead sciences inc included annual report year ended december ernst young llp palo alto california march exhibit certifications john c martin certify reviewed annual report gilead sciences inc based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrants certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules f df registrant designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness registrants disclosure controls procedures presented annual report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change registrants internal control financial reporting occurred registrants recent fiscal quarter materially affected reasonably likely materially affect registrants internal control financial reporting registrants certifying officers disclosed based recent evaluation internal control financial reporting registrants auditors audit committee registrants board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect registrants ability record process summarize report financial information b fraud whether material involves management employees significant role registrants internal control financial reporting registrants certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses john c martin date march john c martin president chief executive officerexhibit certifications john f milligan certify reviewed annual report gilead sciences inc based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrants certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules f df registrant designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness registrants disclosure controls procedures presented annual report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change registrants internal control financial reporting occurred registrants recent fiscal quarter materially affected reasonably likely materially affect registrants internal control financial reporting registrants certifying officers disclosed based recent evaluation internal control financial reporting registrants auditors audit committee registrants board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect registrants ability record process summarize report financial information b fraud whether material involves management employees significant role registrants internal control financial reporting registrants certifying officers indicated quarterly report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses john f milligan date march john f milligan executive vice president chief executive officerexhibit certification pursuant requirements set forth rule ab securities exchange act amended exchange act section chapter title united states code usc adopted john c martin chief executive officer gilead sciences inc company john f milligan chief financial officer company hereby certifies best knowledge companys annual report period ended december certification attached exhibit annual report fully complies requirements section section securities exchange act amended information contained annual report fairly presents material respects financial condition results operations company periods covered annual report witness whereof undersigned set hands hereto th day march dated march john c martin john f milligan john c martin john f milligan chief executive officer chief financial officer certification accompanies relates deemed filed securities exchange commission incorporated reference filing gilead sciences inc securities act amended securities exchange act amended whether made date irrespective general incorporation language contained filing